Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol

Community health worker-led household... | Gates Open Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://gatesopenresearch.org/js/vendor/ckeditor/' window.reactTheme = 'gates'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); Skip to content Gates Open Research file_upload Submit via VeriXiv search clear search menu close clear Search Browse Gateways & Collections How to Publish Submit via VeriXiv My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Publication Charges Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Contact Blog My Account Submissions Content and Tracking Alerts My Details Sign In Submit via VeriXiv { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://gatesopenresearch.org/articles/7-58" }, "headline": "Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural...", "datePublished": "2023-04-21T12:33:56", "dateModified": "2024-01-05T14:22:32", "author": [ { "@type": "Person", "name": "Eric M. Foote" }, { "@type": "Person", "name": "Farjana Jahan" }, { "@type": "Person", "name": "Mahbubur Rahman" }, { "@type": "Person", "name": "Sarker Masood Parvez" }, { "@type": "Person", "name": "Tasnim Ahmed" }, { "@type": "Person", "name": "Rezaul Hasan" }, { "@type": "Person", "name": "Farzana Yeasmin" }, { "@type": "Person", "name": "Shams El Arifeen" }, { "@type": "Person", "name": "Sk Masum Billah" }, { "@type": "Person", "name": "Md. Mahbubul Hoque" }, { "@type": "Person", "name": "Mohammod Shahidullah" }, { "@type": "Person", "name": "Muhammad Shariful Islam" }, { "@type": "Person", "name": "Vinod K Bhutani" }, { "@type": "Person", "name": "Gary L Darmstadt" } ], "publisher": { "@type": "Organization", "name": "Gates Open Research", "logo": { "@type": "ImageObject", "url": "https://gatesopenresearch.org/img/AMP/Gates_image.png", "height": 600, "width": 47 } }, "image": { "@type": "ImageObject", "url": "https://gatesopenresearch.org/img/AMP/Gates_image.png", "height": 1200, "width": 94 }, "description": " Background Extreme hyperbilirubinemia leading to neurologic disability and death is disproportionately higher in low- and middle-income countries (LMIC) such as Bangladesh, and is largely preventable through timely treatment. In LMICs, an estimated half of all newborns are born at home and few receive screening or treatment for hyperbilirubinemia, leading to 6 million newborns per year who need phototherapy treatment for hyperbilirubinemia but are untreated. Household screening and treatment for neonatal hyperbilirubinemia with phototherapy administered by a trained community health worker (CHW) may increase indicated treatment for neonatal hyperbilirubinemia in comparison to the existing care system in Bangladesh. Methods 530 Bangladeshi women in their second or third trimester of pregnancy from the rural community of Sakhipur, Bangladesh will be recruited for a cluster randomized trial and randomized to the intervention arm — home screening and treatment for neonatal hyperbilirubinemia — or the comparison arm to receive usual care. In the intervention arm, CHWs will provide mothers with two prenatal visits, visit newborns by 2 days of age and then daily for 3 days to measure transcutaneous bilirubin (TcB) and monitor for clinical danger signs. Newborns without danger signs but with a TcB above the treatment threshold, but <15 mg/dL will be treated with light-emitting diode (LED) phototherapy at home. Newborns with danger signs or TcB ≥15 mg/dL will be referred to a hospital for treatment. Treatment rates for neonatal hyperbilirubinemia in each arm will be compared. Conclusion This study will evaluate the effectiveness of CHW-led home phototherapy to increase neonatal hyperbilirubinemia treatment rates in rural Bangladesh. LMICs are expanding access to postnatal care by using CHWs, and our work will give CHWs a curative treatment option for neonatal hyperbilirubinemia. Similar projects in other LMICs can be pursued to dramatically extend healthcare access to vulnerable newborns with hyperbilirubinemia. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://gatesopenresearch.org/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://gatesopenresearch.org/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://gatesopenresearch.org/articles/7-58", "name": "Community health worker-led household screening and management of..." } } ] } Home Browse Community health worker-led household screening and management of... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Foote EM, Jahan F, Rahman M et al. Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.12688/gatesopenres.14033.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Study Protocol Revised Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] Eric M. Foote https://orcid.org/0009-0007-3058-3306 1 , Farjana Jahan 2 , Mahbubur Rahman 2 , [...] Sarker Masood Parvez 2,3 , Tasnim Ahmed 1 , Rezaul Hasan 2 , Farzana Yeasmin 2 , Shams El Arifeen 4 , Sk Masum Billah 4,5 , Md. Mahbubul Hoque 6 , Mohammod Shahidullah 7 , Muhammad Shariful Islam 8 , Vinod K Bhutani 1 , Gary L Darmstadt https://orcid.org/0000-0002-7522-5824 1 Eric M. Foote https://orcid.org/0009-0007-3058-3306 1 , Farjana Jahan 2 , [...] Mahbubur Rahman 2 , Sarker Masood Parvez 2,3 , Tasnim Ahmed 1 , Rezaul Hasan 2 , Farzana Yeasmin 2 , Shams El Arifeen 4 , Sk Masum Billah 4,5 , Md. Mahbubul Hoque 6 , Mohammod Shahidullah 7 , Muhammad Shariful Islam 8 , Vinod K Bhutani 1 , Gary L Darmstadt https://orcid.org/0000-0002-7522-5824 1 PUBLISHED 05 Jan 2024 Author details Author details 1 Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA 2 Environmental Health and WASH, International Centre for Diarrheal Disease Research, Dhaka, 1212, Bangladesh 3 Children's Health and Environment Program, Child Health Research Centre, The University of Queensland, QLD, Australia 4 Maternal and Child Health Division, International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, -1212, Bangladesh 5 Faculty of Medicine and Health, Sydney School of Public Health, The University of Sydney, Sydney, Australia 6 Department of Neonatology, Bangladesh Shishu Hospital & Institute Dhaka, Dhaka, Bangladesh 7 Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 8 National Newborn Health Program (NNHP) and Integrated Management of Childhood Illness (IMCI), Directorate General of Health Services, Dhaka, Bangladesh Eric M. Foote Roles: Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing Farjana Jahan Roles: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing Mahbubur Rahman Roles: Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing Sarker Masood Parvez Roles: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing Tasnim Ahmed Roles: Writing – Original Draft Preparation, Writing – Review & Editing Rezaul Hasan Roles: Writing – Original Draft Preparation, Writing – Review & Editing Farzana Yeasmin Roles: Writing – Original Draft Preparation, Writing – Review & Editing Shams El Arifeen Roles: Writing – Original Draft Preparation, Writing – Review & Editing Sk Masum Billah Roles: Conceptualization, Writing – Review & Editing Md. Mahbubul Hoque Roles: Conceptualization, Writing – Review & Editing Mohammod Shahidullah Roles: Supervision, Writing – Review & Editing Muhammad Shariful Islam Roles: Supervision, Writing – Review & Editing Vinod K Bhutani Roles: Conceptualization, Writing – Review & Editing Gary L Darmstadt Roles: Conceptualization, Funding Acquisition, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Background Extreme hyperbilirubinemia leading to neurologic disability and death is disproportionately higher in low- and middle-income countries (LMIC) such as Bangladesh, and is largely preventable through timely treatment. In LMICs, an estimated half of all newborns are born at home and few receive screening or treatment for hyperbilirubinemia, leading to 6 million newborns per year who need phototherapy treatment for hyperbilirubinemia but are untreated. Household screening and treatment for neonatal hyperbilirubinemia with phototherapy administered by a trained community health worker (CHW) may increase indicated treatment for neonatal hyperbilirubinemia in comparison to the existing care system in Bangladesh. Methods 530 Bangladeshi women in their second or third trimester of pregnancy from the rural community of Sakhipur, Bangladesh will be recruited for a cluster randomized trial and randomized to the intervention arm — home screening and treatment for neonatal hyperbilirubinemia — or the comparison arm to receive usual care. In the intervention arm, CHWs will provide mothers with two prenatal visits, visit newborns by 2 days of age and then daily for 3 days to measure transcutaneous bilirubin (TcB) and monitor for clinical danger signs. Newborns without danger signs but with a TcB above the treatment threshold, but <15 mg/dL will be treated with light-emitting diode (LED) phototherapy at home. Newborns with danger signs or TcB ≥15 mg/dL will be referred to a hospital for treatment. Treatment rates for neonatal hyperbilirubinemia in each arm will be compared. Conclusion This study will evaluate the effectiveness of CHW-led home phototherapy to increase neonatal hyperbilirubinemia treatment rates in rural Bangladesh. LMICs are expanding access to postnatal care by using CHWs, and our work will give CHWs a curative treatment option for neonatal hyperbilirubinemia. Similar projects in other LMICs can be pursued to dramatically extend healthcare access to vulnerable newborns with hyperbilirubinemia. READ ALL READ LESS Keywords neonatal hyperbilirubinemia, community health workers, low to middle income country, global health Corresponding Author(s) Gary L Darmstadt ( [email protected] ) Close Corresponding author: Gary L Darmstadt Competing interests: No competing interests were disclosed. Grant information: This work was supported by the Gates Foundation [INV-017234]. This study was also funded by the Grand Challenges Canada (SB-POC-1810-20535). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2024 Foote EM et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Foote EM, Jahan F, Rahman M et al. Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.12688/gatesopenres.14033.2 ) First published: 21 Apr 2023, 7 :58 ( https://doi.org/10.12688/gatesopenres.14033.1 ) Latest published: 05 Jan 2024, 7 :58 ( https://doi.org/10.12688/gatesopenres.14033.2 ) Revised Amendments from Version 1 The new version of paper contains additional clarifying information requested by reviewers of the paper, notably including a change in the order of the study aims, additional detail on community health worker recruitment and training, and clarification of use of the phototherapy device and bilirubin thresholds for phototherapy. The new version of paper contains additional clarifying information requested by reviewers of the paper, notably including a change in the order of the study aims, additional detail on community health worker recruitment and training, and clarification of use of the phototherapy device and bilirubin thresholds for phototherapy. See the authors' detailed response to the review by Tina M. Slusher and Zubaida Farouk See the authors' detailed response to the review by Christian V Hulzebos See the authors' detailed response to the review by Jean-Baptiste Le Pichon READ REVIEWER RESPONSES Introduction Background Approximately 18% of all infants, including approximately 14 million infants per year in low- and middle-income countries (LMIC), are at risk of neonatal hyperbilirubinemia progressing to extreme hyperbilirubinemia and brain damage 1 . Of the 481,000 yearly cases of extreme hyperbilirubinemia, 80% occur in LMICs 1 . The highest burdens of extreme hyperbilirubinemia are in sub-Saharan Africa and South Asia, where the mortality rate of extreme hyperbilirubinemia and rhesus disease is about one hundred times higher and rates of neurologic disability are about eight times higher than rates in high income countries 1 . Too often, newborns in LMICs present at hospitals for treatment too late, having already developed brain damage from extreme hyperbilirubinemia, when phototherapy is no longer effective 2 . It is estimated that 6 million newborns in LMICs need treatment yearly yet do not receive it 3 . There are a cascading series of delays in diagnosis and treatment that occur, resulting in preventable disability and deaths of this time-dependent condition 4 . In many LMICs, more than half of newborns are born at home, where postnatal visits and physical examination screenings or laboratory screening for neonatal hyperbilirubinemia are rarely performed 5 . The World Health Organization (WHO) in the Integrated Management of Childhood Illness (IMCI) guidelines, recommend neonates in LMICs receive home or clinic-based physical examination screenings followed by a referral to a hospital if there is concern for hyperbilirubinemia 6 , 7 . Physical examination-based screening by physicians prior to hospital discharge has been shown in one LMIC to be less effective in reducing cases of severe hyperbilirubinemia than transcutaneous bilirubin (TcB) screening 8 . In LMICs, infants born in health facilities by vaginal delivery are often discharged without bilirubin screening after less than 24 hours leading to missed cases of severe hyperbilirubinemia 8 . Parents often only realize that their child is sick when their newborn develops symptoms from brain damage. Even if newborns are diagnosed in a timely fashion, hospital-based treatment for newborns in LMICs is difficult to access and expensive for families. In a study on neonatal sepsis in rural Bangladesh, only one-third of newborns that were referred to the hospital from home for physical examination findings concerning for sepsis went to the hospital 9 . The costs of bringing the newborn to the hospital and obtaining care were found to be major barriers 9 , 10 . However, families were willing to have their newborns treated at home. Approximately 65% of parents who refused referral for neonatal sepsis evaluation in hospitals consented to home care by CHWs with intramuscular injection with antibiotics, increasing access to care and reducing neonatal mortality by 34% 9 . By providing household treatment for neonatal hyperbilirubinemia, essential care can be expanded to families that would otherwise not have access to treatment, potentially reducing disability and death from neonatal hyperbilirubinemia. Families will not have to travel to hospitals, wages will not be lost from taking days off from work, the cost of nurses and physicians will be replaced with less expensive and easier-to-train CHWs, and hospital bed costs will be eliminated. The risk of newborn exposure to hospital borne infections would also be eliminated. Home screening and treatment for neonatal hyperbilirubinemia has the promise to increase access to treatment and reduce cases of extreme hyperbilirubinemia 11 . Study aims and hypothesis We hypothesize that CHW-led household screening and treatment for neonatal hyperbilirubinemia will increase the rate of indicated treatment for neonatal hyperbilirubinemia when compared to current practices in rural Bangladesh. Aim 1 (Treatment) Assess the impact of CHW-administered home screening and neonatal hyperbilirubinemia treatment on treatment rates in comparison to the current postnatal care system in Bangladesh. The percentage of newborns that receive treatment for neonatal hyperbilirubinemia in the intervention and comparison clusters will be compared. We will evaluate the safety of CHW-administered LED phototherapy. We will measure the number of referrals for danger signs after starting home phototherapy, the need for exchange transfusion after starting home phototherapy, the development of extreme hyperbilirubinemia after starting home phototherapy (total serum bilirubin, TSB) ≥25 mg/dL, the development of severe hyperbilirubinemia (TSB ≥20 mg/dL) after starting home phototherapy, sepsis diagnosed after starting home phototherapy, and newborns diagnosed with hypoglycemia after starting home phototherapy. The acceptability of home and hospital hyperbilirubinemia screening and phototherapy treatment will be assessed qualitatively. Aim 2 (Screening) During appropriately timed home visits, CHWs will screen infants for neonatal hyperbilirubinemia. We will demonstrate: At least 80% of newborns born vaginally in intervention households are screened for neonatal hyperbilirubinemia by two days of age. Aim 3 (Prevention) Develop and conduct two maternal prenatal educational sessions supervised by CHWs in intervention households to encourage breastfeeding initiation within one hour of birth and exclusive breastfeeding through six months of age and help mothers to develop a plan for how to get to the nearest hospital with newborn services if their newborn is sick. We will demonstrate: An absolute increase of at least 20% in breastfeeding rates by one hour of age and exclusive breastfeeding rates through four weeks of age in intervention families. Trial design We will conduct a prospective cluster randomized controlled trial to evaluate the impact of CHW-led home screening and treatment for neonatal hyperbilirubinemia on the percentage of newborns treated for hyperbilirubinemia. In the intervention arm, CHWs will provide home hyperbilirubinemia screening and home treatment with phototherapy or referral for hospital treatment. In the comparison arm, newborns will receive treatment based on the current postnatal care system in rural Bangladesh, where newborns are referred for evaluation for hyperbilirubinemia based on parental concern and physical examination findings during postnatal visits. Methods Study design Study setting This study will enroll pregnant mothers in Sakhipur, Bangladesh, which is a rural agrarian community with a population of 300,000. It is 429 square kilometers in area, includes 132 villages, and is a part of the Tangail District. There are approximately 7,000 births in this community per year and approximately half of births occur at home 12 . There is a government hospital with 50 beds that provides caesarean section, vaginal birthing services, and emergency services 12 . Poverty, crowding, unstable housing, food insecurity, and poor hygiene and sanitation are common throughout the region. Study population About 98% of pregnant women in Sakhipur sub-district receive at least one antenatal care visit from a trained medical provider, and 66% of women receive four antenatal care visits 12 . Approximately half of the mothers deliver at home 12 . Approximately 60% of newborns are seen by a health care provider within the first 48 hours after birth 12 . If neonatal hyperbilirubinemia is diagnosed and phototherapy is needed, newborns are referred for phototherapy treatment to the nearest hospital, which is more than two hours away. Sample size Approximately 18% of infants need treatment for neonatal jaundice 1 . We estimate that of the neonates born in facilities, half of those in need of treatment actually receive the indicated treatment and for home births, none receive the indicated treatment 1 . The indicated treatment rate in the comparison arm will be 25%, or 4.5% of infants. In the intervention arm, we expect that we can provide home phototherapy in 60% of cases of neonatal hyperbilirubinemia that need treatment. Of the other 40% of infants that we identified and referred to the hospital for treatment, we estimate that 33% will receive treatment 9 . The total indicated treatment rate is estimated at 80%, or 14.4% of infants. With a type 1 error rate of 5% and type 2 error rate of 20%, and a design effect of 1.6 due to cluster sampling and a loss to follow-up of 5%, the sample size is 262 in each arm. We aim to enroll 530 pregnant mothers from the Sakhipur sub-district. Participant recruitment The trial will receive oversight from the steering committee composed of eight investigators from icddr,b, three investigators from Stanford University, one investigator from Dhaka Children’s Hospital, and one investigator from Bangabandhu Sheikh Mujib Medical University. Trained fieldworkers from icddr,b will travel to the eligible communities and ask community leaders for permission to conduct research within their community. If the community leaders agree, then the team will proceed with recruitment. The prospect of participation in the study will be discussed with adults in the communities, including the pregnant mothers. The scientific field team will go house-to-house to list all the pregnant women on the basis of documentation of their pregnancy ( i.e. , possession of an antenatal care (ANC) card and/or prescription from the selected unions of the sub-district) to enroll them as study participants if they meet the eligibility criteria. If any pregnant mother does not have an ANC card, but is willing to participate in the study, she will be sent to local health facilities to register for an ANC card. Before recruitment, we will reach out to local government workers to identify pregnant women in the second or third trimester. They maintain a register of all newlyweds and update new pregnancies to encourage ANC, safe delivery and postnatal care services. In addition, the trained fieldworkers will travel to the eligible communities to create an enabling environment to conduct the research in their community. Field workers will confirm that participants have access to a mobile phone. Written informed consent will be obtained from interested participants prior to beginning the study. Inclusion criteria Study participants will be pregnant women 18 years of age or older in their second or third trimester of pregnancy and who consent to enroll as study participants. Exclusion criteria Study participants will be excluded if there is a multiple gestation pregnancy, future plans to leave the area within the next 12 months (e.g., if a mother is planning to give birth at her natal home and then return later to the study area, she will not be a candidate for enrollment), if maternal danger signs are present, if there is a history of severe mental health condition, defined as any mental condition either medically diagnosed or reported by family to affect activities of daily living. There are no inclusion or exclusion criteria for newborns born to study participants. All newborns born to enrolled mothers will be enrolled. A timeline of the study period is described in Table 1 . Table 1. Study timeline. Study period Enrolment Allocation Post-allocation Close- out Timepoint** Month (M) 1–3 M 1–3 M 4–5 M6–7 M8–9 M 10–11 M 12–13 M 14–15 Enrolment: Eligibility screen X Informed consent X Baseline survey, blood grouping of parents X Allocation X X INTERVENTIONS: [Intervention 1-Prenatal educational sessions] [Intervention 2- Transcutaneous bilimeter screening for neonatal hyperbilirubinemia] Intervention 3: Home treatment or hospital referral for treatment for neonatal hyperbilirubinemia ASSESSMENTS: [Socio-demographic variables, obstetrical history, antenatal care history, medical history, breastfeeding, neonatal hyperbilirubinemia knowledge, attitude and practice] X X [breastfeeding within 1 hour of childbirth, hyperbilirubinemia screening within 48 hours of birth, treatment for neonatal hyperbilirubinemia] X X X X X Changes in knowledge, attitude, practice for breastfeeding and neonatal hyperbilirubinemia X X X X X Cluster randomization and intervention allocation Amongst eligible participants, we will form clusters of 25–29 expectant mothers who live close enough to participate in the study based on the geographical proximity ( Figure 1 ). There will be a minimum distance of one hundred meters between households. There will be a minimum distance of one kilometer between clusters. Households that do not form a cluster according to geographical proximity will not be included in the cluster. A statistician not involved in the study will randomly assign 20 clusters using a random number generator. Clusters will be divided equally across intervention and comparison arms. Given the nature of treatment in the intervention group, masking of participants and caretakers will not be feasible in the intervention group. CHWs will know if they are delivering the intervention. However, care will be taken to ensure that the outcome assessors are not aware of the interventions allocated to specific clusters. Individuals involved in delivering the intervention and the evaluation will have minimal contact to minimize bias. Figure 1. Randomization scheme: CONSORT flow diagram. Community health workers recruitment and training CHWs will be recruited through local advertisements and supervised by the Bangladesh-based scientific team. The eligibility criteria to become CHWs include female gender (due to cultural sensitivities with providing breastfeeding support), at least 20 years of age, completion of secondary school, and a minimum passing score of 60% on the written test. The written test will assess the candidates’ knowledge on community mobilization and sensitization. Candidates for study CHWs do not need previous experience as a healthcare worker. Work experience with government community groups will be considered favorably as a hiring criterion. Twelve CHWs who meet the requirements for initial CHW enrollment will be invited for a five-day training conducted by icddr,b staff and physicians from Dhaka Children’s Hospital and physicians from Sakhipur Health Complex. The training model is adopted from the “Validation of community health workers’ assessment of neonatal illness in rural Bangladesh” by Darmstadt et al . 13 The training will contain didactic and hands-on portions taught by physicians at icddr,b, Dhaka Children’s Hospital and the local referral hospital. The first phase of training will be three days and cover the following topics: neonatal jaundice and responsibilities of CHWs, pregnancy care and maternal danger signs, delivery planning and safe delivery preparations, newborn care, infection prevention practices, breastfeeding and management of breastfeeding problems, risk of developing neonatal jaundice and management, neonatal jaundice symptoms and causes, communication and counselling. CHW knowledge acquisition will be assessed by a pre-test and post-test evaluation. The second phase of training over two days at Dhaka Children’s Hospital will primarily focus on hands-on teaching and include the following topics: recognizing neonatal illness and common neonatal problems, newborn danger sign assessment, postnatal services and the responsibilities of CHWs, referral process for sick newborns, neonatal jaundice symptoms and causes, management of neonatal jaundice in the home, and training on use of equipment (transcutaneous bilimeter, phototherapy device, thermometer). Bedside training will include danger sign assessment of neonates and using the transcutaneous bilimeter and phototherapy device. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. There will also be a pre-test and post-test assessment on the content of the second phase of training. Then, the CHWs will be observed performing physical examinations and using equipment in the field for three days under supervision from the study physician. The ten CHWs that performed best on the assessments will be invited to participate in the study. The study physician will observe CHWs’ neonatal danger sign assessments over the course of the study to evaluate the sensitivity and specificity of CHW newborn danger sign assessments in comparison to a physician examination. The study physician will repeat the newborn danger sign assessment independently within 4 hours of the CHW assessment. The study physician will repeat 20% of the newborn danger sign assessments conducted by each CHW. The sensitivity and specificity of CHW physical newborn examination in identifying newborns with clinical danger signs will be determined in comparison to a physician’s physical examination. Feedback will be given to CHWs based on their danger sign assessments. In addition, the study physician and field staff will observe CHWs administering home phototherapy and provide feedback as necessary. CHWs will be taught how to operate the phototherapy device during training at Dhaka Children’s Hospital and in the field. They will be trained to measure the irradiance of the phototherapy unit and that it should measure at least >50 μW/cm2/nm prior to initiating treatment. They will be taught to educate parents on how the newborn should be treated with phototherapy in their absence, and to call the CHW if they need additional help. CHWs will be trained to complete the following operational and educational checklist with caregivers prior to initiating phototherapy. The operational checklist will also be completed at each follow-up visit. CHW Phototherapy Operational Checklist Measured temperature between 25°C -27°C within the bassinet; if the temperature could not be maintained between 25°C -27°C, an electric heater will be provided to maintain the temperature between 25°C -27°C within the bassinet. If this fails, the infant will be referred to the hospital for treatment. Bassinet is covered by a white blanket. Phototherapy device is placed in a safe place on a flat surface. Phototherapy device has a household power source and would turn on. Infant is in a bassinet face-up with eye cover and diaper and no other clothes on. Review of parental log on daily number of breastfeeding attempts, urination, and defecation and if the phototherapy unit was turned off overnight from 0000-0600. CHW Educational Checklist for mothers and caregivers whose newborn will be treated with home phototherapy. CHW to explain the need to treat the newborn with phototherapy for neonatal hyperbilirubinemia. CHW explains that newborns will be treated for 2 days with phototherapy with two 6-hours breaks at night from midnight to 6 am, for approximately 36 hours of phototherapy treatment. CHW explains that mothers should take newborns out from under the phototherapy lights to breastfeed their newborns every two to three hours for approximately twenty to thirty minutes. CHW will return in four to six hours and then daily until phototherapy treatment and post-treatment monitoring was completed. CHW explains how the phototherapy device works and how to operate the phototherapy device in the absence of CHWs. The phototherapy device should be in a safe space on a flat surface. How to cover the newborn’s eyes with a mask when the newborn was being treated with phototherapy. Infant to be placed in phototherapy bassinet face-up with eye cover and diaper and no other clothes on during treatment. Phototherapy unit covered by a white blanket. Instruction on how to use a provided chart to record the daily number of breastfeeding attempts, urination, and defecation and if the phototherapy unit was turned off overnight from 0000-0600. How to use diapers during phototherapy, to clean and dry the bassinet if it gets soiled. Monitor the newborn for danger signs and contact the designated CHW if any issue arose, 14 and to bring their newborn to the hospital if concerned. If the phototherapy device is turned off for more than 2 hours and unable to turn back on due to power loss, bring the newborn to the hospital. Call the CHW if there were issues or questions. We will also conduct a training session with the staff nurses and medical officers of the referral hospital to orient them to the study intervention and ensure proper management of referred newborns. Field staff along with the training team will review performance (knowledge, skill, and attitude) of CHWs every two weeks and provide advice and trainings to maintain skills. Each CHW will manage the care of approximately twenty newborns per month over the course of the study. On average each CHW will perform three home visits per day. Study households will be within one-hour travel time for the CHWs. Intervention arm Intervention 1: Breastfeeding and neonatal hyperbilirubinemia module development We will develop a CHW-led prenatal education module to encourage early and frequent breastfeeding, including initiation within one hour after birth and exclusive breastfeeding through six months of age, and to educate mothers on the neonatal and maternal danger signs as well as the dangers of severe neonatal hyperbilirubinemia 14 . The module will help mothers develop a plan to bring their newborn to an appropriate health facility, if necessary, after birth. We will adapt the guideline from Bangladesh Ministry of Health Comprehensive Newborn Care package 15 . We will share the guideline with our key stakeholders to incorporate their recommendations to make the modules more feasible for CHWs. CHWs will visit enrolled pregnant mothers and conduct two prenatal education sessions which will increase awareness among mothers and other household members about exclusive breastfeeding and risk of neonatal hyperbilirubinemia. The sessions will include education on the importance of attending recommended antenatal and postnatal newborn and maternal care visits, delivery preparation, ante partum, intrapartum and postpartum danger signs, neonatal danger signs, exclusive breastfeeding, and neonatal hyperbilirubinemia (including signs, symptoms, screening via transcutaneous bilimeter and possible need for treatment in the hospital or at home with phototherapy). Newborns in the intervention arm are not restricted from receiving neonatal hyperbilirubinemia care through the existing postnatal care system. Intervention 2: Blood and rhesus typing, noninvasive TcB screening newborns for neonatal hyperbilirubinemia and evaluation of newborn danger signs The mother’s blood and rhesus type will be determined at the birth survey visit, if it was not already determined during antenatal visits, by a medical technologist. Newborn blood grouping and rhesus typing will be determined at the birth survey visit by a medical technologist. Three drops of blood will be collected using a lancet needle. For newborns, the specimen will be taken by heel prick and for mothers it will be taken by the finger prick. The slide test method will use anti-monoclonal blood type antibodies for each blood type and anti-D monoclonal antibodies. We define rhesus incompatibility to be when the mother is rhesus negative and the newborn is rhesus positive, and we define blood type incompatibility to be when the mother is blood group O, and the newborn does not have blood group O. If rhesus incompatibility is present, we will refer the mother for rho(D) immune globulin treatment at a local health facility if she has not already received treatment. We will follow the neonatal hyperbilirubinemia management algorithm in Figure 2a that we developed following the 2004 American Academy of Pediatrics (AAP) guidelines ( Figure 2b ), using intensive >30 μW/cm2/nm irradiance, clinically approved, LED phototherapy (Firefly, Figure 3 ) 16 . CHWs will be supported by an electronic tablet that guides them through the clinical management algorithm ( Figure 2a ) step-by-step. Figure 2a. Neonatal hyperbilirubinemia management algorithm. Figure 2b. Home Phototherapy Transcutaneous Bilirubin Thresholds. Newborns that were at least 35 weeks gestation, had a birthweight of at least 2 kilograms and had no danger signs were eligible for home phototherapy if the transcutaneous bilirubin < 15mg/dL (below solid black) but above the appropriate dotted line based on the 2004 AAP neonatal hyperbilirubinemia management guidelines, or if the transcutaneous bilirubin was = 0.2 mg/dL/hour during home visits. Figure 3. Phototherapy device in use with white blanket covering (Firefly) (Source: icddr,b). Total bilirubin will be measured using a transcutaneous bilimeter (Draeger JM-105). Transcutaneous bilimeters tend to overestimate the serum bilirubin concentration at TcB levels 15 mg/dL, transcutaneous bilimeters do not approximate the serum concentration as well, which is why we will refer all newborns with a TcB >15 mg/dL to the hospital to obtain a serum bilirubin and evaluation by a medical provider 18 , 19 . The assigned CHW will visit each newborn born vaginally within two days after birth and newborns born via caesarean section will be visited the day after hospital discharge then daily for three consecutive days to assess for hyperbilirubinemia and evaluate breastfeeding and institute phototherapy if indicated. During CHW visits, if any danger signs are observed, CHWs will refer newborns to an appropriate medical facility. The phototherapy treatment level is the 2004 AAP phototherapy threshold adjusted for gestational age, and presence of rhesus or blood type incompatibility or if the bilirubin is rising ≥0.2 mg/dL/hour on consecutive visits ( Figure 2b ). Newborns eligible for home treatment will be treated with CHW-led LED phototherapy. The following neonatal and maternal danger signs were adopted from the National Neonatal Health Strategy 2009 and research done in Bangladesh to validate neonatal danger signs to predict need for hospital-based care 19 – 22 . If any of the following neonatal danger signs are present on CHW assessment, the newborn will be referred to the nearest appropriate medical facility for treatment. 1. Poor feeding 2. History of convulsions 3. Tachypnea (>60 breath/min on two consecutive readings) 4. Severe chest in-drawing 5. Hypothermia (37.5 °C or 99.5°F) 7. Movement only when stimulated or no movement at all 8. Umbilical redness extending to abdominal skin 25 9. No void within 24 hours 10. Jaundice of palms or soles (irrespective of measured TcB value) 7 , 26 11. Newborns <35 weeks of gestation 12. Newborn birthweight <2000 grams If the newborn temperature is between 95.9°F and 97.5°F Kangaroo Mother Care at home will be advised 27 . CHWs will also assess for the following maternal danger signs and refer the mother to an appropriate medical facility if any danger sign is present 27 . 1. Any increase in vaginal bleeding 2. Any history of convulsion after delivery 3. Fast or difficulty breathing 4. Chest pain 5. Fever 6. Too weak to get out of bed 7. Severe headache CHWs will make a lactation assessment of the feeding of the newborn and offer the mother tips to improve breastfeeding. Intervention 3: Home management of neonatal hyperbilirubinemia by LED phototherapy The following are the inclusion criteria for newborn home phototherapy. At least one must be present: a) TcB above the AAP phototherapy threshold adjusting for gestational age and presence of rhesus or blood type incompatibility ( Figure 2b ) 16 . b) TcB rising ≥ 0.2 mg/dL/hour The following are the exclusion criteria for newborn home phototherapy: a) Birthweight <2000g b) Gestational age < 35 weeks c) Newborn danger signs present d) Maternal danger signs present e) TcB ≥ 15 mg/dL All newborns will be treated with phototherapy for a 48-hour period. Newborns will be recommended to be placed under the phototherapy lights unless they are feeding, which we estimate to be 30 minutes every three hours and there will be a six-hour phototherapy break overnight. The total treatment duration will be approximately 36 hours of phototherapy, 18 hours per day. The phototherapy device will be checked by the CHW before each use in the home using the manufacturer recommended irradiance meter (Lightmeter V7.0) to ensure that the irradiance is at recommended levels of at least 50 µW/cm 2 /nm. The phototherapy unit will be covered by a white blanket to maintain the temperature and to enhance phototherapy effectiveness. The CHW will measure the temperature inside the phototherapy unit on initiation and during each subsequent visit with a target of 25°C-27°C under the blanket inside the unit. A portable room heater will be available to maintain the room temperature during phototherapy treatment. After diagnosing the need for home phototherapy, the CHW will initiate phototherapy within four hours. CHWs will perform the operational checklist at each phototherapy visit and educate parents following the educational checklist. Parents will be instructed when to seek emergency care. The CHW will survey mothers during phototherapy to explore potential issues with treatment. During home phototherapy treatment, newborns will be evaluated by a CHW daily. If any maternal or newborn danger signs are present, home phototherapy will be stopped, and the newborn or mother will be referred to the nearest appropriate health facility. CHWs will answer any questions parents have about the treatment. CHWs will be able to consult the study physician by phone if there are concerns or questions. Monitoring after home phototherapy CHWs will visit the household daily for two days beginning the day after phototherapy completion and measure the TcB on consecutive days and assess for danger signs ( Figure 2a ). We will consider any newborn that has a TcB <15 mg/dL for two consecutive days after treatment and rising <0.2mg/dL/hour to have resolved hyperbilirubinemia. If the TcB is ≥15 mg/dL or rising ≥0.2mg/dL/hour on the second follow up visit, we will refer the newborn to the hospital for evaluation. If the newborn requires subsequent hospital admission after initial qualification for phototherapy, we will define that as unresolved hyperbilirubinemia. Transcutaneous bilimeters are not as reliable to measure the progress of phototherapy during treatment, as TcB values are less than the serum value while phototherapy is occurring. After 16–24 hours after phototherapy treatment is completed, their reliability is similar to before phototherapy 28 , 29 . We will perform TcB measurements on consecutive days beginning 24 hours after phototherapy to ensure that the transcutaneous bilirubin remains below the treatment threshold and is not rising rapidly. If the family refuses treatment at home, the newborn will be referred to the hospital for treatment. If they refuse home and hospital treatment, CHWs will continue to follow up with the newborn and make three consecutive daily visits in each household and refer the newborn to the hospital if indicated. Mobile health (mHealth) data collection and decision support CHWs will use a program that we developed on CommCare (Dimagi, Cambridge, USA) that is uploaded on electronic handheld tablets to guide CHWs through each task during each encounter with participants ( Figure 4 ). The program will identify which study arm the participant is in and follow the protocols for that arm. The program will guide CHWs on data collection including newborn gestational age calculation, newborn age in hours calculation, newborn and mother danger sign assessment, and TcB measurement and management. The application will calculate an estimated delivery date based on the first day of the last menstrual period collected at the baseline survey and add 280 days. The gestational age will be calculated by subtracting the birth date from the first day of the last menstrual period. The age in hours of TcB measurement will be based on the mother informing the CHW of the time of birth and by reviewing any childbirth records. CommCare will then calculate the age in hours based on the current time and subtracting the time of birth. The age in hours, TcB, gestational age, blood group or rhesus incompatibility between the mother and the newborn will determine the phototherapy threshold for each newborn based on the 2004 AAP guidelines and hours of age for the newborn ( Figure 2b ) 14 . The data on the blood and rhesus type will be entered and stored in CommCare at the time of collection. The rate of rise of TcB will be calculated by CommCare by subtracting the TcB measured the previous day from the current day’s TcB and dividing by the hours that elapsed between the two measurements. Figure 4. Mobile health CommCare platform with newborn danger sign assessment (Source: icddr,b). On completion of newborn danger sign assessment, transcutaneous bilirubin measurement, and maternal danger sign assessment, CommCare will help the CHW decide if the newborn needs to be referred to the hospital for care or can be treated at home with phototherapy for neonatal hyperbilirubinemia. CHWs will be encouraged to consult the study physician by phone or in person if there are concerns or questions. Laboratory evaluation of all newborns referred for danger signs or TcB ≥15 We will obtain the following laboratory studies for any newborn referred for hospital evaluation for danger signs or TcB ≥15 mg/dL: blood glucose, total serum bilirubin and blood culture. Blood glucose will be tested using a rapid field test kit. Hypoglycemia will be defined as serum glucose <50 mg/dL. Serum bilirubin will be tested in Sakhipur Health Complex using a Garnier G-3000 semi-auto analyzer and end point, kinetics, fixed-time, 2-point kinetic, absorbance coagulation method. Blood cultures will be collected by a trained medical technologist from icddr,b with assistance of trained staff nurses of Sakhipur Health Complex. At least 1 mL of blood will be collected, and the specimen will be transferred to icddr,b laboratory within 12 hours of collection. If Candida or multiple bacterial species are identified, the case will be discussed with the study physician and blood cultures will be repeated as indicated to verify the growth as an infection versus the result of contamination. Coagulase-negative Staphylococcus , Diptheroids , and Bacillus species will always be considered to be contaminants. Culture reports of growth or no growth will be provided to the clinical care team within 24 hours. Blood culture measurement will help validate CHW danger sign assessments and to determine if infection may have been a cause for neonatal hyperbilirubinemia. There will be a study physician who will coordinate with hospital and district level managers for any referral issues. Both secondary and tertiary level facility service providers will receive orientation on the study protocol and referral processes. Any newborn who requires exchange transfusion will be referred to Dhaka Children’s Hospital in Dhaka, Bangladesh. During trial implementation, a field monitoring team consisting of a field research officer, a study physician, and a field coordination manager will regularly visit the field to monitor the intervention delivery. The primary responsibility of this team is to monitor if the intervention has been delivered following guidelines, identify, and solve problems regarding field implementation and report to the investigators. Equipment Transcutaneous bilirubin will be measured by Draeger JM-105. Draeger JM-105 is a non-invasive transcutaneous bilirubinometer which has demonstrated high accuracy when compared to total serum bilirubin 30 . Phototherapy treatment will be provided by a double surface portable LED phototherapy device with battery backup, Firefly ( Figure 3 ). Peak wavelength is 455 to 470 nm, lamp duration is 44,000 hours to 30% degradation. Top light: irradiance 34.8 µW/cm 2 /nm, surface area: 53 cm × 25 cm, irradiance uniformity ratio 0.51 (IEC Compliant > 0.4). Bottom light: irradiance 50.4 µW/cm 2 /nm, surface area 50 cm × 20 cm irradiance uniformity 0.72. The overhead light position is fixed at 49.5 cm above the bottom of the device. The dimensions of the bottom of the unit are 66 cm by 38 cm and it weighs 13 kilograms. The LED phototherapy device has an internal battery backup that can maintain operation for 12 hours in case of power outages. The irradiance of the device will be measured using the manufacturer recommended irradiance meter (Lightmeter V7.0). A portable room heater will be available if needed to maintain the temperature between 25°C and 27°C within the bassinet at home during phototherapy. Comparison arm (Existing postnatal care system) In the comparison arm, newborns will receive treatment for neonatal hyperbilirubinemia based on the current postnatal care system in rural Bangladesh. Approximately 7% of newborns born at home have a postnatal visit within 48 hours and are unlikely to be evaluated for neonatal hyperbilirubinemia in a time frame that would result in timely treatment. Infants born vaginally in a hospital delivery often spend 4–8 hours in the hospital prior to discharge. Infants born by vaginal delivery in the hospital or by caesarean section typically have a postnatal care visit by two days of age. If the mother has a concern about the health of their newborn, including concern for jaundice, they may bring the child to the healthcare system, leading to physician assessment, and recommendation for testing. Evaluation plan Baseline survey A group of field research assistants will conduct a baseline survey of all mothers at the time of enrollment. The survey will assess each mother’s previous medical history, family history of treatment for hyperbilirubinemia, family history of disability from hyperbilirubinemia, and family history of hearing loss. The survey will also collect information on parental socioeconomic factors, knowledge of breastfeeding and neonatal hyperbilirubinemia, delivery plans, and plans for emergency neonatal and maternal care. Figure 1 illustrates the various steps for each arm in the study. Birth survey We will establish a direct contact system to inform the research team about a study participant’s delivery. The mother and the head of the household will be given the emergency contact number of the research team. They will be instructed to inform the research team once the mother is in labor. The survey will occur approximately one day after discharge of the hospital or by two days of age for home births in intervention households and by seven days of age in comparison households. The assigned field worker will go to the home and survey the family on the circumstances of the birth, inquire on how long after birth breastfeeding was initiated, measure the birth weight, and calculate the gestational age based on last menstrual period and birth date with the assistance of an electronic tablet. Endline survey We will carry out a household survey in each study arm at infant age four weeks to evaluate the health status of the newborns. We will survey for newborn hospitalizations, maternal hospitalizations, presence of neonatal hyperbilirubinemia, screening for neonatal hyperbilirubinemia with blood or TcB measurement, phototherapy treatment for hyperbilirubinemia, neonatal sepsis, exclusive breastfeeding percentage, and maternal depression. The endline survey data will be used to evaluate if the newborn received phototherapy treatment for hyperbilirubinemia. Primary outcome The primary outcome will be the proportion of neonates that receive phototherapy treatment, either at home or in a facility in each study arm. At the end of this intervention period, we will compare the primary outcomes between the intervention and comparison newborns using a chi-square test while adjusting for cluster study design. The significance level will be p <0.05. The quantitative analysis will be conducted by the original assigned groups in an intention-to-treat analysis. Investigators will have no access to outcome data until field activities are complete. CONSORT guidelines will be followed to conduct the analysis 31 . This analysis will be conducted by the scientific team using a variety of software including R Project for Statistical Computing (RRID:SCR_001905) and STATA RRID:SCR_012763). We are not planning an interim analysis. Secondary outcomes Secondary outcomes include the proportion of mothers who initiated breastfeeding within one hour of childbirth in each study arm, the percentage of mothers exclusively breastfeeding at four weeks in each study arm, the proportion of neonates born vaginally that are screened for neonatal hyperbilirubinemia by 48 hours of age in each study arm, and any neonatal deaths during that period in each study arm. At the end of this intervention period, we will compare these secondary outcomes between intervention and comparison group newborns using chi-square test while adjusting for cluster study design. The significance level will be p <0.05. The quantitative analysis will be conducted by the original assigned groups in an intention-to-treat analysis. We will also evaluate for safety measures in Table 2 . This includes the number of referrals for danger signs after starting home phototherapy, the need for exchange transfusion after starting home phototherapy, the development of extreme hyperbilirubinemia (total serum bilirubin ≥25 mg/dL) after starting home phototherapy and severe hyperbilirubinemia (total serum bilirubin ≥20 mg/dL) after starting home phototherapy. We will measure the number of newborns with sepsis (positive blood culture) diagnosed after starting home phototherapy, and the number of newborns diagnosed with hypoglycemia (serum blood glucose <50 mg/dL) after starting home phototherapy. Table 2. Safety outcomes assessed after home phototherapy was started. % newborns with resolved hyperbilirubinemia after starting home phototherapy % newborns referred to the hospital for treatment for phototherapy at the first visit after completing home phototherapy % newborns referred to the hospital for treatment for phototherapy at the second visit after completing home phototherapy % newborns with total bilirubin ≥20mg/dL % newborns with total bilirubin ≥25mg/dL % newborns receiving exchange transfusion % newborns exclusive breastfeeding % newborns with any formula feeding % newborns completed 36 hours of phototherapy % newborns receiving intravenous fluids % newborns with hypothermia (temperature <35.5°C) % newborns whose mothers refused treatment after starting home phototherapy Number of newborn deaths Number of newborns with acute bilirubin encephalopathy % newborns with sepsis diagnosed Number of newborns with positive blood culture % newborns diagnosed with hypoglycemia Missing data CHWs will communicate with the participants throughout the study over the phone to monitor their health condition. This will build a sense of trust and reliability between study participants and CHWs. The research team will also arrange community meetings to gain overall community and community leader support on neonatal hyperbilirubinemia screening and management. This outreach will be integral to encouraging protocol adherence. However, in the case of protocol non-adherence we will use an intention to treat analysis to assess the main study outcome. For any other missing data, we will document the cause of missing data. For analysis, we will not count the missing data and will set the denominator excluding the missing data Data and safety monitoring board (DSMB) and safety review plan An independent five-member DSMB will be assembled in Bangladesh to monitor adverse events and to advise investigators. The board will be composed of two neonatologists, two epidemiologists, and one demographer. We will collect data on treatment progress, side effects of treatment, and adverse events during the study. The indicators to be monitored and reported to the DSMB are listed below, as specified by the research team: i) Number of newborns referred to the hospital due to danger signs after starting phototherapy at home ii) Number of newborns died from to neonatal hyperbilirubinemia at home or hospital after starting phototherapy iii) iv) Number of newborns that developed severe hyperbilirubinemia (total serum bilirubin ≥ 20 mg/dL) after starting home phototherapy v) Number of newborns that developed extreme hyperbilirubinemia (total serum bilirubin ≥ 25 mg/dL) after starting home phototherapy vi) Number of newborns needing exchange transfusion after starting home phototherapy vii) Number of newborns with acute bilirubin encephalopathy after starting home phototherapy viii) Number of newborns with sepsis diagnosed after starting home phototherapy ix) Number of newborns diagnosed with hypoglycemia after starting home phototherapy. x) Number of newborns with hypothermia after starting home phototherapy Any cases of acute bilirubin encephalopathy, exchange transfusion, or death during the trial will be considered a serious adverse event and reported to the DSMB. The investigators will report serious adverse events to the DSMB within 24 hours of the event. For any serious adverse event, a follow-up report will be submitted withing 48 hours and a final report will be submitted within 72 hours of first report submission. The DSMB will be responsible for evaluating the event and decide if the principal investigator’s report is satisfactory or not. If the event is not a serious adverse event but determined by the principal investigator to be reportable, an initial report will be submitted to the DSMB as soon as possible, but no later than seven days after the investigators learns of the event. The DSMB will disseminate the outcome of the review to the principal investigator of the study. Side effects from phototherapy treatment are rare and the AAP regards the treatment as safe 16 . A rare complication of phototherapy, bronze baby syndrome, occurs in some infants with cholestatic jaundice when treated with phototherapy 32 . With exposure to phototherapy, infants develop a dark, gray-brown discoloration of skin, urine, and serum. For newborns with a bilirubin above the phototherapy threshold, it is recommended to treat infants with cholestatic jaundice with phototherapy. The incidence of cholestatic jaundice in newborns is 1 in 2500 33 . Not all newborns with cholestatic jaundice need phototherapy and the long terms effects of bronze baby syndrome are not thought to be deleterious and resolve over time. CHWs will screen and monitor to determine the possibility of the development of this complication. Another possibility is the development of purpura or bullae in infants with cholestatic jaundice or congenital erythropoietic porphyria 34 . There are approximately 200 cases of congenital erythropoietic porphyria reported. Because the photosensitivity and blistering can be severe in infants with porphyria, infants who have this diagnosis or a positive family history for this disorder have an absolute contraindication for phototherapy. CHWs will screen and monitor neonates to determine the possibility of the development of this complication. Qualitative analysis We will use focus group discussions (FGD) and in-depth interviews (IDI) to assess barriers and facilitators of home treatment and hospital treatment amongst the implementers and the participants. Discussions will assess for challenges with using the phototherapy device and explore mothers’ concerns with the treatment and whether they felt they could ask for help in using the device. We will explore if mothers felt like using the device made breastfeeding more difficult. Facilitators will query if CHWs provided adequate explanations for why treatment was necessary and if they educated the mother sufficiently on how to do the treatment. For mothers whose newborns were referred to the hospital for treatment, we will assess if there was difficulty breastfeeding due to treatment, if there was difficulty traveling to the hospital, and if the hospital provided adequate resources for treatment. We will discuss barriers and facilitators of a successful referral to the hospital. Facilitators will query if CHWs provided adequate explanations for why referral was needed. Facilitators will explore mothers’ comfort with CHWs and their trust in their recommendations. We will explore if diagnosis of hyperbilirubinemia needing treatment with the transcutaneous bilimeter was more likely to result in successful referral in comparison to diagnosis with danger signs by CHW physical examination. Data collection plan for qualitative analysis The qualitative data will be collected by qualitative researchers, and they will be trained on the proposed guideline before going to the field. The collection plan is outlined in Table 3 . All the IDIs and FGDs will be recorded using audio recorders. The research team will take field notes of informal discussions, observations on the tone and attitudes of the respondents during data collection. Table 3. Selection criteria for qualitative analysis of hyperbilirubinemia management. Participant N Selection Criteria IDI CHWs 10 All CHWs Mothers 60 Convenience, 20 whose newborns were recommended for home phototherapy, 20 in the hospital referral arm whose newborns were otherwise healthy and referred to the hospital for treatment, 20 whose newborn was referred for danger signs or TcB ≥15 Hospital health worker 10 Hospital physicians, nurses, and hospital administrators will be selected by convenience CHW Supervisors 3 All supervisors will be interviewed FGD Parents, grandparents 80 Geographic area, Mothers not participating in IDIs IDI – in-depth interviews, FGD – focus group discussions Audio recorded data of IDIs and FGDs will be transcribed into Bengali and then translated to English. Some portions of the interviews that contain local terms and expressions will be highlighted to understand the tone of the interviewees. Code lists for each of the tool, i.e., FGD, IDI will be prepared separately. All the data will be coded accordingly using ATLAS.ti version no. 5.2. Coded data will be summarized according to the study objectives and relevant themes. All data will be analyzed considering the content and context analysis, followed by comparison and triangulation. It is a common phenomenon to have different findings when applying different tools for the same issue with the same unit of analysis. If this occurs, we will conduct additional exploration. One assistant program manager will regularly check the data and will identify any inconsistency, missing data and quality of the data and will report to the investigators. Ethics and dissemination This protocol ( Clinical Trial registration ID # NCT03933423 ) and informed consent was reviewed and approved by the Stanford University School of Medicine Institutional Review Board (protocol #52625) and the icddr,b Ethical Review Boards (PR-19004). Any modifications to the protocol will be communicated to the institutional review boards to be approved for ethical clearance. Trained field research assistants from icddr,b will obtain written informed consent from participants. The purpose of the study, methods and procedures, risks and benefits, confidentiality and future use of information will be explained to the participants. For the collection and use of biological specimens, additional informed consent will be taken from the participants. Trial data will be collected in the CommCare database, which is a secure, web-based application designed to support data capture for research studies. All pregnant women and newborns will have an anonymous study identification number. Any documents linking patient identifiers to the anonymous study identification number will be stored in CommCare. Both icddr,b and Stanford research teams will have access to final trial data and there are no contractual agreements that limit access to investigators. Only aggregate analyses without patient identifiers will be published. The study data will be stored by the principal and co-investigators during the study period and will be stored in the icddr,b data repository under the icddr,b Data Repository committee at the end of the study period. Data from the icddr,b Data Repository (icddr,b Datasets) will be provided upon request for purposes of secondary data analyses upon approval of a Data Licensing Application & Agreement. The Spirit 2013 Checklist and CONSORT 2010 checklist were uploaded to Zenodo 31 . To maintain participants’ anonymity and confidentiality, the data set generated during the study will not be publicly available but are available from the principal investigator on reasonable request. We plan to disseminate the results of this trial in peer-reviewed journals and international conferences. Our target audience are those involved in newborn health management in low-resource settings as well as those who develop and advise on policy, especially the Ministry of Health and Family Welfare, Bangladesh. We will periodically share the progress and challenges of the study to keep the stakeholders updated and seek their support as and when needed. At the end of intervention, we will convene a national level stakeholders’ meeting to disseminate study findings with government and non-government organizations. This convening will also be an opportunity to influence implementers based on the result generated by the project. We will develop an agenda for the convening meeting that addresses key themes that emerge from household-level interventions. Study status The study has completed data collection, and the results are being analyzed. No changes were made to the protocol after the trial commenced. Discussion In this study, we will evaluate the impact of CHW-led home screening and household phototherapy treatment for neonatal hyperbilirubinemia on access to phototherapy treatment in a rural community in Bangladesh where timely postnatal care is limited. The treatment arm will employ improved household screening with a point-of-care TcB measurement, a mHealth platform to extend the capabilities of CHWs, and a phototherapy device that can be used to treat newborns at home. This study leverages relationships with Bangladeshi communities, the government, and health providers. The results of the study will be clinically relevant by developing evidence to show how to successfully expand access to neonatal hyperbilirubinemia care to the most vulnerable newborns in LMICs. It will provide evidence on how to safely extend the capabilities of CHWs through mHealth with a validated treatment algorithm to provide quality postnatal care and curative neonatal hyperbilirubinemia care. LMICs are expanding access to postnatal care by using CHWs, and our work will give CHWs a curative treatment option in the immediate postnatal period. Caring for newborns at home instead of in the hospital offers potential benefits including improved access and acceptability which may lead to improved health outcomes as well as decreased risk of obtaining hospital acquired infections, which could drive widespread adoption and reduce morbidity and mortality from neonatal hyperbilirubinemia care amongst those that are most vulnerable. Similar projects in other LMICs can be pursued to evaluate their effectiveness and dramatically extend healthcare access to the most vulnerable newborns. Prior work has shown that CHWs can accurately detect severe illness in newborns after birth and reduce mortality through postnatal visits which include screening for neonatal danger signs via physical assessment 19 – 26 . CHW home visits in the first days after birth in rural Bangladesh reduced newborn mortality by 34% 9 , 35 , 36 . The performance of CHW physical examination to detect clinical danger signs in newborns was validated and the examinations had 81% sensitivity and 96% specificity to detect clinical danger signs 21 . This research has influenced the WHO guidelines to integrate seven newborn danger signs as a part of the Integrated Management of Childhood Illness guidelines and we used these danger signs as a part of our algorithm to manage neonatal hyperbilirubinemia 7 , 19 , 37 . We will use this validated screening method to identify newborns add with hyperbilirubinemia without danger signs and are otherwise healthy and can safely be treated with home phototherapy. We also screen for maternal danger signs to assess the ability of the mother to successfully provide care at home 20 . The home screening and treatment protocol was developed by applying evidence on neonatal hyperbilirubinemia screening to reduce the incidence of severe hyperbilirubinemia in rural Bangladesh. In South Africa, a study estimated that for newborns born in the hospital, universal newborn TcB screening prior to discharge from the hospital reduced the risk of severe hyperbilirubinemia by 73% in comparison to physical examination screening 8 . Newborns were screened only one time with a TcB at the time of discharge and vaginal births were discharged after six hours and caesarean section births were discharged after 48 hours 8 . With more TcB screenings and beginning at 24–48 hours of age, we believe this program will ultimately reduce hyperbilirubinemia-related disability and death. Universal hospital-based bilirubin screening in the US has reduced the incidence of hyperbilirubinemia above the exchange transfusion threshold 11 . The home screening and treatment arm will rely on mobile health to extend the capabilities of CHWs to manage hyperbilirubinemia at home. Mobile health applications have been used by CHWs in LMICs to improve newborn care 38 . mHealth has been shown to improve the accuracy of CHW newborn clinical assessments, improve the completion of assessments, their speed, and the adherence to clinical management guidelines with high satisfaction 38 . In particular, mHealth has been used by CHWs to improve the classification and management of hypothermia and infant feeding problems 38 . We will use mHealth to improve the management of newborns after birth and extend the capabilities of CHWs to improve management of neonatal hyperbilirubinemia. The home screening and treatment arm leverages evidence-based strategies to reduce the risk of rebound hyperbilirubinemia after treatment and increase the likelihood of resolution of hyperbilirubinemia with CHW-led home treatment. Chang et al. found that diagnosing the need for phototherapy early and treating early reduces the risk of rebound hyperbilirubinemia by about 50% per day 39 . In addition, stopping treatment after longer phototherapy durations when the difference between the bilirubin on stopping treatment and the bilirubin treatment threshold is larger reduces the risk of rebound hyperbilirubinemia by about 50% for each mg/dL decrease in bilirubin 39 . We will begin TcB screening early, by day two after birth and screen daily for 3 days. We will diagnose and treat cases of hyperbilirubinemia early reducing the risk of rebound hyperbilirubinemia. CHWs will treat with high intensity phototherapy (>50 μW/cm 2 /nm) for 36-hour total treatment duration ( Figure 2b ). The 36-hour treatment duration will decrease the bilirubin below the treatment threshold and reduce the risk of rebound hyperbilirubinemia and hospital referral after phototherapy. Treatment with high intensity phototherapy with irradiances >30 μW/cm 2 /nm cause a faster and larger declines in bilirubin than phototherapy of lower intensity and cause a 50% reduction in the first 24 hours of treatment 16 . In a past study of a population of newborns that needed phototherapy, 82% completed treatment within a single hospitalization with a typical duration phototherapy of 22–27 h using 22–25 μW/cm 2 /nm phototherapy 40 . LED phototherapy has minimal side effects and uses light of blue wavelength (455–470nm) to help lower the concentration of bilirubin in the body 16 . We propose a 6-hour break overnight so that the mother does not have to monitor at night. Intermittent phototherapy is successful in reducing hyperbilirubinemia 16 . We chose to use the 2004 AAP management of hyperbilirubinemia guideline for phototherapy thresholds because we wanted to use an internationally recognized guideline that had a clear phototherapy treatment threshold based on age in hours that was tied to risk of developing hyperbilirubinemia related morbidity 16 . Since the study protocol was designed, an updated AAP management of hyperbilirubinemia guideline was released in 2022 which increased the bilirubin thresholds for phototherapy treatment by 0-2 mg/dL compared to the 2004 guidelines 16 , 41 . For home phototherapy in the 2022 guideline, the phototherapy treatment thresholds could be considered at a bilirubin level 2 mg/dL less than the hospital level treatment thresholds 41 . The home phototherapy thresholds in the 2022 are similar to the 2004 AAP phototherapy thresholds that were used in this protocol 16 , 41 . LMICs often use bilirubin thresholds for phototherapy treatment that are less than the 2004 and 2022 guidelines and the WHO recommends using a bilirubin treatment threshold for phototherapy of 10–15 mg/dL which is in general lower than the levels in the 2004 and 2022 guidelines 42 – 44 . The 2022 guideline also recommends considering the local healthcare resources when determining treatment thresholds for low-resource settings 41 . We were concerned that adopting the WHO guideline would result in a high percentage of all newborns being recommended to be treated with phototherapy that would be difficult to adopt in Bangladesh and other LMIC settings with potentially unclear benefit. Accessing neonatal hospital-based care can be a barrier for families in LMICs and home-based care has been used to increase the percentage of newborns receiving the recommended treatment. In a prior study, only one-third of newborns in rural Bangladesh that were referred to the hospital from home for physical examination findings concerning for sepsis completed the referral 9 . The costs of traveling to the hospital and obtaining care were found to be a major barrier 9 , 10 . However, families were willing to have their newborns treated at home. Approximately 65% of parents who refused referral for neonatal sepsis evaluation in hospitals, consented to home care by CHWs with intramuscular injection with antibiotics, increasing access to care and reducing neonatal mortality by 34% 9 . Because we are increasing access to hyperbilirubinemia treatment by treating newborns at home, we believe that the home screening and treatment arm will treat more newborns than the existing system in Bangladesh and has the potential to prevent morbidity and mortality from neonatal hyperbilirubinemia. Data availability Extended data Zenodo: Community health worker led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol Spirit 2013 Checklist, Consort 2010 Checklist, and Consent forms https://doi.org/10.5281/zenodo.7488226 31 . This project contains the following extended data: - Consent Form for participants enrollment.docx Reporting guidelines Zenodo: Community health worker led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol Spirit 2013 Checklist, Consort 2010 Checklist, and Consent forms https://doi.org/10.5281/zenodo.7488226 31 . - Consort 2010 CHecklist12_9.doc - Spirit checklist_Homephoto trial protocol12_27.doc Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Role of protocol contributor EF and FJ developed the protocol. MR, VKB, SMP contributed to developing the protocol. RH, FY, SEA, SMB, MMH, MS, MSI, TA were substantial contributors in reviewing and editing the protocol. MR was the Principal Investigator and overall implementer of the study. GLD was a major contributor in developing and reviewing the protocol. All authors have read and approved the final protocol. Faculty Opinions recommended References 1. Bhutani VK, Zipursky A, Blencowe H, et al. : Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res. 2013; 74 Suppl 1 (Suppl 1): 86–100. PubMed Abstract | Publisher Full Text | Free Full Text 2. Owa JA, Ogunlesi TA: Why we are still doing so many exchange blood transfusion for neonatal jaundice in Nigeria. World J Pediatr. 2009; 5 (1): 51–5. PubMed Abstract | Publisher Full Text 3. Cline B, Vilms R, McGraw K, et al. : Global Burden and Unmet Need for Hyperbilirubinemia Treatment. Pediatric Academic Societies. 2011. 4. Olusanya BO, Ogunlesi TA, Slusher TM: Why is kernicterus still a major cause of death and disability in low-income and middle-income countries? Arch Dis Child. 2014; 99 (12): 1117–21. PubMed Abstract | Publisher Full Text 5. Montagu D, Yamey G, Visconti A, et al. : Where do poor women in developing countries give birth? A multi-country analysis of demographic and health survey data. PLoS One. 2011; 6 (2): e17155. PubMed Abstract | Publisher Full Text | Free Full Text 6. Chang PW, Waite WM: Evaluation of Home Phototherapy for Neonatal Hyperbilirubinemia. J Pediatr. 2020; 220 : 80–85. PubMed Abstract | Publisher Full Text 7. Darmstadt GL, Hamer DH, Carlin JB, et al. : Validation of visual estimation of neonatal jaundice in low-income and middle-income countries: a multicentre observational cohort study. BMJ Open. 2021; 11 (12): e048145. PubMed Abstract | Publisher Full Text | Free Full Text 8. Okwundu C, Bhutani VK, Smith J, et al. : Predischarge transcutaneous bilirubin screening reduces readmission rate for hyperbilirubinaemia in diverse South African newborns: A randomised controlled trial. S Afr Med J. 2020; 110 (3): 249–254. PubMed Abstract | Publisher Full Text 9. Baqui AH, El-Arifeen S, Darmstadt GL, et al. : Effect of community-based newborn-care intervention package implemented through two service-delivery strategies in Sylhet district, Bangladesh: a cluster-randomised controlled trial. Lancet. 2008; 371 (9628): 1936–44. PubMed Abstract | Publisher Full Text 10. Darmstadt GL, El Arifeen S, Choi Y, et al. : Household surveillance of severe neonatal illness by community health workers in Mirzapur, Bangladesh: coverage and compliance with referral. Health Policy Plan. 2010; 25 (2): 112–24. PubMed Abstract | Publisher Full Text | Free Full Text 11. Kuzniewicz MW, Escobar GJ, Newman TB: Impact of Universal Bilirubin Screening on Severe Hyperbilirubinemia and Phototherapy Use. Pediatrics. 2009; 124 (4): 1031–9. PubMed Abstract | Publisher Full Text | Free Full Text 12. Sakhipur Upazila Health Complex Health Bulletin January to December 2015. Reference Source 13. Darmstadt GL, Baqui AH, Choi Y, et al. : Validation of a clinical algorithm to identify neonates with severe illness during routine household visits in rural Bangladesh. Arch Dis Child. 2011; 96 (12): 1140–6. PubMed Abstract | Publisher Full Text 14. Choi Y, El Arifeen S, Mannan I, et al. : Can mothers recognize neonatal illness correctly? Comparison of maternal report and assessment by community health workers in rural Bangladesh. Trop Med Int Health. 2010; 15 (6): 743–53. PubMed Abstract | Publisher Full Text 15. Ministry of Health and Family Welfare GotPsRoB: Comprehensive Newborn Care Package. 2017. 16. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004; 114 (1): 297–316. PubMed Abstract | Publisher Full Text 17. Taylor JA, Burgos AE, Flaherman V, et al. : Discrepancies between transcutaneous and serum bilirubin measurements. Pediatrics. 2015; 135 (2): 224–31. PubMed Abstract | Publisher Full Text | Free Full Text 18. Maisels MJ, Engle WD, Wainer S, et al. : Transcutaneous bilirubin levels in an outpatient and office population. J Perinatol. 2011; 31 (9): 621–4. PubMed Abstract | Publisher Full Text 19. Young Infants Clinical Signs Study Group: Clinical signs that predict severe illness in children under age 2 months: a multicentre study. Lancet. 2008; 371 (9607): 135–42. PubMed Abstract | Publisher Full Text 20. Ministry of Health and Family Welfare Government of the People's Republic of Bangladesh: National Neonatal Health Strategy and Guidelines for Bangladesh. 2009. Reference Source 21. Darmstadt GL, Baqui AH, Choi Y, et al. : Validation of a clinical algorithm to identify neonates with severe illness during routine household visits in rural Bangladesh. Arch Dis Child. 2011; 96 (12): 1140–6. PubMed Abstract | Publisher Full Text 22. Baqui AH, Arifeen SE, Rosen HE, et al. : Community-based validation of assessment of newborn illnesses by trained community health workers in Sylhet district of Bangladesh. Trop Med Int Health. 2009; 14 (12): 1448–56. PubMed Abstract | Publisher Full Text | Free Full Text 23. Mullany LC, Katz J, Khatry SK, et al. : Neonatal hypothermia and associated risk factors among newborns of southern Nepal. BMC Med. 2010; 8 : 43. PubMed Abstract | Publisher Full Text | Free Full Text 24. Mullany LC, Katz J, Khatry SK, et al. : Risk of mortality associated with neonatal hypothermia in southern Nepal. Arch Pediatr Adolesc Med. 2010; 164 (7): 650–6. PubMed Abstract | Publisher Full Text 25. Mullany LC, Darmstadt GL, Katz J, et al. : Development of clinical sign based algorithms for community based assessment of omphalitis. Arch Dis Child Fetal Neonatal Ed. 2006; 91 (2): F99–104. PubMed Abstract | Publisher Full Text | Free Full Text 26. Hatzenbuehler L, Zaidi AKM, Sundar S, et al. : Validity of neonatal jaundice evaluation by primary health-care workers and physicians in Karachi, Pakistan. J Perinatol. 2010; 30 (9): 616–21. PubMed Abstract | Publisher Full Text 27. Mazumder S, Taneja S, Dube B, et al. : Effect of community-initiated kangaroo mother care on survival of infants with low birthweight: a randomised controlled trial. Lancet. 2019; 394 (10210): 1724–1736. PubMed Abstract | Publisher Full Text 28. Grabenhenrich J, Grabenhenrich L, Bührer C, et al. : Transcutaneous bilirubin after phototherapy in term and preterm infants. Pediatrics. 2014; 134 (5): e1324–9. PubMed Abstract | Publisher Full Text 29. Tan KL, Dong F: Transcutaneous bilirubinometry during and after phototherapy. Acta Paediatr. 2003; 92 (3): 327–31. PubMed Abstract 30. Kurnianto A, Bermawi H, Bahar E, et al. : The correlation study of transcutaneous bilirubin measurements in neonates. European Journal of Biotechnology and Bioscience. 2016; 4 (11): 34–37. Reference Source 31. Foote E, Jahan F, Rahman M, et al. : Community health worker led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol Spirit 2013 Checklist, Consort 2010 Checklist, and Consent forms. [Data], 2022. http://www.doi.org/10.5281/zenodo.7488226 32. Kopelman AE, Brown RS, Odell GB: The "bronze" baby syndrome: a complication of phototherapy. J Pediatr. 1972; 81 (3): 466–72. PubMed Abstract | Publisher Full Text 33. Balistreri WF: Neonatal cholestasis. J Pediatr. 1985; 106 (2): 171–184. PubMed Abstract | Publisher Full Text 34. Feldman AG, Sokol RJ: Neonatal Cholestasis: Updates on Diagnostics, Therapeutics, and Prevention. NeoReviews. 2021; 22 (12): e819–e836. PubMed Abstract | Publisher Full Text 35. Baqui AH, Ahmed S, El Arifeen S, et al. : Effect of timing of first postnatal care home visit on neonatal mortality in Bangladesh: a observational cohort study. BMJ. 2009; 339 : b2826. PubMed Abstract | Publisher Full Text | Free Full Text 36. Baqui AH, Arifeen SE, Williams EK, et al. : Effectiveness of home-based management of newborn infections by community health workers in rural Bangladesh. Pediatr Infect Dis J. 2009; 28 (4): 304–10. PubMed Abstract | Publisher Full Text | Free Full Text 37. World Health Organization: Integrated Management of Childhood Illness (IMCI): Chart Booklet. Geneva, Switzerland: WHO, 2014. Reference Source 38. Schaeffer LE, Ahmed S, Rahman M, et al. : Development and evaluation of a mobile application for case management of small and sick newborns in Bangladesh. BMC Med Inform Decis Mak. 2019; 19 (1): 116. PubMed Abstract | Publisher Full Text | Free Full Text 39. Chang PW, Kuzniewicz MW, McCulloch CE, et al. : A Clinical Prediction Rule for Rebound Hyperbilirubinemia Following Inpatient Phototherapy. Pediatrics. 2017; 139 (3): e20162896. PubMed Abstract | Publisher Full Text 40. Barak M, Berger I, Dollberg S, et al. : When should phototherapy be stopped? A pilot study comparing two targets of serum bilirubin concentration. Acta Paediatr. 2009; 98 (2): 277–81. PubMed Abstract | Publisher Full Text 41. Kemper AR, Newman TB, Slaughter JL, et al. : Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022; 150 (3): e2022058859. PubMed Abstract | Publisher Full Text 42. World Health Organization: Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Childhood Illnesses. 2nd ed WHO Press; 2012. PubMed Abstract 43. Sampurna MTA, Pratama DC, Visuddho V, et al. : A review of existing neonatal hyperbilirubinemia guidelines in Indonesia [version 2; peer review: 2 approved]. F1000Res. 2023; 11 : 1534. PubMed Abstract | Publisher Full Text | Free Full Text 44. Clinical Practice Guidelines: Management of Newborn Jaundice. Second Edition. Malaysia Health Technology Assessment Section (MaHTAS) Medical Development Division, Ministry of Health Malaysia, 2015. Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 21 Apr 2023 ADD YOUR COMMENT Comment Author details Author details 1 Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA 2 Environmental Health and WASH, International Centre for Diarrheal Disease Research, Dhaka, 1212, Bangladesh 3 Children's Health and Environment Program, Child Health Research Centre, The University of Queensland, QLD, Australia 4 Maternal and Child Health Division, International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, -1212, Bangladesh 5 Faculty of Medicine and Health, Sydney School of Public Health, The University of Sydney, Sydney, Australia 6 Department of Neonatology, Bangladesh Shishu Hospital & Institute Dhaka, Dhaka, Bangladesh 7 Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 8 National Newborn Health Program (NNHP) and Integrated Management of Childhood Illness (IMCI), Directorate General of Health Services, Dhaka, Bangladesh Eric M. Foote Roles: Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing Farjana Jahan Roles: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing Mahbubur Rahman Roles: Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing Sarker Masood Parvez Roles: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing Tasnim Ahmed Roles: Writing – Original Draft Preparation, Writing – Review & Editing Rezaul Hasan Roles: Writing – Original Draft Preparation, Writing – Review & Editing Farzana Yeasmin Roles: Writing – Original Draft Preparation, Writing – Review & Editing Shams El Arifeen Roles: Writing – Original Draft Preparation, Writing – Review & Editing Sk Masum Billah Roles: Conceptualization, Writing – Review & Editing Md. Mahbubul Hoque Roles: Conceptualization, Writing – Review & Editing Mohammod Shahidullah Roles: Supervision, Writing – Review & Editing Muhammad Shariful Islam Roles: Supervision, Writing – Review & Editing Vinod K Bhutani Roles: Conceptualization, Writing – Review & Editing Gary L Darmstadt Roles: Conceptualization, Funding Acquisition, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information This work was supported by the Gates Foundation [INV-017234]. This study was also funded by the Grand Challenges Canada (SB-POC-1810-20535). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (2) version 2 Revised Published: 05 Jan 2024, 7:58 https://doi.org/10.12688/gatesopenres.14033.2 version 1 Published: 21 Apr 2023, 7:58 https://doi.org/10.12688/gatesopenres.14033.1 Copyright © 2024 Foote EM et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads Gates Open Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Foote EM, Jahan F, Rahman M et al. Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.12688/gatesopenres.14033.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 2 VERSION 2 PUBLISHED 05 Jan 2024 Revised Views 0 Cite How to cite this report: Le Pichon JB. Reviewer Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.16516.r36817 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v2#referee-response-36817 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 15 Jul 2024 Jean-Baptiste Le Pichon , Children’s Mercy Hospital, Kansas City, MO, United States Virgin Islands Approved VIEWS 0 https://doi.org/10.21956/gatesopenres.16516.r36817 In this paper, Foote et al. develop an intervention protocol to identify and treat newborn hyperbilirubinemia in a province of rural Bangladesh. The proposed intervention is a cluster randomized trial of 530 families randomly assigned to routine care or home ... Continue reading READ ALL In this paper, Foote et al. develop an intervention protocol to identify and treat newborn hyperbilirubinemia in a province of rural Bangladesh. The proposed intervention is a cluster randomized trial of 530 families randomly assigned to routine care or home visits pre- and postpartum by clinical health workers (CHW). Strengths: This study addresses a major cause of mortality and morbidity in LMICs. The intervention proposed is cost-efficient and feasible in an LMIC. The results are actionable and, if successful, will immediately benefit the affected populations. The proposal is well-designed and relies on an existing solid medical and social infrastructure (a well-organized, already-existing system of registration and follow-up of pregnant women in the Sakhipur sub-district of Bangladesh). The authors propose three specific aims targeted to measure the effectiveness of: Parental education in the prevention of disease Screening in detecting treatable hyperbilirubinemia Home treatment for hyperbilirubinemia. The specific aims are clear and independent of each other. However, the SA's order is somewhat counterintuitive. I suggest rearranging them to follow the more logical prevention, intervention, and treatment order (as outlined above). Areas of possible improvement: The authors anticipate a 5% loss to follow-up. This is an unusually low rate, even in high-income countries. In LMICs this is expected to be much higher. For example, in one study of infants conducted in Chandigarh India, more than ½ of the cohort was lost to follow-up by the end of one year (Mathew et al, 2021)(Ref-1). While it will greatly help in the present study that it is on a much shorter time scale and the CHW will be visiting the homes, a loss of follow-up of 5% still seems unrealistically optimistic. It is surprising that there is no discussion of G6PD. G6PD is a major risk for bilirubin encephalopathy (Olusanya et al, 2014)(Ref-2). There are several point of care G6PD tests that could be easily added to this protocol at a minor cost. The proximity cluster design is ingenious and well thought out, but it introduces a small risk of sample bias (for example, the cluster proximity could result in women influencing each other’s behaviors or low heterozygosity within the cluster that could result in an unusually high rate of G6PD within a cluster). It would be good if the authors addressed this issue as a potential limitation. It would help to have a better description of how the authors plan on blinding the outcome assessors. As it stands, the only method for binding the outcome assessors is to have “minimal contact” with the CHWs. How will the assessors be blinded to knowledge of the intervention? Will they have any contact with the mothers? Will they see only medical records? If so, what medical records will the assessors see? The protocol for home interventions is solid and well thought through. The authors readily acknowledge the limitations of TcB measurements and address these limitations effectively. However, it is surprising that no mention is made anywhere of the Bilirubin Induced Neurologic Dysfunction (BIND) scale (Radmacher, et al., 2015)(Ref-3). The modified BIND scale is a proven and effective way to assess the risk for acute bilirubin encephalopathy in newborns . It was also shown recently to be highly sensitive in predicting of kernicterus (Gelineau-Morel et al.,2023)(ref-3). Minor issues: In the abstract, the authors state that “Newborns without danger signs but with a TcB above the treatment threshold, but >15 mg/dL will be treated with light-emitting diode (LED) phototherapy at home”. I believe they meant “Newborns without danger signs but with a TcB above the treatment threshold, but <15 mg/dL will be treated with light-emitting diode (LED) phototherapy at home. The abbreviation for clinical health worker (CHW) is never defined. Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Yes Are the datasets clearly presented in a useable and accessible format? Yes References 1. Mathew JL, Patel PN, Wagner AL, Suri V, et al.: Analysis of reasons for loss to follow up in a prospective study in Chandigarh, India and impact from telecom changes. BMC Res Notes . 2021; 14 (1): 419 PubMed Abstract | Publisher Full Text 2. Olusanya BO, Emokpae AA, Zamora TG, Slusher TM: Addressing the burden of neonatal hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency. Acta Paediatr . 2014; 103 (11): 1102-9 PubMed Abstract | Publisher Full Text 3. Radmacher PG, Groves FD, Owa JA, Ofovwe GE, et al.: A modified Bilirubin-induced neurologic dysfunction (BIND-M) algorithm is useful in evaluating severity of jaundice in a resource-limited setting. BMC Pediatr . 2015; 15 : 28 PubMed Abstract | Publisher Full Text 4. Gelineau-Morel R, Usman F, Shehu S, Yeh HW, et al.: Predictive and diagnostic measures for kernicterus spectrum disorder: a prospective cohort study. Pediatr Res . 2024; 95 (1): 285-292 PubMed Abstract | Publisher Full Text Competing Interests: No competing interests were disclosed. Reviewer Expertise: Hyperbilirubinemia, bilirubin encephalopathy, kernicterus spectrum disorder, epilepsy, neurogenomics. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Le Pichon JB. Reviewer Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.16516.r36817 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v2#referee-response-36817 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 17 Sep 2024 Eric Foote , Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, USA 17 Sep 2024 Author Response Responses to reviewer 3 comments Comment: The authors anticipate a 5% loss to follow-up. This is an unusually low rate, even in high-income countries. In LMICs this is expected ... Continue reading Responses to reviewer 3 comments Comment: The authors anticipate a 5% loss to follow-up. This is an unusually low rate, even in high-income countries. In LMICs this is expected to be much higher. For example, in one study of infants conducted in Chandigarh India, more than ½ of the cohort was lost to follow-up by the end of one year (Mathew et al, 2021)(Ref-1). While it will greatly help in the present study that it is on a much shorter time scale and the CHW will be visiting the homes, a loss of follow-up of 5% still seems unrealistically optimistic. Response: We appreciate the feedback. Based on our experience working in rural Bangladesh, we anticipate a low loss to follow-up rate. Part of the study enrollment criteria includes a commitment to stay in the study area during the postnatal period. Comment: It is surprising that there is no discussion of G6PD. G6PD is a major risk for bilirubin encephalopathy (Olusanya et al, 2014)(Ref-2). There are several point of care G6PD tests that could be easily added to this protocol at a minor cost. Response: We addressed similar feedback in response to another reviewer. We did not find a G6PD test that we could readily deploy in the field, with a turnaround time fast enough to change newborn hyperbilirubinemia risk categorization and treatment decisions for the participants. If such an easily administered point of care test becomes available, this could be added to future protocols. Comment: The proximity cluster design is ingenious and well thought out, but it introduces a small risk of sample bias (for example, the cluster proximity could result in women influencing each other’s behaviors or low heterozygosity within the cluster that could result in an unusually high rate of G6PD within a cluster). It would be good if the authors addressed this issue as a potential limitation. Response: We acknowledge this limitation, and we plan to adjust for cluster design in the analysis. Comment: It would help to have a better description of how the authors plan on blinding the outcome assessors. As it stands, the only method for binding the outcome assessors is to have “minimal contact” with the CHWs. How will the assessors be blinded to knowledge of the intervention? Will they have any contact with the mothers? Will they see only medical records? If so, what medical records will the assessors see? Response: The outcome assessors who perform the endline evaluation will not be involved in the administration of the study intervention. They will not know which households or clusters received the intervention. The outcome assessors did not have a relationship with the CHWs. Comment: The protocol for home interventions is solid and well thought through. The authors readily acknowledge the limitations of TcB measurements and address these limitations effectively. However, it is surprising that no mention is made anywhere of the Bilirubin Induced Neurologic Dysfunction (BIND) scale (Radmacher, et al., 2015)(Ref-3). The modified BIND scale is a proven and effective way to assess the risk for acute bilirubin encephalopathy in newborns . It was also shown recently to be highly sensitive in predicting of kernicterus (Gelineau-Morel et al.,2023)(ref-3). Response: We addressed similar feedback in response to reviewer 1. Please refer to that response. Responses to reviewer 3 comments Comment: The authors anticipate a 5% loss to follow-up. This is an unusually low rate, even in high-income countries. In LMICs this is expected to be much higher. For example, in one study of infants conducted in Chandigarh India, more than ½ of the cohort was lost to follow-up by the end of one year (Mathew et al, 2021)(Ref-1). While it will greatly help in the present study that it is on a much shorter time scale and the CHW will be visiting the homes, a loss of follow-up of 5% still seems unrealistically optimistic. Response: We appreciate the feedback. Based on our experience working in rural Bangladesh, we anticipate a low loss to follow-up rate. Part of the study enrollment criteria includes a commitment to stay in the study area during the postnatal period. Comment: It is surprising that there is no discussion of G6PD. G6PD is a major risk for bilirubin encephalopathy (Olusanya et al, 2014)(Ref-2). There are several point of care G6PD tests that could be easily added to this protocol at a minor cost. Response: We addressed similar feedback in response to another reviewer. We did not find a G6PD test that we could readily deploy in the field, with a turnaround time fast enough to change newborn hyperbilirubinemia risk categorization and treatment decisions for the participants. If such an easily administered point of care test becomes available, this could be added to future protocols. Comment: The proximity cluster design is ingenious and well thought out, but it introduces a small risk of sample bias (for example, the cluster proximity could result in women influencing each other’s behaviors or low heterozygosity within the cluster that could result in an unusually high rate of G6PD within a cluster). It would be good if the authors addressed this issue as a potential limitation. Response: We acknowledge this limitation, and we plan to adjust for cluster design in the analysis. Comment: It would help to have a better description of how the authors plan on blinding the outcome assessors. As it stands, the only method for binding the outcome assessors is to have “minimal contact” with the CHWs. How will the assessors be blinded to knowledge of the intervention? Will they have any contact with the mothers? Will they see only medical records? If so, what medical records will the assessors see? Response: The outcome assessors who perform the endline evaluation will not be involved in the administration of the study intervention. They will not know which households or clusters received the intervention. The outcome assessors did not have a relationship with the CHWs. Comment: The protocol for home interventions is solid and well thought through. The authors readily acknowledge the limitations of TcB measurements and address these limitations effectively. However, it is surprising that no mention is made anywhere of the Bilirubin Induced Neurologic Dysfunction (BIND) scale (Radmacher, et al., 2015)(Ref-3). The modified BIND scale is a proven and effective way to assess the risk for acute bilirubin encephalopathy in newborns . It was also shown recently to be highly sensitive in predicting of kernicterus (Gelineau-Morel et al.,2023)(ref-3). Response: We addressed similar feedback in response to reviewer 1. Please refer to that response. Competing Interests: None Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 17 Sep 2024 Eric Foote , Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, USA 17 Sep 2024 Author Response Responses to reviewer 3 comments Comment: The authors anticipate a 5% loss to follow-up. This is an unusually low rate, even in high-income countries. In LMICs this is expected ... Continue reading Responses to reviewer 3 comments Comment: The authors anticipate a 5% loss to follow-up. This is an unusually low rate, even in high-income countries. In LMICs this is expected to be much higher. For example, in one study of infants conducted in Chandigarh India, more than ½ of the cohort was lost to follow-up by the end of one year (Mathew et al, 2021)(Ref-1). While it will greatly help in the present study that it is on a much shorter time scale and the CHW will be visiting the homes, a loss of follow-up of 5% still seems unrealistically optimistic. Response: We appreciate the feedback. Based on our experience working in rural Bangladesh, we anticipate a low loss to follow-up rate. Part of the study enrollment criteria includes a commitment to stay in the study area during the postnatal period. Comment: It is surprising that there is no discussion of G6PD. G6PD is a major risk for bilirubin encephalopathy (Olusanya et al, 2014)(Ref-2). There are several point of care G6PD tests that could be easily added to this protocol at a minor cost. Response: We addressed similar feedback in response to another reviewer. We did not find a G6PD test that we could readily deploy in the field, with a turnaround time fast enough to change newborn hyperbilirubinemia risk categorization and treatment decisions for the participants. If such an easily administered point of care test becomes available, this could be added to future protocols. Comment: The proximity cluster design is ingenious and well thought out, but it introduces a small risk of sample bias (for example, the cluster proximity could result in women influencing each other’s behaviors or low heterozygosity within the cluster that could result in an unusually high rate of G6PD within a cluster). It would be good if the authors addressed this issue as a potential limitation. Response: We acknowledge this limitation, and we plan to adjust for cluster design in the analysis. Comment: It would help to have a better description of how the authors plan on blinding the outcome assessors. As it stands, the only method for binding the outcome assessors is to have “minimal contact” with the CHWs. How will the assessors be blinded to knowledge of the intervention? Will they have any contact with the mothers? Will they see only medical records? If so, what medical records will the assessors see? Response: The outcome assessors who perform the endline evaluation will not be involved in the administration of the study intervention. They will not know which households or clusters received the intervention. The outcome assessors did not have a relationship with the CHWs. Comment: The protocol for home interventions is solid and well thought through. The authors readily acknowledge the limitations of TcB measurements and address these limitations effectively. However, it is surprising that no mention is made anywhere of the Bilirubin Induced Neurologic Dysfunction (BIND) scale (Radmacher, et al., 2015)(Ref-3). The modified BIND scale is a proven and effective way to assess the risk for acute bilirubin encephalopathy in newborns . It was also shown recently to be highly sensitive in predicting of kernicterus (Gelineau-Morel et al.,2023)(ref-3). Response: We addressed similar feedback in response to reviewer 1. Please refer to that response. Responses to reviewer 3 comments Comment: The authors anticipate a 5% loss to follow-up. This is an unusually low rate, even in high-income countries. In LMICs this is expected to be much higher. For example, in one study of infants conducted in Chandigarh India, more than ½ of the cohort was lost to follow-up by the end of one year (Mathew et al, 2021)(Ref-1). While it will greatly help in the present study that it is on a much shorter time scale and the CHW will be visiting the homes, a loss of follow-up of 5% still seems unrealistically optimistic. Response: We appreciate the feedback. Based on our experience working in rural Bangladesh, we anticipate a low loss to follow-up rate. Part of the study enrollment criteria includes a commitment to stay in the study area during the postnatal period. Comment: It is surprising that there is no discussion of G6PD. G6PD is a major risk for bilirubin encephalopathy (Olusanya et al, 2014)(Ref-2). There are several point of care G6PD tests that could be easily added to this protocol at a minor cost. Response: We addressed similar feedback in response to another reviewer. We did not find a G6PD test that we could readily deploy in the field, with a turnaround time fast enough to change newborn hyperbilirubinemia risk categorization and treatment decisions for the participants. If such an easily administered point of care test becomes available, this could be added to future protocols. Comment: The proximity cluster design is ingenious and well thought out, but it introduces a small risk of sample bias (for example, the cluster proximity could result in women influencing each other’s behaviors or low heterozygosity within the cluster that could result in an unusually high rate of G6PD within a cluster). It would be good if the authors addressed this issue as a potential limitation. Response: We acknowledge this limitation, and we plan to adjust for cluster design in the analysis. Comment: It would help to have a better description of how the authors plan on blinding the outcome assessors. As it stands, the only method for binding the outcome assessors is to have “minimal contact” with the CHWs. How will the assessors be blinded to knowledge of the intervention? Will they have any contact with the mothers? Will they see only medical records? If so, what medical records will the assessors see? Response: The outcome assessors who perform the endline evaluation will not be involved in the administration of the study intervention. They will not know which households or clusters received the intervention. The outcome assessors did not have a relationship with the CHWs. Comment: The protocol for home interventions is solid and well thought through. The authors readily acknowledge the limitations of TcB measurements and address these limitations effectively. However, it is surprising that no mention is made anywhere of the Bilirubin Induced Neurologic Dysfunction (BIND) scale (Radmacher, et al., 2015)(Ref-3). The modified BIND scale is a proven and effective way to assess the risk for acute bilirubin encephalopathy in newborns . It was also shown recently to be highly sensitive in predicting of kernicterus (Gelineau-Morel et al.,2023)(ref-3). Response: We addressed similar feedback in response to reviewer 1. Please refer to that response. Competing Interests: None Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Slusher TM and Farouk Z. Reviewer Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.16516.r35758 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v2#referee-response-35758 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 31 May 2024 Tina M. Slusher , Department of Pediatrics, Global Health Program, Critical Care Division, University of Minnesota, Minneapolis, MN, USA Zubaida Farouk , Bayero University Kano, Kano, Nigeria Approved with Reservations VIEWS 0 https://doi.org/10.21956/gatesopenres.16516.r35758 The revisions that the authors have made have addressed many of my/our concerns but there are still a few that need to be addressed. They have re-ordered their aims which was an essential correction needed in this arm, further clarified community ... Continue reading READ ALL The revisions that the authors have made have addressed many of my/our concerns but there are still a few that need to be addressed. They have re-ordered their aims which was an essential correction needed in this arm, further clarified community health worker training and included the bilirubin graph and access to cell phone. The authors still have not addressed the problem of G6PD deficiency and make no mention of screening for G6PD deficiency. If they cannot screen for G6PD deficiency that should be stated and authors should mention at a minimum that mothers will be taught to avoid triggers of hemolysis. Again it would be helpful to know the outcomes of the control group that have EBT, ABE, or jaundice-related death. This data will be very important when determining the success of the home PT and should be relatively easy to obtain. Additionally it would be helpful to state how the diagnosis of ABE will be made and BIND score encouraged for any neonate referred to the hospital for treatment of jaundice. Please clarify that the distance from the neonate to the PT will be fixed and not adjustable by the mother/family. Thank you for this very important work. If shown to be safe and effective it will likely be an important tool in preventing severe neonatal hyperbilirubinemia and the tragic sequelae including ABE and KSD. Competing Interests: No competing interests were disclosed. We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Slusher TM and Farouk Z. Reviewer Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.16516.r35758 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v2#referee-response-35758 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 21 Apr 2023 Views 0 Cite How to cite this report: Hulzebos CV. Reviewer Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.15331.r34000 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v1#referee-response-34000 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 03 Aug 2023 Christian V Hulzebos , Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands Approved with Reservations VIEWS 0 https://doi.org/10.21956/gatesopenres.15331.r34000 In this study protocol entitled “Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh” Foot and colleagues scrutinously describe their research proposal to improve management of neonatal hyperbilirubinemia (NHB) in a low-resource country. ... Continue reading READ ALL In this study protocol entitled “Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh” Foot and colleagues scrutinously describe their research proposal to improve management of neonatal hyperbilirubinemia (NHB) in a low-resource country. The authors aim to prevent NHB by antenatal education on the importance of breastfeeding and inform mothers how to seek help when their offspring is sick, to prevent NHB by transcutaneous bilirubin (TcB) screening at home, and to start early phototherapy (PT). PT is started at home whenever TcB < 15 mg/dL (257 µmol/L) is higher than the treatment threshold, and in-hospital when TcB ≥ 15 mg/dL or in case of danger signs. Considering the important aim on prevention I suggest to adapt the title, and incorporate prevention in the title as well! And please incorporate this in the intervention arm as well. For example in the abstract the intervention arm reads as home screening and treatment, which is in fact not completely true. I agree with the other reviewers that this study does have potential to change the future of many infants with NHB. Yet, apart from the scientific issues, economic and financial factors are as well important and need some clarification. An important question that arises is how resources are guaranteed after this study with a clear but relatively small sample size. And what about future costs for regular calibration of TcB and PT devices? I have also a question on the effectiveness of home PT to increase treatment rates (as can be read in the abstract). The authors have defined treatment rate as primary outcome. But this is not the same as PT effectiveness, usually defined as reduction of bilirubin below the treatment threshold that is considered appropriate. Especially when treatment is TcB based < 15 mg/dL, and not TSB-based, overtreatment may occur. And this unnecessarily started PT will contribute to the primary outcome. Therefore I suggest to measure TSB also in newborns with TcB above treatment threshold treatment threshold. I have provided my suggestions and questions in the linked PDF . This PDF also contains the comments from Tina M. Slusher and Zubaida L. Farouk as part of their review of version 1 of this article 1 . Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Partly Are sufficient details of the methods provided to allow replication by others? Yes Are the datasets clearly presented in a useable and accessible format? Not applicable References 1. Slusher TM, Farouk ZL: Peer Review Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh:a cluster randomized control trial protocol [version 1; peer review: 1 approved with reservations]. Gates Open Res . 2023; 7 (58). Publisher Full Text | Reference Source Competing Interests: No competing interests were disclosed. Reviewer Expertise: Neonatal hyperbilirubimemia, prevention, screening, treatment, management guidelines. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Hulzebos CV. Reviewer Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.15331.r34000 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v1#referee-response-34000 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 18 Sep 2024 Eric Foote , Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, USA 18 Sep 2024 Author Response Responses to reviewer 2 comments Comment: Considering the important aim on prevention I suggest to adapt the title, and incorporate prevention in the title as well! And please ... Continue reading Responses to reviewer 2 comments Comment: Considering the important aim on prevention I suggest to adapt the title, and incorporate prevention in the title as well! And please incorporate this in the intervention arm as well. For example in the abstract the intervention arm reads as home screening and treatment, which is in fact not completely true. Response : Thank you for your comments. We will add prevention to the title and abstract. Comment: An important question that arises is how resources are guaranteed after this study with a clear but relatively small sample size. And what about future costs for regular calibration of TcB and PT devices? Response: Thank you for your comment. We agree that developing a low cost intervention is important for the scalability of the intervention. This study focused on evaluating the acceptability and impact of a community health worker (CHW)-led prevention, diagnosis and treatment intervention on phototherapy treatment rates. In future work, we will evaluate the scalability of the intervention. We also believe that showing that CHW-led home screening and treatment is possible is the first step in developing a low-cost scalable intervention. Comment: I have also a question on the effectiveness of home PT to increase treatment rates (as can be read in the abstract). The authors have defined treatment rate as primary outcome. But this is not the same as PT effectiveness, usually defined as reduction of bilirubin below the treatment threshold that is considered appropriate. Especially when treatment is TcB based < 15 mg/dL, and not TSB-based, overtreatment may occur. And this unnecessarily started PT will contribute to the primary outcome. Therefore I suggest to measure TSB also in newborns with TcB above treatment threshold treatment threshold. I suggest to use a decision rule when to measure TSB after TcB, e.g., TcB +50 micromol/L > treatment thresholds is heel prick for TSB measurement Response: Thanks for your comment. This study was designed to evaluate the impact of the intervention on phototherapy treatment rates in intervention and comparison households. Phototherapy is known to be effective in treating neonatal hyperbilirubinemia. As a result, we did not design the study to assess the effectiveness of home phototherapy. Nevertheless, the study will report the number and percent of infants that met the treatment criteria and are treated at home, and who have a transcutaneous bilirubin (TcB) <15 mg/dL on consecutive days after the intervention is completed. This will give a measure of household phototherapy intervention effectiveness. Measuring the total serum bilirubin (TSB) in newborns who had a TcB greater than the treatment threshold in rural Bangladesh and using the TSB to determine home treatment eligibility is not feasible for this intervention in this community. The households are far from a laboratory and obtaining a TSB result from a newborn where the specimen was collected at home and brought to the laboratory will take a long time. Waiting to start treatment until the TSB result is available will substantially reduce the effectiveness of the intervention. One of the main advantages of the TcB device is providing instant diagnostic data to begin treatment if indicated immediately. Waiting as much as one day to obtain a TSB result may result in the TSB rising to a level where we would not recommend home treatment but rather would focus on hospital referral. In addition, CHWs in low- to middle-income countries may not be comfortable or trained to collect blood on newborns and specialized personnel would be needed which would increase the intervention costs and reduce the intervention scalability. The acceptability of the intervention could also decrease as parents may not want blood to be drawn on their newborn and refuse blood collection. TcB values are highly correlated to TSB at levels less than 15 mg/dL and the risk of substantial overtreatment is low. Comment : Prenatal education should also be mentioned here - in the intervention arm Response: This was updated. Comment: Is this because she will probably not be back in time or because she will leave before prenatal education? Response: Thanks for the comment. It is because the mother will not be present in the study area at the time of birth. Comment: When you consider the first aim important in the prevention this is appropriate to list here, but it is not your main outcome. See comments of other reviewers. Response: Thanks, the order of the Aims was reversed. Comment: Sample size calculations are based on many estimations, the percentage of jaundiced newborns that need treatment is based on a literature reference, and it is estimated that 50% of the infants born in facilities receive treatment, and none of the newborns who are born at home. I suggest that the authors use numbers that arise from the population in the research area. This may affect sample size. Response: The figures used for the calculation were based on birth statistics from the local hospital in Shakipur and from talking to local doctors. Comment : Intervention arm consists of three interventions. Should be stated earlier (see major comments). Response: We updated the title and the abstract to highlight this. Comment: ....danger signs including signs of ABE (using the BIND-M score), Response: This comment was addressed in response to the other reviewers Comment: Why do you choose to use the old (2004) AAP guideline and not the more recent one (2022)? Response: Thanks, this comment was addressed in the response to the other reviewers. Comment: On which part of the body is TcB measured? How often are TcB measurements done in the same session? Response: The TcB was measured by gently pressing the meter on the middle part of the sternum. In the same session, three consecutive measurements were taken, and an algorithm took the average of three measurements for the decision-making process. Comment: But how is this overnight pause handled when the jaundiced infant has just started PT? It seems a little bit dangerous to stop for 6 hours when PT has just been started. Please define a minimal PT duration before stopping 6 hours (e.g., 6 hours) and else ... maybe every one should accept one night with less sleep (more will probably follow for other reasons). Response: The timing for the overnight pause was set to be between midnight and 0600. This is highlighted in the operational description that was added. CHW visits will occur in the morning, and then they will visit again 4-6 hours after starting phototherapy in the eligible newborns. The newborns will receive at least 7 hours of treatment, but probably 12 hours of treatment before the overnight pause. We think having a pause overnight will increase the acceptability of the intervention. Comment: And what about signs of infection/sepsis? Are these factors that lower the treatment threshold? Or reason to be admitted to an hospital, which may be difficult (as I understood from the authors). Response: All newborns with signs of sepsis will be referred to a hospital for care. We will not attempt to treat newborns with signs of sepsis at home as a part of this study. Comment: iii....text is missing Response: Updated. Comment : 80 participants seem a rather large sample for these focus groups. Usually no other answers are obtained after fewer than the suggested 80 participants. Please see literature on satiety points in focus groups. Response : We agree with your comments. We will conduct four focus group discussions (8-10 participants in each session) and depending on the saturation of data, will further adjust the numbers. Comment: detect neonatal infection? Words are missing. Response: Updated. Comment: The prenatal education and home..... Response: Updated. Comments: #12: What is the reference source? #13: please provide website or link to appropriate docs Response: Updated Responses to reviewer 2 comments Comment: Considering the important aim on prevention I suggest to adapt the title, and incorporate prevention in the title as well! And please incorporate this in the intervention arm as well. For example in the abstract the intervention arm reads as home screening and treatment, which is in fact not completely true. Response : Thank you for your comments. We will add prevention to the title and abstract. Comment: An important question that arises is how resources are guaranteed after this study with a clear but relatively small sample size. And what about future costs for regular calibration of TcB and PT devices? Response: Thank you for your comment. We agree that developing a low cost intervention is important for the scalability of the intervention. This study focused on evaluating the acceptability and impact of a community health worker (CHW)-led prevention, diagnosis and treatment intervention on phototherapy treatment rates. In future work, we will evaluate the scalability of the intervention. We also believe that showing that CHW-led home screening and treatment is possible is the first step in developing a low-cost scalable intervention. Comment: I have also a question on the effectiveness of home PT to increase treatment rates (as can be read in the abstract). The authors have defined treatment rate as primary outcome. But this is not the same as PT effectiveness, usually defined as reduction of bilirubin below the treatment threshold that is considered appropriate. Especially when treatment is TcB based < 15 mg/dL, and not TSB-based, overtreatment may occur. And this unnecessarily started PT will contribute to the primary outcome. Therefore I suggest to measure TSB also in newborns with TcB above treatment threshold treatment threshold. I suggest to use a decision rule when to measure TSB after TcB, e.g., TcB +50 micromol/L > treatment thresholds is heel prick for TSB measurement Response: Thanks for your comment. This study was designed to evaluate the impact of the intervention on phototherapy treatment rates in intervention and comparison households. Phototherapy is known to be effective in treating neonatal hyperbilirubinemia. As a result, we did not design the study to assess the effectiveness of home phototherapy. Nevertheless, the study will report the number and percent of infants that met the treatment criteria and are treated at home, and who have a transcutaneous bilirubin (TcB) <15 mg/dL on consecutive days after the intervention is completed. This will give a measure of household phototherapy intervention effectiveness. Measuring the total serum bilirubin (TSB) in newborns who had a TcB greater than the treatment threshold in rural Bangladesh and using the TSB to determine home treatment eligibility is not feasible for this intervention in this community. The households are far from a laboratory and obtaining a TSB result from a newborn where the specimen was collected at home and brought to the laboratory will take a long time. Waiting to start treatment until the TSB result is available will substantially reduce the effectiveness of the intervention. One of the main advantages of the TcB device is providing instant diagnostic data to begin treatment if indicated immediately. Waiting as much as one day to obtain a TSB result may result in the TSB rising to a level where we would not recommend home treatment but rather would focus on hospital referral. In addition, CHWs in low- to middle-income countries may not be comfortable or trained to collect blood on newborns and specialized personnel would be needed which would increase the intervention costs and reduce the intervention scalability. The acceptability of the intervention could also decrease as parents may not want blood to be drawn on their newborn and refuse blood collection. TcB values are highly correlated to TSB at levels less than 15 mg/dL and the risk of substantial overtreatment is low. Comment : Prenatal education should also be mentioned here - in the intervention arm Response: This was updated. Comment: Is this because she will probably not be back in time or because she will leave before prenatal education? Response: Thanks for the comment. It is because the mother will not be present in the study area at the time of birth. Comment: When you consider the first aim important in the prevention this is appropriate to list here, but it is not your main outcome. See comments of other reviewers. Response: Thanks, the order of the Aims was reversed. Comment: Sample size calculations are based on many estimations, the percentage of jaundiced newborns that need treatment is based on a literature reference, and it is estimated that 50% of the infants born in facilities receive treatment, and none of the newborns who are born at home. I suggest that the authors use numbers that arise from the population in the research area. This may affect sample size. Response: The figures used for the calculation were based on birth statistics from the local hospital in Shakipur and from talking to local doctors. Comment : Intervention arm consists of three interventions. Should be stated earlier (see major comments). Response: We updated the title and the abstract to highlight this. Comment: ....danger signs including signs of ABE (using the BIND-M score), Response: This comment was addressed in response to the other reviewers Comment: Why do you choose to use the old (2004) AAP guideline and not the more recent one (2022)? Response: Thanks, this comment was addressed in the response to the other reviewers. Comment: On which part of the body is TcB measured? How often are TcB measurements done in the same session? Response: The TcB was measured by gently pressing the meter on the middle part of the sternum. In the same session, three consecutive measurements were taken, and an algorithm took the average of three measurements for the decision-making process. Comment: But how is this overnight pause handled when the jaundiced infant has just started PT? It seems a little bit dangerous to stop for 6 hours when PT has just been started. Please define a minimal PT duration before stopping 6 hours (e.g., 6 hours) and else ... maybe every one should accept one night with less sleep (more will probably follow for other reasons). Response: The timing for the overnight pause was set to be between midnight and 0600. This is highlighted in the operational description that was added. CHW visits will occur in the morning, and then they will visit again 4-6 hours after starting phototherapy in the eligible newborns. The newborns will receive at least 7 hours of treatment, but probably 12 hours of treatment before the overnight pause. We think having a pause overnight will increase the acceptability of the intervention. Comment: And what about signs of infection/sepsis? Are these factors that lower the treatment threshold? Or reason to be admitted to an hospital, which may be difficult (as I understood from the authors). Response: All newborns with signs of sepsis will be referred to a hospital for care. We will not attempt to treat newborns with signs of sepsis at home as a part of this study. Comment: iii....text is missing Response: Updated. Comment : 80 participants seem a rather large sample for these focus groups. Usually no other answers are obtained after fewer than the suggested 80 participants. Please see literature on satiety points in focus groups. Response : We agree with your comments. We will conduct four focus group discussions (8-10 participants in each session) and depending on the saturation of data, will further adjust the numbers. Comment: detect neonatal infection? Words are missing. Response: Updated. Comment: The prenatal education and home..... Response: Updated. Comments: #12: What is the reference source? #13: please provide website or link to appropriate docs Response: Updated Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 18 Sep 2024 Eric Foote , Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, USA 18 Sep 2024 Author Response Responses to reviewer 2 comments Comment: Considering the important aim on prevention I suggest to adapt the title, and incorporate prevention in the title as well! And please ... Continue reading Responses to reviewer 2 comments Comment: Considering the important aim on prevention I suggest to adapt the title, and incorporate prevention in the title as well! And please incorporate this in the intervention arm as well. For example in the abstract the intervention arm reads as home screening and treatment, which is in fact not completely true. Response : Thank you for your comments. We will add prevention to the title and abstract. Comment: An important question that arises is how resources are guaranteed after this study with a clear but relatively small sample size. And what about future costs for regular calibration of TcB and PT devices? Response: Thank you for your comment. We agree that developing a low cost intervention is important for the scalability of the intervention. This study focused on evaluating the acceptability and impact of a community health worker (CHW)-led prevention, diagnosis and treatment intervention on phototherapy treatment rates. In future work, we will evaluate the scalability of the intervention. We also believe that showing that CHW-led home screening and treatment is possible is the first step in developing a low-cost scalable intervention. Comment: I have also a question on the effectiveness of home PT to increase treatment rates (as can be read in the abstract). The authors have defined treatment rate as primary outcome. But this is not the same as PT effectiveness, usually defined as reduction of bilirubin below the treatment threshold that is considered appropriate. Especially when treatment is TcB based < 15 mg/dL, and not TSB-based, overtreatment may occur. And this unnecessarily started PT will contribute to the primary outcome. Therefore I suggest to measure TSB also in newborns with TcB above treatment threshold treatment threshold. I suggest to use a decision rule when to measure TSB after TcB, e.g., TcB +50 micromol/L > treatment thresholds is heel prick for TSB measurement Response: Thanks for your comment. This study was designed to evaluate the impact of the intervention on phototherapy treatment rates in intervention and comparison households. Phototherapy is known to be effective in treating neonatal hyperbilirubinemia. As a result, we did not design the study to assess the effectiveness of home phototherapy. Nevertheless, the study will report the number and percent of infants that met the treatment criteria and are treated at home, and who have a transcutaneous bilirubin (TcB) <15 mg/dL on consecutive days after the intervention is completed. This will give a measure of household phototherapy intervention effectiveness. Measuring the total serum bilirubin (TSB) in newborns who had a TcB greater than the treatment threshold in rural Bangladesh and using the TSB to determine home treatment eligibility is not feasible for this intervention in this community. The households are far from a laboratory and obtaining a TSB result from a newborn where the specimen was collected at home and brought to the laboratory will take a long time. Waiting to start treatment until the TSB result is available will substantially reduce the effectiveness of the intervention. One of the main advantages of the TcB device is providing instant diagnostic data to begin treatment if indicated immediately. Waiting as much as one day to obtain a TSB result may result in the TSB rising to a level where we would not recommend home treatment but rather would focus on hospital referral. In addition, CHWs in low- to middle-income countries may not be comfortable or trained to collect blood on newborns and specialized personnel would be needed which would increase the intervention costs and reduce the intervention scalability. The acceptability of the intervention could also decrease as parents may not want blood to be drawn on their newborn and refuse blood collection. TcB values are highly correlated to TSB at levels less than 15 mg/dL and the risk of substantial overtreatment is low. Comment : Prenatal education should also be mentioned here - in the intervention arm Response: This was updated. Comment: Is this because she will probably not be back in time or because she will leave before prenatal education? Response: Thanks for the comment. It is because the mother will not be present in the study area at the time of birth. Comment: When you consider the first aim important in the prevention this is appropriate to list here, but it is not your main outcome. See comments of other reviewers. Response: Thanks, the order of the Aims was reversed. Comment: Sample size calculations are based on many estimations, the percentage of jaundiced newborns that need treatment is based on a literature reference, and it is estimated that 50% of the infants born in facilities receive treatment, and none of the newborns who are born at home. I suggest that the authors use numbers that arise from the population in the research area. This may affect sample size. Response: The figures used for the calculation were based on birth statistics from the local hospital in Shakipur and from talking to local doctors. Comment : Intervention arm consists of three interventions. Should be stated earlier (see major comments). Response: We updated the title and the abstract to highlight this. Comment: ....danger signs including signs of ABE (using the BIND-M score), Response: This comment was addressed in response to the other reviewers Comment: Why do you choose to use the old (2004) AAP guideline and not the more recent one (2022)? Response: Thanks, this comment was addressed in the response to the other reviewers. Comment: On which part of the body is TcB measured? How often are TcB measurements done in the same session? Response: The TcB was measured by gently pressing the meter on the middle part of the sternum. In the same session, three consecutive measurements were taken, and an algorithm took the average of three measurements for the decision-making process. Comment: But how is this overnight pause handled when the jaundiced infant has just started PT? It seems a little bit dangerous to stop for 6 hours when PT has just been started. Please define a minimal PT duration before stopping 6 hours (e.g., 6 hours) and else ... maybe every one should accept one night with less sleep (more will probably follow for other reasons). Response: The timing for the overnight pause was set to be between midnight and 0600. This is highlighted in the operational description that was added. CHW visits will occur in the morning, and then they will visit again 4-6 hours after starting phototherapy in the eligible newborns. The newborns will receive at least 7 hours of treatment, but probably 12 hours of treatment before the overnight pause. We think having a pause overnight will increase the acceptability of the intervention. Comment: And what about signs of infection/sepsis? Are these factors that lower the treatment threshold? Or reason to be admitted to an hospital, which may be difficult (as I understood from the authors). Response: All newborns with signs of sepsis will be referred to a hospital for care. We will not attempt to treat newborns with signs of sepsis at home as a part of this study. Comment: iii....text is missing Response: Updated. Comment : 80 participants seem a rather large sample for these focus groups. Usually no other answers are obtained after fewer than the suggested 80 participants. Please see literature on satiety points in focus groups. Response : We agree with your comments. We will conduct four focus group discussions (8-10 participants in each session) and depending on the saturation of data, will further adjust the numbers. Comment: detect neonatal infection? Words are missing. Response: Updated. Comment: The prenatal education and home..... Response: Updated. Comments: #12: What is the reference source? #13: please provide website or link to appropriate docs Response: Updated Responses to reviewer 2 comments Comment: Considering the important aim on prevention I suggest to adapt the title, and incorporate prevention in the title as well! And please incorporate this in the intervention arm as well. For example in the abstract the intervention arm reads as home screening and treatment, which is in fact not completely true. Response : Thank you for your comments. We will add prevention to the title and abstract. Comment: An important question that arises is how resources are guaranteed after this study with a clear but relatively small sample size. And what about future costs for regular calibration of TcB and PT devices? Response: Thank you for your comment. We agree that developing a low cost intervention is important for the scalability of the intervention. This study focused on evaluating the acceptability and impact of a community health worker (CHW)-led prevention, diagnosis and treatment intervention on phototherapy treatment rates. In future work, we will evaluate the scalability of the intervention. We also believe that showing that CHW-led home screening and treatment is possible is the first step in developing a low-cost scalable intervention. Comment: I have also a question on the effectiveness of home PT to increase treatment rates (as can be read in the abstract). The authors have defined treatment rate as primary outcome. But this is not the same as PT effectiveness, usually defined as reduction of bilirubin below the treatment threshold that is considered appropriate. Especially when treatment is TcB based < 15 mg/dL, and not TSB-based, overtreatment may occur. And this unnecessarily started PT will contribute to the primary outcome. Therefore I suggest to measure TSB also in newborns with TcB above treatment threshold treatment threshold. I suggest to use a decision rule when to measure TSB after TcB, e.g., TcB +50 micromol/L > treatment thresholds is heel prick for TSB measurement Response: Thanks for your comment. This study was designed to evaluate the impact of the intervention on phototherapy treatment rates in intervention and comparison households. Phototherapy is known to be effective in treating neonatal hyperbilirubinemia. As a result, we did not design the study to assess the effectiveness of home phototherapy. Nevertheless, the study will report the number and percent of infants that met the treatment criteria and are treated at home, and who have a transcutaneous bilirubin (TcB) <15 mg/dL on consecutive days after the intervention is completed. This will give a measure of household phototherapy intervention effectiveness. Measuring the total serum bilirubin (TSB) in newborns who had a TcB greater than the treatment threshold in rural Bangladesh and using the TSB to determine home treatment eligibility is not feasible for this intervention in this community. The households are far from a laboratory and obtaining a TSB result from a newborn where the specimen was collected at home and brought to the laboratory will take a long time. Waiting to start treatment until the TSB result is available will substantially reduce the effectiveness of the intervention. One of the main advantages of the TcB device is providing instant diagnostic data to begin treatment if indicated immediately. Waiting as much as one day to obtain a TSB result may result in the TSB rising to a level where we would not recommend home treatment but rather would focus on hospital referral. In addition, CHWs in low- to middle-income countries may not be comfortable or trained to collect blood on newborns and specialized personnel would be needed which would increase the intervention costs and reduce the intervention scalability. The acceptability of the intervention could also decrease as parents may not want blood to be drawn on their newborn and refuse blood collection. TcB values are highly correlated to TSB at levels less than 15 mg/dL and the risk of substantial overtreatment is low. Comment : Prenatal education should also be mentioned here - in the intervention arm Response: This was updated. Comment: Is this because she will probably not be back in time or because she will leave before prenatal education? Response: Thanks for the comment. It is because the mother will not be present in the study area at the time of birth. Comment: When you consider the first aim important in the prevention this is appropriate to list here, but it is not your main outcome. See comments of other reviewers. Response: Thanks, the order of the Aims was reversed. Comment: Sample size calculations are based on many estimations, the percentage of jaundiced newborns that need treatment is based on a literature reference, and it is estimated that 50% of the infants born in facilities receive treatment, and none of the newborns who are born at home. I suggest that the authors use numbers that arise from the population in the research area. This may affect sample size. Response: The figures used for the calculation were based on birth statistics from the local hospital in Shakipur and from talking to local doctors. Comment : Intervention arm consists of three interventions. Should be stated earlier (see major comments). Response: We updated the title and the abstract to highlight this. Comment: ....danger signs including signs of ABE (using the BIND-M score), Response: This comment was addressed in response to the other reviewers Comment: Why do you choose to use the old (2004) AAP guideline and not the more recent one (2022)? Response: Thanks, this comment was addressed in the response to the other reviewers. Comment: On which part of the body is TcB measured? How often are TcB measurements done in the same session? Response: The TcB was measured by gently pressing the meter on the middle part of the sternum. In the same session, three consecutive measurements were taken, and an algorithm took the average of three measurements for the decision-making process. Comment: But how is this overnight pause handled when the jaundiced infant has just started PT? It seems a little bit dangerous to stop for 6 hours when PT has just been started. Please define a minimal PT duration before stopping 6 hours (e.g., 6 hours) and else ... maybe every one should accept one night with less sleep (more will probably follow for other reasons). Response: The timing for the overnight pause was set to be between midnight and 0600. This is highlighted in the operational description that was added. CHW visits will occur in the morning, and then they will visit again 4-6 hours after starting phototherapy in the eligible newborns. The newborns will receive at least 7 hours of treatment, but probably 12 hours of treatment before the overnight pause. We think having a pause overnight will increase the acceptability of the intervention. Comment: And what about signs of infection/sepsis? Are these factors that lower the treatment threshold? Or reason to be admitted to an hospital, which may be difficult (as I understood from the authors). Response: All newborns with signs of sepsis will be referred to a hospital for care. We will not attempt to treat newborns with signs of sepsis at home as a part of this study. Comment: iii....text is missing Response: Updated. Comment : 80 participants seem a rather large sample for these focus groups. Usually no other answers are obtained after fewer than the suggested 80 participants. Please see literature on satiety points in focus groups. Response : We agree with your comments. We will conduct four focus group discussions (8-10 participants in each session) and depending on the saturation of data, will further adjust the numbers. Comment: detect neonatal infection? Words are missing. Response: Updated. Comment: The prenatal education and home..... Response: Updated. Comments: #12: What is the reference source? #13: please provide website or link to appropriate docs Response: Updated Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Slusher TM and Farouk Z. Reviewer Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.15331.r33065 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v1#referee-response-33065 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 15 May 2023 Tina M. Slusher , Department of Pediatrics, Global Health Program, Critical Care Division, University of Minnesota, Minneapolis, MN, USA Zubaida Farouk , Bayero University Kano, Kano, Nigeria Approved with Reservations VIEWS 0 https://doi.org/10.21956/gatesopenres.15331.r33065 This study does have the potential to improve outcome in neonates with significant hyperbilirubinemia in Bangladesh and other LMICs if shown to be safe and effective. Obviously, it should be possible to provide more timely access to phototherapy and to ... Continue reading READ ALL This study does have the potential to improve outcome in neonates with significant hyperbilirubinemia in Bangladesh and other LMICs if shown to be safe and effective. Obviously, it should be possible to provide more timely access to phototherapy and to treat neonates who are having difficulty getting to their referral center and to do it less expensively—all very important in LMICs. It is well designed as a cluster randomized trial. The most recent 2022 AAP guidelines do allow for careful and limited home phototherapy but as these authors clearly realize a protocol for home phototherapy in other countries including LMICs needs to be carefully studied for safety and efficacy before widespread implementation. We congratulate these authors for this idea. The study team is strong and quite experienced. We do have questions to which we feel answers will improve the study substantially. Thank you for allowing us to review this protocol. We suggest attaching survey questionnaires and other tools including checklists for the study. These materials would likely fill in many of the gaps we mention below. The focus of the study is timely identification and treatment of hyperbilirubinemia, why should aim 1 be about exclusive breastfeeding? We would suggest reversing the aims or simply including encouraging and supporting breastfeeding as a means to decrease hyperbilirubinemia. You do not mention training for the mothers on preventative practices like avoiding triggers for hemolysis in G6PD deficient neonates such as avoiding henna and mentholated products or jaundiced preventative measures beyond adequate breastfeeding. G6PD screening should be included in the baseline labs as Bangladesh has a G6PD deficiency rate greater than 5% in males. Without knowing G6PD status determining risk of significant or severe jaundice will be more difficult. We also wonder about neonates with set up for Rhesus or ABO incompatibility? Will these neonates be enrolled in the study and not transferred to the referral center until after 36-48 hours or will they be excluded and referred sooner? We would be okay with starting home phototherapy in these neonates while transport was arranged but would be uncomfortable keeping these neonates on home phototherapy for a prolonged time because of their risk of rapidly developing severe hyperbilirubinemia which might be missed with only daily bilirubin checks. It would be important to know the outcomes of the comparative group i.e., the number in both the treatment arm and control arms that need hospital referral, EBT and have ABE or die from complication of the treatment or jaundice-related death. Are you looking at the proportion of newborns receiving treatment in both groups? Will the comparative or control group ever get home phototherapy? Will both groups be receiving intensive phototherapy? Agree with need to specifically look for ABE and would suggest either the BIND or modified BIND score in any neonate with possible ABE on exam in both groups. Suggest looking for signs of ABE at the time of starting phototherapy and each time the neonate is examined. You should also assess for ABE at timepoint of referral to the hospital for exchange. We also would strongly suggest surveying/examining for signs of ABE at the endpoint. What is the definition of geographical proximity for the purpose of this study? Suggest minimum distance or some other objective criteria, can individual villages or wards serve as clusters? What is this written test that the CHW will take? Is an aptitude test? Do CHW have any prior medical training? Are they certified health workers? Please clarify in more detail what assessment the CHW’s will carry out and specify how it will be done. Please clarify tool that will be used to assess CHWs. What is the qualification of the field staff that will review performance of the CHW, what is the qualification of the training team? What will be used to assess the knowledge, skill, and attitude? Exactly what type of training and specific skill sets of CHW’s varies from country to country therefore needs to be specified. Is the distance between the neonate and the phototherapy lights/lamps fixed in a way that parents cannot adjust the distance otherwise I would be concerned that they might change the distance which of course affect the PT intensity. What does the training on phototherapy device entails? Does it cover how to provide effective phototherapy to an infant, where to place the infant, eye cover, indications for phototherapy, safety issues regarding phototherapy, exposure? Who is responsible for checking the irradiance of the photo units? CHW? Are the CHWs measuring it and if so, will they be trained how to do it accurately? How will the phototherapy be powered at home? Is there constant and availability of electricity at all homes in the study area? Also please explain why you chose to use the AAP guidelines and if they were adapted for use in Bangladesh as strongly suggested by the AAP themselves. Please state range of values rather than TcB above phototherapy threshold or simply include the graph showing used to determine when phototherapy will be begun. If using the AAP guidelines, then should almost certainly use the more conservative 2004 guidelines not the new 2022 guidelines but it would be much better would be to adapt guidelines specifically for your locale as stated above. Comprehensive guidelines already include jaundice as a danger sign therefore you are already going against these guidelines by keeping the neonate at home therefore you will need to explain this in your protocol. Is visual jaundice on the palm and sole despite TcB a requirement for referral to a hospital in this study? Please clarify. Who will be responsible for checking of the ambient temperature? The parents or CHW? State whether all parents have access to a phone? Please provide a checklist stating the potentials issues that the CHW will be checking. Who is going to do the blood groups CHWs? Are they certified to do heel pricks and run these tests in Bangladesh or is that certification required or is training CHWs to do these test all that is required for them to be able to do them? With training are the CHWs or other study staff able to do these tests in this setting? We are not statisticians, but we do not believe t-test is the appropriate test because t-test is used to compare between means and Chi Square test is used to compare proportions. This would also be true in secondary outcomes. Please find further comments in the annotated pdf hyperlinked above or at the following link: https://gatesopenresearch.s3.eu-west-1.amazonaws.com/linked/208927.Annotated_pdf_-_Review_Drs._Tina_Slusher_and_Zubaida_Farouk_for_Home_PT_in_Bangladesh_%28002%29.pdf Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Partly Are the datasets clearly presented in a useable and accessible format? Not applicable Competing Interests: No competing interests were disclosed. We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Slusher TM and Farouk Z. Reviewer Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.15331.r33065 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v1#referee-response-33065 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 17 Sep 2024 Eric Foote , Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, USA 17 Sep 2024 Author Response Responses to reviewer 1 comments Comment: We suggest attaching survey questionnaires and other tools including checklists for the study. These materials would likely fill in many of the gaps ... Continue reading Responses to reviewer 1 comments Comment: We suggest attaching survey questionnaires and other tools including checklists for the study. These materials would likely fill in many of the gaps we mention below. Response: These were added. Comment: The focus of the study is timely identification and treatment of hyperbilirubinemia, why should aim 1 be about exclusive breastfeeding? We would suggest reversing the aims or simply including encouraging and supporting breastfeeding as a means to decrease hyperbilirubinemia. Response: Thanks, we reversed the aims as suggested. Comment: You do not mention training for the mothers on preventative practices like avoiding triggers for hemolysis in G6PD deficient neonates such as avoiding henna and mentholated products or jaundiced preventative measures beyond adequate breastfeeding. G6PD screening should be included in the baseline labs as Bangladesh has a G6PD deficiency rate greater than 5% in males. Without knowing G6PD status determining risk of significant or severe jaundice will be more difficult. Response: We did not provide training on practices to avoid triggers for hemolysis. This is something we could add to future protocols. We thought for this protocol it was best to focus on breastfeeding, identifying newborn danger signs and developing a plan to go to the hospital for care. The ability to measure G6PD and obtain results could not be completed in the study region in a time frame to have the results change management or provide risk stratification. In addition, not all newborns with G6PD deficiency develop hemolytic hyperbilirubinemia. We think providing a longer duration phototherapy of 36 hour at high intensity (~50 µW/cm2/nm) and evaluating newborns twice on the day of phototherapy initiation and daily thereafter for danger signs and referring newborns to the hospital who have danger signs during phototherapy also provides a margin of safety. Initiating phototherapy at a transcutaneous bilirubin (TcB) level <15mg/dL will also provide a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels = 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most to nearly all cases of neonatal hyperbilirubinemia either through treatment at home or hospital referral and will markedly improve care for those newborns who would not otherwise be diagnosed or treated. Newborns will be provided high quality treatment at home where it was otherwise not available. Comment: We also wonder about neonates with set up for Rhesus or ABO incompatibility? Will these neonates be enrolled in the study and not transferred to the referral center until after 36-48 hours or will they be excluded and referred sooner? We would be okay with starting home phototherapy in these neonates while transport was arranged but would be uncomfortable keeping these neonates on home phototherapy for a prolonged time because of their risk of rapidly developing severe hyperbilirubinemia which might be missed with only daily bilirubin checks. Response: We limited the home treatment population to newborns >=35 weeks and >= 2kg without danger signs. We think that referring newborns >= 35 weeks and >= 2kg who are identified initially with a TcB >=15 mg/dL or with danger signs to the hospital provides a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels <15 mg/dL, providing a margin of safety. Likely those with severe hemolytic hyperbilirubinemia will be referred for care based on these criteria. The AAP 2004 phototherapy treatment thresholds are lower for hemolytic disease, and those at risk for ABO or rhesus incompatibility in this study will be treated at home at these lower thresholds provided the TcB is <15 mg/dL and no danger signs are present, providing a margin of safety. The newborns we identified whose mother is blood type O and the newborn blood type is A or B or whose mother is rhesus negative and the newborn is rhesus positive are not known to have ABO or rhesus disease, but are at risk based on their and their mother’s blood type and rhesus type. We think providing a longer duration phototherapy of 36 hours at high intensity (>50 µW/cm2/nm), evaluating newborns twice on the day of phototherapy initiation and daily thereafter, and referring newborns who have danger signs during phototherapy also provides a margin of safety. We will also check the TcB level daily for 2 days after treatment completion and refer those with a TcB>= 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most cases of neonatal hyperbilirubinemia either through home treatment or hospital referral and will markedly improve care for those newborns who would not otherwise be treated. We think referring every newborn at risk for hemolytic disease due to rhesus or ABO incompatibility will not be feasible in a setting where newborn care is already limited. Newborns will be provided high quality treatment at home where it was otherwise not available. In addition, we are not limiting study participants from seeking care outside of what is provided by the CHWs. Comment: It would be important to know the outcomes of the comparative group i.e., the number in both the treatment arm and control arms that need hospital referral, EBT and have ABE or die from complication of the treatment or jaundice-related death. Response: We will provide data in both arms on hospitalization for hyperbilirubinemia, exchange transfusion, phototherapy treatment, and mortality. We think these outcomes are sufficient to provide awareness of the safety of the treatment. We will not have hospitalization referral data in both arms as the study design does not make it possible to collect this information. Comment: Are you looking at the proportion of newborns receiving treatment in both groups? Response: Yes Comment: Will the comparative or control group ever get home phototherapy? Response: In the comparison group, newborns could receive hospital phototherapy if they obtain it through the existing postnatal care system in rural Bangladesh. The comparison group will not be provided home phototherapy by the study. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Will both groups be receiving intensive phototherapy? Response: See the response directly above. Newborns in the intervention group could receive phototherapy through the existing health care system, at home by study CHWs or by study CHW referral for hospital care. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Agree with need to specifically look for ABE and would suggest either the BIND or modified BIND score in any neonate with possible ABE on exam in both groups. Suggest looking for signs of ABE at the time of starting phototherapy and each time the neonate is examined. You should also assess for ABE at timepoint of referral to the hospital for exchange. We also would strongly suggest surveying/examining for signs of ABE at the endpoint. Response: We did not do this and do not think this is indicated. Neonatal danger sign measurement is an evidence-based method for CHWs to identify sick newborns in need of referral level care and is widely used in Bangladesh and in other LMICs. The likelihood of a newborn having ABE with a transcutaneous bilirubin <15 mg/dL is extremely low. Neonatal danger sign assessment could also identify newborns who may have ABE or BIND and they would then be referred for hospital level care, since a newborn with BIND or ABE will likely have newborn danger signs. There is no evidence that CHWs determining the BIND score or evaluating for ABE by CHWs will necessarily improve outcomes for newborns. Adding this procedure will make the CHW process more burdensome for unclear benefit, potentially making the process untenable to adopt at scale. In addition, rates of ABE and newborn related mortality are low ~1-2/1000 in South Asia. There would be a limited number of cases in our study population of 530 infants. It is unlikely we would find a statistically significant difference, given the sample size of the study. We think evaluating serum bilirubin levels in newborns that are referred, deaths, hospitalizations and need for exchange transfusion will sufficiently determine potential risks of the intervention. Comment: What is the definition of geographical proximity for the purpose of this study? Suggest minimum distance or some other objective criteria, can individual villages or wards serve as clusters? Response: We enrolled pregnant mothers fulfilling our enrollment criteria and formed a cluster of households that share a minimum distance of 100 meters between two households. Between two clusters we maintained a buffer zone of 1 km. Comment: What is this written test that the CHW will take? Is an aptitude test? Do CHW have any prior medical training? Are they certified health workers? Please clarify in more detail what assessment the CHW’s will carry out and specify how it will be done. Response: The eligibility criteria to become CHWs include female gender (due to cultural sensitivities with providing breastfeeding support), at least 20 years of age, completion of secondary school, and a minimum passing score of 60% on the written test. The written test will assess the candidates’ knowledge on community mobilization and sensitization. Candidates for study CHWs do not need previous experience as a healthcare worker. Work experience with government community groups will be considered favorably as a hiring criterion. Twelve CHWs who meet the requirements for initial CHW enrollment will be invited for a five-day training conducted by icddr,b staff and physicians from Dhaka Shishu (Children’s) Hospital and physicians from Sakhipur Health Complex. The training model is adopted from the “Validation of community health workers’ assessment of neonatal illness in rural Bangladesh” by Darmstadt et al. 13 The training will contain didactic and hands-on portions taught by physicians at icddr,b, Dhaka Shishu Hospital, and the local referral hospital. The first phase of training will be three days and cover the following topics: neonatal jaundice and responsibilities of CHWs, pregnancy care and maternal danger signs, delivery planning and safe delivery preparations, newborn care, infection prevention practices, breastfeeding and management of breastfeeding problems, risk of developing neonatal jaundice and management, neonatal jaundice symptoms and causes, communication and counselling. CHW knowledge acquisition will be assessed by a pre-test and post-test evaluation. The second phase of training over two days at Dhaka Shishu Hospital will primarily focus on hands-on teaching and include the following topics: recognizing neonatal illness and common neonatal problems, newborn danger sign assessment, postnatal services and the responsibilities of CHWs, referral process for sick newborns, neonatal jaundice symptoms and causes, management of neonatal jaundice in the home, and training on use of equipment (transcutaneous bilimeter, phototherapy device, thermometer). Bedside training will include danger sign assessment of neonates and using the transcutaneous bilimeter and phototherapy device. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Comment: Please clarify tool that will be used to assess CHWs. What is the qualification of the field staff that will review performance of the CHW, what is the qualification of the training team? What will be used to assess the knowledge, skill, and attitude? Exactly what type of training and specific skill sets of CHW’s varies from country to country therefore needs to be specified. Response: CHW knowledge acquisition in the first phase of training will be assessed by a pre-test and post-test evaluation. There will also be a pre-test and post-test assessment on the content of the second phase of training. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Then, the CHWs will be observed performing physical examinations and using equipment in the field for three days under supervision from the study physician. The ten CHWs that performed best on the assessments will be invited to participate in the study. The study physician will observe CHWs’ neonatal danger sign assessments over the course of the study to evaluate the sensitivity and specificity of CHW newborn danger sign assessments in comparison to physician examination. The study physician will repeat the newborn danger sign assessment independently within 4 hours of the CHW assessment. The study physician will repeat 20% of the newborn danger sign assessments conducted by each CHW. The sensitivity and specificity of CHW physical newborn examination in identifying newborns with clinical danger signs will be determined in comparison to a physician’s physical examination. Feedback will be given to CHWs based on their danger sign assessments. In addition, the study physician and field staff will observe CHWs administering home phototherapy and provide feedback as necessary. Comment: Is the distance between the neonate and the phototherapy lights/lamps fixed in a way that parents cannot adjust the distance otherwise I would be concerned that they might change the distance which of course affect the PT intensity. Response: The phototherapy arm distance is fixed at 49.5 centimeters above the newborn and cannot be adjusted. This is indicated now in the text. Comment: What does the training on phototherapy device entails? Does it cover how to provide effective phototherapy to an infant, where to place the infant, eye cover, indications for phototherapy, safety issues regarding phototherapy, exposure? Response: Yes. We added the checklist that will be used. Comment: Who is responsible for checking the irradiance of the photo units? CHW? Response: The CHW on initiation of phototherapy. Comment: Are the CHWs measuring it and if so, will they be trained how to do it accurately? Response: Yes Comment: How will the phototherapy be powered at home? Response: It will be powered via home electricity. The units have a 12-hour battery backup that can help the unit maintain power during intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Is there constant and availability of electricity at all homes in the study area? Response: Power is available at all homes. The units have a 12-hour battery backup that can help the unit maintain power for intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Also please explain why you chose to use the AAP guidelines and if they were adapted for use in Bangladesh as strongly suggested by the AAP themselves. Response: We wanted to use an internationally recognized guideline that could be applied in different countries. We also wanted to have a clear phototherapy threshold based on age in hours. Comment: Please state range of values rather than TcB above phototherapy threshold or simply include the graph showing used to determine when phototherapy will be begun. If using the AAP guidelines, then should almost certainly use the more conservative 2004 guidelines not the new 2022 guidelines but it would be much better would be to adapt guidelines specifically for your locale as stated above. Response: We will add the 2004 AAP phototherapy threshold graph. Comment: Comprehensive guidelines already include jaundice as a danger sign therefore you are already going against these guidelines by keeping the neonate at home therefore you will need to explain this in your protocol. Is visual jaundice on the palm and sole despite TcB a requirement for referral to a hospital in this study? Please clarify. Response: Visible jaundice of the palms of the hands or soles of the feet is considered a danger sign and those newborns will be referred for hospital-level care irrespective of the TcB value and will be checked with every single CHW assessment. Comment: Who will be responsible for checking of the ambient temperature? The parents or CHW? Response: The CHW. Comment: State whether all parents have access to a phone? Response: During enrollment we conducted a short survey and found all the parents have access to a mobile phone, which was important for CHWs to arrange to follow-up. Comment: Please provide a checklist stating the potentials issues that the CHW will be checking. Response: We have included the phototherapy checklist that CHWs will be using. Comment: Who is going to do the blood groups CHWs? Are they certified to do heel pricks and run these tests in Bangladesh or is that certification required or is training CHWs to do these test all that is required for them to be able to do them? With training are the CHWs or other study staff able to do these tests in this setting? Response: The blood grouping and rhesus type will be done by trained medical technologists during the birth survey. CHWs are not certified to do heel pricks and run tests. The trained medical technologist will conduct the on-spot blood grouping of parents and newborns. Comment: We are not statisticians, but we do not believe t-test is the appropriate test because t-test is used to compare between means and Chi Square test is used to compare proportions. This would also be true in secondary outcomes. Response: We will change this to a chi-square test. Responses to reviewer 1 comments Comment: We suggest attaching survey questionnaires and other tools including checklists for the study. These materials would likely fill in many of the gaps we mention below. Response: These were added. Comment: The focus of the study is timely identification and treatment of hyperbilirubinemia, why should aim 1 be about exclusive breastfeeding? We would suggest reversing the aims or simply including encouraging and supporting breastfeeding as a means to decrease hyperbilirubinemia. Response: Thanks, we reversed the aims as suggested. Comment: You do not mention training for the mothers on preventative practices like avoiding triggers for hemolysis in G6PD deficient neonates such as avoiding henna and mentholated products or jaundiced preventative measures beyond adequate breastfeeding. G6PD screening should be included in the baseline labs as Bangladesh has a G6PD deficiency rate greater than 5% in males. Without knowing G6PD status determining risk of significant or severe jaundice will be more difficult. Response: We did not provide training on practices to avoid triggers for hemolysis. This is something we could add to future protocols. We thought for this protocol it was best to focus on breastfeeding, identifying newborn danger signs and developing a plan to go to the hospital for care. The ability to measure G6PD and obtain results could not be completed in the study region in a time frame to have the results change management or provide risk stratification. In addition, not all newborns with G6PD deficiency develop hemolytic hyperbilirubinemia. We think providing a longer duration phototherapy of 36 hour at high intensity (~50 µW/cm2/nm) and evaluating newborns twice on the day of phototherapy initiation and daily thereafter for danger signs and referring newborns to the hospital who have danger signs during phototherapy also provides a margin of safety. Initiating phototherapy at a transcutaneous bilirubin (TcB) level <15mg/dL will also provide a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels = 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most to nearly all cases of neonatal hyperbilirubinemia either through treatment at home or hospital referral and will markedly improve care for those newborns who would not otherwise be diagnosed or treated. Newborns will be provided high quality treatment at home where it was otherwise not available. Comment: We also wonder about neonates with set up for Rhesus or ABO incompatibility? Will these neonates be enrolled in the study and not transferred to the referral center until after 36-48 hours or will they be excluded and referred sooner? We would be okay with starting home phototherapy in these neonates while transport was arranged but would be uncomfortable keeping these neonates on home phototherapy for a prolonged time because of their risk of rapidly developing severe hyperbilirubinemia which might be missed with only daily bilirubin checks. Response: We limited the home treatment population to newborns >=35 weeks and >= 2kg without danger signs. We think that referring newborns >= 35 weeks and >= 2kg who are identified initially with a TcB >=15 mg/dL or with danger signs to the hospital provides a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels <15 mg/dL, providing a margin of safety. Likely those with severe hemolytic hyperbilirubinemia will be referred for care based on these criteria. The AAP 2004 phototherapy treatment thresholds are lower for hemolytic disease, and those at risk for ABO or rhesus incompatibility in this study will be treated at home at these lower thresholds provided the TcB is <15 mg/dL and no danger signs are present, providing a margin of safety. The newborns we identified whose mother is blood type O and the newborn blood type is A or B or whose mother is rhesus negative and the newborn is rhesus positive are not known to have ABO or rhesus disease, but are at risk based on their and their mother’s blood type and rhesus type. We think providing a longer duration phototherapy of 36 hours at high intensity (>50 µW/cm2/nm), evaluating newborns twice on the day of phototherapy initiation and daily thereafter, and referring newborns who have danger signs during phototherapy also provides a margin of safety. We will also check the TcB level daily for 2 days after treatment completion and refer those with a TcB>= 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most cases of neonatal hyperbilirubinemia either through home treatment or hospital referral and will markedly improve care for those newborns who would not otherwise be treated. We think referring every newborn at risk for hemolytic disease due to rhesus or ABO incompatibility will not be feasible in a setting where newborn care is already limited. Newborns will be provided high quality treatment at home where it was otherwise not available. In addition, we are not limiting study participants from seeking care outside of what is provided by the CHWs. Comment: It would be important to know the outcomes of the comparative group i.e., the number in both the treatment arm and control arms that need hospital referral, EBT and have ABE or die from complication of the treatment or jaundice-related death. Response: We will provide data in both arms on hospitalization for hyperbilirubinemia, exchange transfusion, phototherapy treatment, and mortality. We think these outcomes are sufficient to provide awareness of the safety of the treatment. We will not have hospitalization referral data in both arms as the study design does not make it possible to collect this information. Comment: Are you looking at the proportion of newborns receiving treatment in both groups? Response: Yes Comment: Will the comparative or control group ever get home phototherapy? Response: In the comparison group, newborns could receive hospital phototherapy if they obtain it through the existing postnatal care system in rural Bangladesh. The comparison group will not be provided home phototherapy by the study. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Will both groups be receiving intensive phototherapy? Response: See the response directly above. Newborns in the intervention group could receive phototherapy through the existing health care system, at home by study CHWs or by study CHW referral for hospital care. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Agree with need to specifically look for ABE and would suggest either the BIND or modified BIND score in any neonate with possible ABE on exam in both groups. Suggest looking for signs of ABE at the time of starting phototherapy and each time the neonate is examined. You should also assess for ABE at timepoint of referral to the hospital for exchange. We also would strongly suggest surveying/examining for signs of ABE at the endpoint. Response: We did not do this and do not think this is indicated. Neonatal danger sign measurement is an evidence-based method for CHWs to identify sick newborns in need of referral level care and is widely used in Bangladesh and in other LMICs. The likelihood of a newborn having ABE with a transcutaneous bilirubin <15 mg/dL is extremely low. Neonatal danger sign assessment could also identify newborns who may have ABE or BIND and they would then be referred for hospital level care, since a newborn with BIND or ABE will likely have newborn danger signs. There is no evidence that CHWs determining the BIND score or evaluating for ABE by CHWs will necessarily improve outcomes for newborns. Adding this procedure will make the CHW process more burdensome for unclear benefit, potentially making the process untenable to adopt at scale. In addition, rates of ABE and newborn related mortality are low ~1-2/1000 in South Asia. There would be a limited number of cases in our study population of 530 infants. It is unlikely we would find a statistically significant difference, given the sample size of the study. We think evaluating serum bilirubin levels in newborns that are referred, deaths, hospitalizations and need for exchange transfusion will sufficiently determine potential risks of the intervention. Comment: What is the definition of geographical proximity for the purpose of this study? Suggest minimum distance or some other objective criteria, can individual villages or wards serve as clusters? Response: We enrolled pregnant mothers fulfilling our enrollment criteria and formed a cluster of households that share a minimum distance of 100 meters between two households. Between two clusters we maintained a buffer zone of 1 km. Comment: What is this written test that the CHW will take? Is an aptitude test? Do CHW have any prior medical training? Are they certified health workers? Please clarify in more detail what assessment the CHW’s will carry out and specify how it will be done. Response: The eligibility criteria to become CHWs include female gender (due to cultural sensitivities with providing breastfeeding support), at least 20 years of age, completion of secondary school, and a minimum passing score of 60% on the written test. The written test will assess the candidates’ knowledge on community mobilization and sensitization. Candidates for study CHWs do not need previous experience as a healthcare worker. Work experience with government community groups will be considered favorably as a hiring criterion. Twelve CHWs who meet the requirements for initial CHW enrollment will be invited for a five-day training conducted by icddr,b staff and physicians from Dhaka Shishu (Children’s) Hospital and physicians from Sakhipur Health Complex. The training model is adopted from the “Validation of community health workers’ assessment of neonatal illness in rural Bangladesh” by Darmstadt et al. 13 The training will contain didactic and hands-on portions taught by physicians at icddr,b, Dhaka Shishu Hospital, and the local referral hospital. The first phase of training will be three days and cover the following topics: neonatal jaundice and responsibilities of CHWs, pregnancy care and maternal danger signs, delivery planning and safe delivery preparations, newborn care, infection prevention practices, breastfeeding and management of breastfeeding problems, risk of developing neonatal jaundice and management, neonatal jaundice symptoms and causes, communication and counselling. CHW knowledge acquisition will be assessed by a pre-test and post-test evaluation. The second phase of training over two days at Dhaka Shishu Hospital will primarily focus on hands-on teaching and include the following topics: recognizing neonatal illness and common neonatal problems, newborn danger sign assessment, postnatal services and the responsibilities of CHWs, referral process for sick newborns, neonatal jaundice symptoms and causes, management of neonatal jaundice in the home, and training on use of equipment (transcutaneous bilimeter, phototherapy device, thermometer). Bedside training will include danger sign assessment of neonates and using the transcutaneous bilimeter and phototherapy device. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Comment: Please clarify tool that will be used to assess CHWs. What is the qualification of the field staff that will review performance of the CHW, what is the qualification of the training team? What will be used to assess the knowledge, skill, and attitude? Exactly what type of training and specific skill sets of CHW’s varies from country to country therefore needs to be specified. Response: CHW knowledge acquisition in the first phase of training will be assessed by a pre-test and post-test evaluation. There will also be a pre-test and post-test assessment on the content of the second phase of training. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Then, the CHWs will be observed performing physical examinations and using equipment in the field for three days under supervision from the study physician. The ten CHWs that performed best on the assessments will be invited to participate in the study. The study physician will observe CHWs’ neonatal danger sign assessments over the course of the study to evaluate the sensitivity and specificity of CHW newborn danger sign assessments in comparison to physician examination. The study physician will repeat the newborn danger sign assessment independently within 4 hours of the CHW assessment. The study physician will repeat 20% of the newborn danger sign assessments conducted by each CHW. The sensitivity and specificity of CHW physical newborn examination in identifying newborns with clinical danger signs will be determined in comparison to a physician’s physical examination. Feedback will be given to CHWs based on their danger sign assessments. In addition, the study physician and field staff will observe CHWs administering home phototherapy and provide feedback as necessary. Comment: Is the distance between the neonate and the phototherapy lights/lamps fixed in a way that parents cannot adjust the distance otherwise I would be concerned that they might change the distance which of course affect the PT intensity. Response: The phototherapy arm distance is fixed at 49.5 centimeters above the newborn and cannot be adjusted. This is indicated now in the text. Comment: What does the training on phototherapy device entails? Does it cover how to provide effective phototherapy to an infant, where to place the infant, eye cover, indications for phototherapy, safety issues regarding phototherapy, exposure? Response: Yes. We added the checklist that will be used. Comment: Who is responsible for checking the irradiance of the photo units? CHW? Response: The CHW on initiation of phototherapy. Comment: Are the CHWs measuring it and if so, will they be trained how to do it accurately? Response: Yes Comment: How will the phototherapy be powered at home? Response: It will be powered via home electricity. The units have a 12-hour battery backup that can help the unit maintain power during intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Is there constant and availability of electricity at all homes in the study area? Response: Power is available at all homes. The units have a 12-hour battery backup that can help the unit maintain power for intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Also please explain why you chose to use the AAP guidelines and if they were adapted for use in Bangladesh as strongly suggested by the AAP themselves. Response: We wanted to use an internationally recognized guideline that could be applied in different countries. We also wanted to have a clear phototherapy threshold based on age in hours. Comment: Please state range of values rather than TcB above phototherapy threshold or simply include the graph showing used to determine when phototherapy will be begun. If using the AAP guidelines, then should almost certainly use the more conservative 2004 guidelines not the new 2022 guidelines but it would be much better would be to adapt guidelines specifically for your locale as stated above. Response: We will add the 2004 AAP phototherapy threshold graph. Comment: Comprehensive guidelines already include jaundice as a danger sign therefore you are already going against these guidelines by keeping the neonate at home therefore you will need to explain this in your protocol. Is visual jaundice on the palm and sole despite TcB a requirement for referral to a hospital in this study? Please clarify. Response: Visible jaundice of the palms of the hands or soles of the feet is considered a danger sign and those newborns will be referred for hospital-level care irrespective of the TcB value and will be checked with every single CHW assessment. Comment: Who will be responsible for checking of the ambient temperature? The parents or CHW? Response: The CHW. Comment: State whether all parents have access to a phone? Response: During enrollment we conducted a short survey and found all the parents have access to a mobile phone, which was important for CHWs to arrange to follow-up. Comment: Please provide a checklist stating the potentials issues that the CHW will be checking. Response: We have included the phototherapy checklist that CHWs will be using. Comment: Who is going to do the blood groups CHWs? Are they certified to do heel pricks and run these tests in Bangladesh or is that certification required or is training CHWs to do these test all that is required for them to be able to do them? With training are the CHWs or other study staff able to do these tests in this setting? Response: The blood grouping and rhesus type will be done by trained medical technologists during the birth survey. CHWs are not certified to do heel pricks and run tests. The trained medical technologist will conduct the on-spot blood grouping of parents and newborns. Comment: We are not statisticians, but we do not believe t-test is the appropriate test because t-test is used to compare between means and Chi Square test is used to compare proportions. This would also be true in secondary outcomes. Response: We will change this to a chi-square test. Competing Interests: None Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 17 Sep 2024 Eric Foote , Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, USA 17 Sep 2024 Author Response Responses to reviewer 1 comments Comment: We suggest attaching survey questionnaires and other tools including checklists for the study. These materials would likely fill in many of the gaps ... Continue reading Responses to reviewer 1 comments Comment: We suggest attaching survey questionnaires and other tools including checklists for the study. These materials would likely fill in many of the gaps we mention below. Response: These were added. Comment: The focus of the study is timely identification and treatment of hyperbilirubinemia, why should aim 1 be about exclusive breastfeeding? We would suggest reversing the aims or simply including encouraging and supporting breastfeeding as a means to decrease hyperbilirubinemia. Response: Thanks, we reversed the aims as suggested. Comment: You do not mention training for the mothers on preventative practices like avoiding triggers for hemolysis in G6PD deficient neonates such as avoiding henna and mentholated products or jaundiced preventative measures beyond adequate breastfeeding. G6PD screening should be included in the baseline labs as Bangladesh has a G6PD deficiency rate greater than 5% in males. Without knowing G6PD status determining risk of significant or severe jaundice will be more difficult. Response: We did not provide training on practices to avoid triggers for hemolysis. This is something we could add to future protocols. We thought for this protocol it was best to focus on breastfeeding, identifying newborn danger signs and developing a plan to go to the hospital for care. The ability to measure G6PD and obtain results could not be completed in the study region in a time frame to have the results change management or provide risk stratification. In addition, not all newborns with G6PD deficiency develop hemolytic hyperbilirubinemia. We think providing a longer duration phototherapy of 36 hour at high intensity (~50 µW/cm2/nm) and evaluating newborns twice on the day of phototherapy initiation and daily thereafter for danger signs and referring newborns to the hospital who have danger signs during phototherapy also provides a margin of safety. Initiating phototherapy at a transcutaneous bilirubin (TcB) level <15mg/dL will also provide a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels = 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most to nearly all cases of neonatal hyperbilirubinemia either through treatment at home or hospital referral and will markedly improve care for those newborns who would not otherwise be diagnosed or treated. Newborns will be provided high quality treatment at home where it was otherwise not available. Comment: We also wonder about neonates with set up for Rhesus or ABO incompatibility? Will these neonates be enrolled in the study and not transferred to the referral center until after 36-48 hours or will they be excluded and referred sooner? We would be okay with starting home phototherapy in these neonates while transport was arranged but would be uncomfortable keeping these neonates on home phototherapy for a prolonged time because of their risk of rapidly developing severe hyperbilirubinemia which might be missed with only daily bilirubin checks. Response: We limited the home treatment population to newborns >=35 weeks and >= 2kg without danger signs. We think that referring newborns >= 35 weeks and >= 2kg who are identified initially with a TcB >=15 mg/dL or with danger signs to the hospital provides a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels <15 mg/dL, providing a margin of safety. Likely those with severe hemolytic hyperbilirubinemia will be referred for care based on these criteria. The AAP 2004 phototherapy treatment thresholds are lower for hemolytic disease, and those at risk for ABO or rhesus incompatibility in this study will be treated at home at these lower thresholds provided the TcB is <15 mg/dL and no danger signs are present, providing a margin of safety. The newborns we identified whose mother is blood type O and the newborn blood type is A or B or whose mother is rhesus negative and the newborn is rhesus positive are not known to have ABO or rhesus disease, but are at risk based on their and their mother’s blood type and rhesus type. We think providing a longer duration phototherapy of 36 hours at high intensity (>50 µW/cm2/nm), evaluating newborns twice on the day of phototherapy initiation and daily thereafter, and referring newborns who have danger signs during phototherapy also provides a margin of safety. We will also check the TcB level daily for 2 days after treatment completion and refer those with a TcB>= 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most cases of neonatal hyperbilirubinemia either through home treatment or hospital referral and will markedly improve care for those newborns who would not otherwise be treated. We think referring every newborn at risk for hemolytic disease due to rhesus or ABO incompatibility will not be feasible in a setting where newborn care is already limited. Newborns will be provided high quality treatment at home where it was otherwise not available. In addition, we are not limiting study participants from seeking care outside of what is provided by the CHWs. Comment: It would be important to know the outcomes of the comparative group i.e., the number in both the treatment arm and control arms that need hospital referral, EBT and have ABE or die from complication of the treatment or jaundice-related death. Response: We will provide data in both arms on hospitalization for hyperbilirubinemia, exchange transfusion, phototherapy treatment, and mortality. We think these outcomes are sufficient to provide awareness of the safety of the treatment. We will not have hospitalization referral data in both arms as the study design does not make it possible to collect this information. Comment: Are you looking at the proportion of newborns receiving treatment in both groups? Response: Yes Comment: Will the comparative or control group ever get home phototherapy? Response: In the comparison group, newborns could receive hospital phototherapy if they obtain it through the existing postnatal care system in rural Bangladesh. The comparison group will not be provided home phototherapy by the study. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Will both groups be receiving intensive phototherapy? Response: See the response directly above. Newborns in the intervention group could receive phototherapy through the existing health care system, at home by study CHWs or by study CHW referral for hospital care. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Agree with need to specifically look for ABE and would suggest either the BIND or modified BIND score in any neonate with possible ABE on exam in both groups. Suggest looking for signs of ABE at the time of starting phototherapy and each time the neonate is examined. You should also assess for ABE at timepoint of referral to the hospital for exchange. We also would strongly suggest surveying/examining for signs of ABE at the endpoint. Response: We did not do this and do not think this is indicated. Neonatal danger sign measurement is an evidence-based method for CHWs to identify sick newborns in need of referral level care and is widely used in Bangladesh and in other LMICs. The likelihood of a newborn having ABE with a transcutaneous bilirubin <15 mg/dL is extremely low. Neonatal danger sign assessment could also identify newborns who may have ABE or BIND and they would then be referred for hospital level care, since a newborn with BIND or ABE will likely have newborn danger signs. There is no evidence that CHWs determining the BIND score or evaluating for ABE by CHWs will necessarily improve outcomes for newborns. Adding this procedure will make the CHW process more burdensome for unclear benefit, potentially making the process untenable to adopt at scale. In addition, rates of ABE and newborn related mortality are low ~1-2/1000 in South Asia. There would be a limited number of cases in our study population of 530 infants. It is unlikely we would find a statistically significant difference, given the sample size of the study. We think evaluating serum bilirubin levels in newborns that are referred, deaths, hospitalizations and need for exchange transfusion will sufficiently determine potential risks of the intervention. Comment: What is the definition of geographical proximity for the purpose of this study? Suggest minimum distance or some other objective criteria, can individual villages or wards serve as clusters? Response: We enrolled pregnant mothers fulfilling our enrollment criteria and formed a cluster of households that share a minimum distance of 100 meters between two households. Between two clusters we maintained a buffer zone of 1 km. Comment: What is this written test that the CHW will take? Is an aptitude test? Do CHW have any prior medical training? Are they certified health workers? Please clarify in more detail what assessment the CHW’s will carry out and specify how it will be done. Response: The eligibility criteria to become CHWs include female gender (due to cultural sensitivities with providing breastfeeding support), at least 20 years of age, completion of secondary school, and a minimum passing score of 60% on the written test. The written test will assess the candidates’ knowledge on community mobilization and sensitization. Candidates for study CHWs do not need previous experience as a healthcare worker. Work experience with government community groups will be considered favorably as a hiring criterion. Twelve CHWs who meet the requirements for initial CHW enrollment will be invited for a five-day training conducted by icddr,b staff and physicians from Dhaka Shishu (Children’s) Hospital and physicians from Sakhipur Health Complex. The training model is adopted from the “Validation of community health workers’ assessment of neonatal illness in rural Bangladesh” by Darmstadt et al. 13 The training will contain didactic and hands-on portions taught by physicians at icddr,b, Dhaka Shishu Hospital, and the local referral hospital. The first phase of training will be three days and cover the following topics: neonatal jaundice and responsibilities of CHWs, pregnancy care and maternal danger signs, delivery planning and safe delivery preparations, newborn care, infection prevention practices, breastfeeding and management of breastfeeding problems, risk of developing neonatal jaundice and management, neonatal jaundice symptoms and causes, communication and counselling. CHW knowledge acquisition will be assessed by a pre-test and post-test evaluation. The second phase of training over two days at Dhaka Shishu Hospital will primarily focus on hands-on teaching and include the following topics: recognizing neonatal illness and common neonatal problems, newborn danger sign assessment, postnatal services and the responsibilities of CHWs, referral process for sick newborns, neonatal jaundice symptoms and causes, management of neonatal jaundice in the home, and training on use of equipment (transcutaneous bilimeter, phototherapy device, thermometer). Bedside training will include danger sign assessment of neonates and using the transcutaneous bilimeter and phototherapy device. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Comment: Please clarify tool that will be used to assess CHWs. What is the qualification of the field staff that will review performance of the CHW, what is the qualification of the training team? What will be used to assess the knowledge, skill, and attitude? Exactly what type of training and specific skill sets of CHW’s varies from country to country therefore needs to be specified. Response: CHW knowledge acquisition in the first phase of training will be assessed by a pre-test and post-test evaluation. There will also be a pre-test and post-test assessment on the content of the second phase of training. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Then, the CHWs will be observed performing physical examinations and using equipment in the field for three days under supervision from the study physician. The ten CHWs that performed best on the assessments will be invited to participate in the study. The study physician will observe CHWs’ neonatal danger sign assessments over the course of the study to evaluate the sensitivity and specificity of CHW newborn danger sign assessments in comparison to physician examination. The study physician will repeat the newborn danger sign assessment independently within 4 hours of the CHW assessment. The study physician will repeat 20% of the newborn danger sign assessments conducted by each CHW. The sensitivity and specificity of CHW physical newborn examination in identifying newborns with clinical danger signs will be determined in comparison to a physician’s physical examination. Feedback will be given to CHWs based on their danger sign assessments. In addition, the study physician and field staff will observe CHWs administering home phototherapy and provide feedback as necessary. Comment: Is the distance between the neonate and the phototherapy lights/lamps fixed in a way that parents cannot adjust the distance otherwise I would be concerned that they might change the distance which of course affect the PT intensity. Response: The phototherapy arm distance is fixed at 49.5 centimeters above the newborn and cannot be adjusted. This is indicated now in the text. Comment: What does the training on phototherapy device entails? Does it cover how to provide effective phototherapy to an infant, where to place the infant, eye cover, indications for phototherapy, safety issues regarding phototherapy, exposure? Response: Yes. We added the checklist that will be used. Comment: Who is responsible for checking the irradiance of the photo units? CHW? Response: The CHW on initiation of phototherapy. Comment: Are the CHWs measuring it and if so, will they be trained how to do it accurately? Response: Yes Comment: How will the phototherapy be powered at home? Response: It will be powered via home electricity. The units have a 12-hour battery backup that can help the unit maintain power during intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Is there constant and availability of electricity at all homes in the study area? Response: Power is available at all homes. The units have a 12-hour battery backup that can help the unit maintain power for intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Also please explain why you chose to use the AAP guidelines and if they were adapted for use in Bangladesh as strongly suggested by the AAP themselves. Response: We wanted to use an internationally recognized guideline that could be applied in different countries. We also wanted to have a clear phototherapy threshold based on age in hours. Comment: Please state range of values rather than TcB above phototherapy threshold or simply include the graph showing used to determine when phototherapy will be begun. If using the AAP guidelines, then should almost certainly use the more conservative 2004 guidelines not the new 2022 guidelines but it would be much better would be to adapt guidelines specifically for your locale as stated above. Response: We will add the 2004 AAP phototherapy threshold graph. Comment: Comprehensive guidelines already include jaundice as a danger sign therefore you are already going against these guidelines by keeping the neonate at home therefore you will need to explain this in your protocol. Is visual jaundice on the palm and sole despite TcB a requirement for referral to a hospital in this study? Please clarify. Response: Visible jaundice of the palms of the hands or soles of the feet is considered a danger sign and those newborns will be referred for hospital-level care irrespective of the TcB value and will be checked with every single CHW assessment. Comment: Who will be responsible for checking of the ambient temperature? The parents or CHW? Response: The CHW. Comment: State whether all parents have access to a phone? Response: During enrollment we conducted a short survey and found all the parents have access to a mobile phone, which was important for CHWs to arrange to follow-up. Comment: Please provide a checklist stating the potentials issues that the CHW will be checking. Response: We have included the phototherapy checklist that CHWs will be using. Comment: Who is going to do the blood groups CHWs? Are they certified to do heel pricks and run these tests in Bangladesh or is that certification required or is training CHWs to do these test all that is required for them to be able to do them? With training are the CHWs or other study staff able to do these tests in this setting? Response: The blood grouping and rhesus type will be done by trained medical technologists during the birth survey. CHWs are not certified to do heel pricks and run tests. The trained medical technologist will conduct the on-spot blood grouping of parents and newborns. Comment: We are not statisticians, but we do not believe t-test is the appropriate test because t-test is used to compare between means and Chi Square test is used to compare proportions. This would also be true in secondary outcomes. Response: We will change this to a chi-square test. Responses to reviewer 1 comments Comment: We suggest attaching survey questionnaires and other tools including checklists for the study. These materials would likely fill in many of the gaps we mention below. Response: These were added. Comment: The focus of the study is timely identification and treatment of hyperbilirubinemia, why should aim 1 be about exclusive breastfeeding? We would suggest reversing the aims or simply including encouraging and supporting breastfeeding as a means to decrease hyperbilirubinemia. Response: Thanks, we reversed the aims as suggested. Comment: You do not mention training for the mothers on preventative practices like avoiding triggers for hemolysis in G6PD deficient neonates such as avoiding henna and mentholated products or jaundiced preventative measures beyond adequate breastfeeding. G6PD screening should be included in the baseline labs as Bangladesh has a G6PD deficiency rate greater than 5% in males. Without knowing G6PD status determining risk of significant or severe jaundice will be more difficult. Response: We did not provide training on practices to avoid triggers for hemolysis. This is something we could add to future protocols. We thought for this protocol it was best to focus on breastfeeding, identifying newborn danger signs and developing a plan to go to the hospital for care. The ability to measure G6PD and obtain results could not be completed in the study region in a time frame to have the results change management or provide risk stratification. In addition, not all newborns with G6PD deficiency develop hemolytic hyperbilirubinemia. We think providing a longer duration phototherapy of 36 hour at high intensity (~50 µW/cm2/nm) and evaluating newborns twice on the day of phototherapy initiation and daily thereafter for danger signs and referring newborns to the hospital who have danger signs during phototherapy also provides a margin of safety. Initiating phototherapy at a transcutaneous bilirubin (TcB) level <15mg/dL will also provide a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels = 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most to nearly all cases of neonatal hyperbilirubinemia either through treatment at home or hospital referral and will markedly improve care for those newborns who would not otherwise be diagnosed or treated. Newborns will be provided high quality treatment at home where it was otherwise not available. Comment: We also wonder about neonates with set up for Rhesus or ABO incompatibility? Will these neonates be enrolled in the study and not transferred to the referral center until after 36-48 hours or will they be excluded and referred sooner? We would be okay with starting home phototherapy in these neonates while transport was arranged but would be uncomfortable keeping these neonates on home phototherapy for a prolonged time because of their risk of rapidly developing severe hyperbilirubinemia which might be missed with only daily bilirubin checks. Response: We limited the home treatment population to newborns >=35 weeks and >= 2kg without danger signs. We think that referring newborns >= 35 weeks and >= 2kg who are identified initially with a TcB >=15 mg/dL or with danger signs to the hospital provides a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels <15 mg/dL, providing a margin of safety. Likely those with severe hemolytic hyperbilirubinemia will be referred for care based on these criteria. The AAP 2004 phototherapy treatment thresholds are lower for hemolytic disease, and those at risk for ABO or rhesus incompatibility in this study will be treated at home at these lower thresholds provided the TcB is <15 mg/dL and no danger signs are present, providing a margin of safety. The newborns we identified whose mother is blood type O and the newborn blood type is A or B or whose mother is rhesus negative and the newborn is rhesus positive are not known to have ABO or rhesus disease, but are at risk based on their and their mother’s blood type and rhesus type. We think providing a longer duration phototherapy of 36 hours at high intensity (>50 µW/cm2/nm), evaluating newborns twice on the day of phototherapy initiation and daily thereafter, and referring newborns who have danger signs during phototherapy also provides a margin of safety. We will also check the TcB level daily for 2 days after treatment completion and refer those with a TcB>= 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most cases of neonatal hyperbilirubinemia either through home treatment or hospital referral and will markedly improve care for those newborns who would not otherwise be treated. We think referring every newborn at risk for hemolytic disease due to rhesus or ABO incompatibility will not be feasible in a setting where newborn care is already limited. Newborns will be provided high quality treatment at home where it was otherwise not available. In addition, we are not limiting study participants from seeking care outside of what is provided by the CHWs. Comment: It would be important to know the outcomes of the comparative group i.e., the number in both the treatment arm and control arms that need hospital referral, EBT and have ABE or die from complication of the treatment or jaundice-related death. Response: We will provide data in both arms on hospitalization for hyperbilirubinemia, exchange transfusion, phototherapy treatment, and mortality. We think these outcomes are sufficient to provide awareness of the safety of the treatment. We will not have hospitalization referral data in both arms as the study design does not make it possible to collect this information. Comment: Are you looking at the proportion of newborns receiving treatment in both groups? Response: Yes Comment: Will the comparative or control group ever get home phototherapy? Response: In the comparison group, newborns could receive hospital phototherapy if they obtain it through the existing postnatal care system in rural Bangladesh. The comparison group will not be provided home phototherapy by the study. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Will both groups be receiving intensive phototherapy? Response: See the response directly above. Newborns in the intervention group could receive phototherapy through the existing health care system, at home by study CHWs or by study CHW referral for hospital care. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Agree with need to specifically look for ABE and would suggest either the BIND or modified BIND score in any neonate with possible ABE on exam in both groups. Suggest looking for signs of ABE at the time of starting phototherapy and each time the neonate is examined. You should also assess for ABE at timepoint of referral to the hospital for exchange. We also would strongly suggest surveying/examining for signs of ABE at the endpoint. Response: We did not do this and do not think this is indicated. Neonatal danger sign measurement is an evidence-based method for CHWs to identify sick newborns in need of referral level care and is widely used in Bangladesh and in other LMICs. The likelihood of a newborn having ABE with a transcutaneous bilirubin <15 mg/dL is extremely low. Neonatal danger sign assessment could also identify newborns who may have ABE or BIND and they would then be referred for hospital level care, since a newborn with BIND or ABE will likely have newborn danger signs. There is no evidence that CHWs determining the BIND score or evaluating for ABE by CHWs will necessarily improve outcomes for newborns. Adding this procedure will make the CHW process more burdensome for unclear benefit, potentially making the process untenable to adopt at scale. In addition, rates of ABE and newborn related mortality are low ~1-2/1000 in South Asia. There would be a limited number of cases in our study population of 530 infants. It is unlikely we would find a statistically significant difference, given the sample size of the study. We think evaluating serum bilirubin levels in newborns that are referred, deaths, hospitalizations and need for exchange transfusion will sufficiently determine potential risks of the intervention. Comment: What is the definition of geographical proximity for the purpose of this study? Suggest minimum distance or some other objective criteria, can individual villages or wards serve as clusters? Response: We enrolled pregnant mothers fulfilling our enrollment criteria and formed a cluster of households that share a minimum distance of 100 meters between two households. Between two clusters we maintained a buffer zone of 1 km. Comment: What is this written test that the CHW will take? Is an aptitude test? Do CHW have any prior medical training? Are they certified health workers? Please clarify in more detail what assessment the CHW’s will carry out and specify how it will be done. Response: The eligibility criteria to become CHWs include female gender (due to cultural sensitivities with providing breastfeeding support), at least 20 years of age, completion of secondary school, and a minimum passing score of 60% on the written test. The written test will assess the candidates’ knowledge on community mobilization and sensitization. Candidates for study CHWs do not need previous experience as a healthcare worker. Work experience with government community groups will be considered favorably as a hiring criterion. Twelve CHWs who meet the requirements for initial CHW enrollment will be invited for a five-day training conducted by icddr,b staff and physicians from Dhaka Shishu (Children’s) Hospital and physicians from Sakhipur Health Complex. The training model is adopted from the “Validation of community health workers’ assessment of neonatal illness in rural Bangladesh” by Darmstadt et al. 13 The training will contain didactic and hands-on portions taught by physicians at icddr,b, Dhaka Shishu Hospital, and the local referral hospital. The first phase of training will be three days and cover the following topics: neonatal jaundice and responsibilities of CHWs, pregnancy care and maternal danger signs, delivery planning and safe delivery preparations, newborn care, infection prevention practices, breastfeeding and management of breastfeeding problems, risk of developing neonatal jaundice and management, neonatal jaundice symptoms and causes, communication and counselling. CHW knowledge acquisition will be assessed by a pre-test and post-test evaluation. The second phase of training over two days at Dhaka Shishu Hospital will primarily focus on hands-on teaching and include the following topics: recognizing neonatal illness and common neonatal problems, newborn danger sign assessment, postnatal services and the responsibilities of CHWs, referral process for sick newborns, neonatal jaundice symptoms and causes, management of neonatal jaundice in the home, and training on use of equipment (transcutaneous bilimeter, phototherapy device, thermometer). Bedside training will include danger sign assessment of neonates and using the transcutaneous bilimeter and phototherapy device. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Comment: Please clarify tool that will be used to assess CHWs. What is the qualification of the field staff that will review performance of the CHW, what is the qualification of the training team? What will be used to assess the knowledge, skill, and attitude? Exactly what type of training and specific skill sets of CHW’s varies from country to country therefore needs to be specified. Response: CHW knowledge acquisition in the first phase of training will be assessed by a pre-test and post-test evaluation. There will also be a pre-test and post-test assessment on the content of the second phase of training. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Then, the CHWs will be observed performing physical examinations and using equipment in the field for three days under supervision from the study physician. The ten CHWs that performed best on the assessments will be invited to participate in the study. The study physician will observe CHWs’ neonatal danger sign assessments over the course of the study to evaluate the sensitivity and specificity of CHW newborn danger sign assessments in comparison to physician examination. The study physician will repeat the newborn danger sign assessment independently within 4 hours of the CHW assessment. The study physician will repeat 20% of the newborn danger sign assessments conducted by each CHW. The sensitivity and specificity of CHW physical newborn examination in identifying newborns with clinical danger signs will be determined in comparison to a physician’s physical examination. Feedback will be given to CHWs based on their danger sign assessments. In addition, the study physician and field staff will observe CHWs administering home phototherapy and provide feedback as necessary. Comment: Is the distance between the neonate and the phototherapy lights/lamps fixed in a way that parents cannot adjust the distance otherwise I would be concerned that they might change the distance which of course affect the PT intensity. Response: The phototherapy arm distance is fixed at 49.5 centimeters above the newborn and cannot be adjusted. This is indicated now in the text. Comment: What does the training on phototherapy device entails? Does it cover how to provide effective phototherapy to an infant, where to place the infant, eye cover, indications for phototherapy, safety issues regarding phototherapy, exposure? Response: Yes. We added the checklist that will be used. Comment: Who is responsible for checking the irradiance of the photo units? CHW? Response: The CHW on initiation of phototherapy. Comment: Are the CHWs measuring it and if so, will they be trained how to do it accurately? Response: Yes Comment: How will the phototherapy be powered at home? Response: It will be powered via home electricity. The units have a 12-hour battery backup that can help the unit maintain power during intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Is there constant and availability of electricity at all homes in the study area? Response: Power is available at all homes. The units have a 12-hour battery backup that can help the unit maintain power for intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Also please explain why you chose to use the AAP guidelines and if they were adapted for use in Bangladesh as strongly suggested by the AAP themselves. Response: We wanted to use an internationally recognized guideline that could be applied in different countries. We also wanted to have a clear phototherapy threshold based on age in hours. Comment: Please state range of values rather than TcB above phototherapy threshold or simply include the graph showing used to determine when phototherapy will be begun. If using the AAP guidelines, then should almost certainly use the more conservative 2004 guidelines not the new 2022 guidelines but it would be much better would be to adapt guidelines specifically for your locale as stated above. Response: We will add the 2004 AAP phototherapy threshold graph. Comment: Comprehensive guidelines already include jaundice as a danger sign therefore you are already going against these guidelines by keeping the neonate at home therefore you will need to explain this in your protocol. Is visual jaundice on the palm and sole despite TcB a requirement for referral to a hospital in this study? Please clarify. Response: Visible jaundice of the palms of the hands or soles of the feet is considered a danger sign and those newborns will be referred for hospital-level care irrespective of the TcB value and will be checked with every single CHW assessment. Comment: Who will be responsible for checking of the ambient temperature? The parents or CHW? Response: The CHW. Comment: State whether all parents have access to a phone? Response: During enrollment we conducted a short survey and found all the parents have access to a mobile phone, which was important for CHWs to arrange to follow-up. Comment: Please provide a checklist stating the potentials issues that the CHW will be checking. Response: We have included the phototherapy checklist that CHWs will be using. Comment: Who is going to do the blood groups CHWs? Are they certified to do heel pricks and run these tests in Bangladesh or is that certification required or is training CHWs to do these test all that is required for them to be able to do them? With training are the CHWs or other study staff able to do these tests in this setting? Response: The blood grouping and rhesus type will be done by trained medical technologists during the birth survey. CHWs are not certified to do heel pricks and run tests. The trained medical technologist will conduct the on-spot blood grouping of parents and newborns. Comment: We are not statisticians, but we do not believe t-test is the appropriate test because t-test is used to compare between means and Chi Square test is used to compare proportions. This would also be true in secondary outcomes. Response: We will change this to a chi-square test. Competing Interests: None Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 21 Apr 2023 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 Version 2 (revision) 05 Jan 24 read read Version 1 21 Apr 23 read read Tina M. Slusher , University of Minnesota, Minneapolis, USA Zubaida Farouk , Bayero University Kano, Kano, Nigeria Christian V Hulzebos , Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands Jean-Baptiste Le Pichon , Children’s Mercy Hospital, Kansas City, United States Virgin Islands Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Le Pichon J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 15 Jul 2024 | for Version 2 Jean-Baptiste Le Pichon , Children’s Mercy Hospital, Kansas City, MO, United States Virgin Islands 0 Views copyright © 2024 Le Pichon J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions In this paper, Foote et al. develop an intervention protocol to identify and treat newborn hyperbilirubinemia in a province of rural Bangladesh. The proposed intervention is a cluster randomized trial of 530 families randomly assigned to routine care or home visits pre- and postpartum by clinical health workers (CHW). Strengths: This study addresses a major cause of mortality and morbidity in LMICs. The intervention proposed is cost-efficient and feasible in an LMIC. The results are actionable and, if successful, will immediately benefit the affected populations. The proposal is well-designed and relies on an existing solid medical and social infrastructure (a well-organized, already-existing system of registration and follow-up of pregnant women in the Sakhipur sub-district of Bangladesh). The authors propose three specific aims targeted to measure the effectiveness of: Parental education in the prevention of disease Screening in detecting treatable hyperbilirubinemia Home treatment for hyperbilirubinemia. The specific aims are clear and independent of each other. However, the SA's order is somewhat counterintuitive. I suggest rearranging them to follow the more logical prevention, intervention, and treatment order (as outlined above). Areas of possible improvement: The authors anticipate a 5% loss to follow-up. This is an unusually low rate, even in high-income countries. In LMICs this is expected to be much higher. For example, in one study of infants conducted in Chandigarh India, more than ½ of the cohort was lost to follow-up by the end of one year (Mathew et al, 2021)(Ref-1). While it will greatly help in the present study that it is on a much shorter time scale and the CHW will be visiting the homes, a loss of follow-up of 5% still seems unrealistically optimistic. It is surprising that there is no discussion of G6PD. G6PD is a major risk for bilirubin encephalopathy (Olusanya et al, 2014)(Ref-2). There are several point of care G6PD tests that could be easily added to this protocol at a minor cost. The proximity cluster design is ingenious and well thought out, but it introduces a small risk of sample bias (for example, the cluster proximity could result in women influencing each other’s behaviors or low heterozygosity within the cluster that could result in an unusually high rate of G6PD within a cluster). It would be good if the authors addressed this issue as a potential limitation. It would help to have a better description of how the authors plan on blinding the outcome assessors. As it stands, the only method for binding the outcome assessors is to have “minimal contact” with the CHWs. How will the assessors be blinded to knowledge of the intervention? Will they have any contact with the mothers? Will they see only medical records? If so, what medical records will the assessors see? The protocol for home interventions is solid and well thought through. The authors readily acknowledge the limitations of TcB measurements and address these limitations effectively. However, it is surprising that no mention is made anywhere of the Bilirubin Induced Neurologic Dysfunction (BIND) scale (Radmacher, et al., 2015)(Ref-3). The modified BIND scale is a proven and effective way to assess the risk for acute bilirubin encephalopathy in newborns . It was also shown recently to be highly sensitive in predicting of kernicterus (Gelineau-Morel et al.,2023)(ref-3). Minor issues: In the abstract, the authors state that “Newborns without danger signs but with a TcB above the treatment threshold, but >15 mg/dL will be treated with light-emitting diode (LED) phototherapy at home”. I believe they meant “Newborns without danger signs but with a TcB above the treatment threshold, but <15 mg/dL will be treated with light-emitting diode (LED) phototherapy at home. The abbreviation for clinical health worker (CHW) is never defined. Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Yes Are the datasets clearly presented in a useable and accessible format? Yes References 1. Mathew JL, Patel PN, Wagner AL, Suri V, et al.: Analysis of reasons for loss to follow up in a prospective study in Chandigarh, India and impact from telecom changes. BMC Res Notes . 2021; 14 (1): 419 PubMed Abstract | Publisher Full Text 2. Olusanya BO, Emokpae AA, Zamora TG, Slusher TM: Addressing the burden of neonatal hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency. Acta Paediatr . 2014; 103 (11): 1102-9 PubMed Abstract | Publisher Full Text 3. Radmacher PG, Groves FD, Owa JA, Ofovwe GE, et al.: A modified Bilirubin-induced neurologic dysfunction (BIND-M) algorithm is useful in evaluating severity of jaundice in a resource-limited setting. BMC Pediatr . 2015; 15 : 28 PubMed Abstract | Publisher Full Text 4. Gelineau-Morel R, Usman F, Shehu S, Yeh HW, et al.: Predictive and diagnostic measures for kernicterus spectrum disorder: a prospective cohort study. Pediatr Res . 2024; 95 (1): 285-292 PubMed Abstract | Publisher Full Text Competing Interests No competing interests were disclosed. Reviewer Expertise Hyperbilirubinemia, bilirubin encephalopathy, kernicterus spectrum disorder, epilepsy, neurogenomics. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 17 Sep 2024 Eric Foote, Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, USA Responses to reviewer 3 comments Comment: The authors anticipate a 5% loss to follow-up. This is an unusually low rate, even in high-income countries. In LMICs this is expected to be much higher. For example, in one study of infants conducted in Chandigarh India, more than ½ of the cohort was lost to follow-up by the end of one year (Mathew et al, 2021)(Ref-1). While it will greatly help in the present study that it is on a much shorter time scale and the CHW will be visiting the homes, a loss of follow-up of 5% still seems unrealistically optimistic. Response: We appreciate the feedback. Based on our experience working in rural Bangladesh, we anticipate a low loss to follow-up rate. Part of the study enrollment criteria includes a commitment to stay in the study area during the postnatal period. Comment: It is surprising that there is no discussion of G6PD. G6PD is a major risk for bilirubin encephalopathy (Olusanya et al, 2014)(Ref-2). There are several point of care G6PD tests that could be easily added to this protocol at a minor cost. Response: We addressed similar feedback in response to another reviewer. We did not find a G6PD test that we could readily deploy in the field, with a turnaround time fast enough to change newborn hyperbilirubinemia risk categorization and treatment decisions for the participants. If such an easily administered point of care test becomes available, this could be added to future protocols. Comment: The proximity cluster design is ingenious and well thought out, but it introduces a small risk of sample bias (for example, the cluster proximity could result in women influencing each other’s behaviors or low heterozygosity within the cluster that could result in an unusually high rate of G6PD within a cluster). It would be good if the authors addressed this issue as a potential limitation. Response: We acknowledge this limitation, and we plan to adjust for cluster design in the analysis. Comment: It would help to have a better description of how the authors plan on blinding the outcome assessors. As it stands, the only method for binding the outcome assessors is to have “minimal contact” with the CHWs. How will the assessors be blinded to knowledge of the intervention? Will they have any contact with the mothers? Will they see only medical records? If so, what medical records will the assessors see? Response: The outcome assessors who perform the endline evaluation will not be involved in the administration of the study intervention. They will not know which households or clusters received the intervention. The outcome assessors did not have a relationship with the CHWs. Comment: The protocol for home interventions is solid and well thought through. The authors readily acknowledge the limitations of TcB measurements and address these limitations effectively. However, it is surprising that no mention is made anywhere of the Bilirubin Induced Neurologic Dysfunction (BIND) scale (Radmacher, et al., 2015)(Ref-3). The modified BIND scale is a proven and effective way to assess the risk for acute bilirubin encephalopathy in newborns . It was also shown recently to be highly sensitive in predicting of kernicterus (Gelineau-Morel et al.,2023)(ref-3). Response: We addressed similar feedback in response to reviewer 1. Please refer to that response. View more View less Competing Interests None reply Respond Report a concern Le Pichon JB. Peer Review Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.16516.r36817) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v2#referee-response-36817 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Slusher T et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 31 May 2024 | for Version 2 Tina M. Slusher , Department of Pediatrics, Global Health Program, Critical Care Division, University of Minnesota, Minneapolis, MN, USA Zubaida Farouk , Bayero University Kano, Kano, Nigeria 0 Views copyright © 2024 Slusher T et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The revisions that the authors have made have addressed many of my/our concerns but there are still a few that need to be addressed. They have re-ordered their aims which was an essential correction needed in this arm, further clarified community health worker training and included the bilirubin graph and access to cell phone. The authors still have not addressed the problem of G6PD deficiency and make no mention of screening for G6PD deficiency. If they cannot screen for G6PD deficiency that should be stated and authors should mention at a minimum that mothers will be taught to avoid triggers of hemolysis. Again it would be helpful to know the outcomes of the control group that have EBT, ABE, or jaundice-related death. This data will be very important when determining the success of the home PT and should be relatively easy to obtain. Additionally it would be helpful to state how the diagnosis of ABE will be made and BIND score encouraged for any neonate referred to the hospital for treatment of jaundice. Please clarify that the distance from the neonate to the PT will be fixed and not adjustable by the mother/family. Thank you for this very important work. If shown to be safe and effective it will likely be an important tool in preventing severe neonatal hyperbilirubinemia and the tragic sequelae including ABE and KSD. Competing Interests No competing interests were disclosed. We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. reply Respond to this report Responses (0) Slusher TM and Farouk Z. Peer Review Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.16516.r35758) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v2#referee-response-35758 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2023 Hulzebos C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 03 Aug 2023 | for Version 1 Christian V Hulzebos , Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands 0 Views copyright © 2023 Hulzebos C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions In this study protocol entitled “Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh” Foot and colleagues scrutinously describe their research proposal to improve management of neonatal hyperbilirubinemia (NHB) in a low-resource country. The authors aim to prevent NHB by antenatal education on the importance of breastfeeding and inform mothers how to seek help when their offspring is sick, to prevent NHB by transcutaneous bilirubin (TcB) screening at home, and to start early phototherapy (PT). PT is started at home whenever TcB < 15 mg/dL (257 µmol/L) is higher than the treatment threshold, and in-hospital when TcB ≥ 15 mg/dL or in case of danger signs. Considering the important aim on prevention I suggest to adapt the title, and incorporate prevention in the title as well! And please incorporate this in the intervention arm as well. For example in the abstract the intervention arm reads as home screening and treatment, which is in fact not completely true. I agree with the other reviewers that this study does have potential to change the future of many infants with NHB. Yet, apart from the scientific issues, economic and financial factors are as well important and need some clarification. An important question that arises is how resources are guaranteed after this study with a clear but relatively small sample size. And what about future costs for regular calibration of TcB and PT devices? I have also a question on the effectiveness of home PT to increase treatment rates (as can be read in the abstract). The authors have defined treatment rate as primary outcome. But this is not the same as PT effectiveness, usually defined as reduction of bilirubin below the treatment threshold that is considered appropriate. Especially when treatment is TcB based < 15 mg/dL, and not TSB-based, overtreatment may occur. And this unnecessarily started PT will contribute to the primary outcome. Therefore I suggest to measure TSB also in newborns with TcB above treatment threshold treatment threshold. I have provided my suggestions and questions in the linked PDF . This PDF also contains the comments from Tina M. Slusher and Zubaida L. Farouk as part of their review of version 1 of this article 1 . Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Partly Are sufficient details of the methods provided to allow replication by others? Yes Are the datasets clearly presented in a useable and accessible format? Not applicable References 1. Slusher TM, Farouk ZL: Peer Review Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh:a cluster randomized control trial protocol [version 1; peer review: 1 approved with reservations]. Gates Open Res . 2023; 7 (58). Publisher Full Text | Reference Source Competing Interests No competing interests were disclosed. Reviewer Expertise Neonatal hyperbilirubimemia, prevention, screening, treatment, management guidelines. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 18 Sep 2024 Eric Foote, Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, USA Responses to reviewer 2 comments Comment: Considering the important aim on prevention I suggest to adapt the title, and incorporate prevention in the title as well! And please incorporate this in the intervention arm as well. For example in the abstract the intervention arm reads as home screening and treatment, which is in fact not completely true. Response : Thank you for your comments. We will add prevention to the title and abstract. Comment: An important question that arises is how resources are guaranteed after this study with a clear but relatively small sample size. And what about future costs for regular calibration of TcB and PT devices? Response: Thank you for your comment. We agree that developing a low cost intervention is important for the scalability of the intervention. This study focused on evaluating the acceptability and impact of a community health worker (CHW)-led prevention, diagnosis and treatment intervention on phototherapy treatment rates. In future work, we will evaluate the scalability of the intervention. We also believe that showing that CHW-led home screening and treatment is possible is the first step in developing a low-cost scalable intervention. Comment: I have also a question on the effectiveness of home PT to increase treatment rates (as can be read in the abstract). The authors have defined treatment rate as primary outcome. But this is not the same as PT effectiveness, usually defined as reduction of bilirubin below the treatment threshold that is considered appropriate. Especially when treatment is TcB based < 15 mg/dL, and not TSB-based, overtreatment may occur. And this unnecessarily started PT will contribute to the primary outcome. Therefore I suggest to measure TSB also in newborns with TcB above treatment threshold treatment threshold. I suggest to use a decision rule when to measure TSB after TcB, e.g., TcB +50 micromol/L > treatment thresholds is heel prick for TSB measurement Response: Thanks for your comment. This study was designed to evaluate the impact of the intervention on phototherapy treatment rates in intervention and comparison households. Phototherapy is known to be effective in treating neonatal hyperbilirubinemia. As a result, we did not design the study to assess the effectiveness of home phototherapy. Nevertheless, the study will report the number and percent of infants that met the treatment criteria and are treated at home, and who have a transcutaneous bilirubin (TcB) <15 mg/dL on consecutive days after the intervention is completed. This will give a measure of household phototherapy intervention effectiveness. Measuring the total serum bilirubin (TSB) in newborns who had a TcB greater than the treatment threshold in rural Bangladesh and using the TSB to determine home treatment eligibility is not feasible for this intervention in this community. The households are far from a laboratory and obtaining a TSB result from a newborn where the specimen was collected at home and brought to the laboratory will take a long time. Waiting to start treatment until the TSB result is available will substantially reduce the effectiveness of the intervention. One of the main advantages of the TcB device is providing instant diagnostic data to begin treatment if indicated immediately. Waiting as much as one day to obtain a TSB result may result in the TSB rising to a level where we would not recommend home treatment but rather would focus on hospital referral. In addition, CHWs in low- to middle-income countries may not be comfortable or trained to collect blood on newborns and specialized personnel would be needed which would increase the intervention costs and reduce the intervention scalability. The acceptability of the intervention could also decrease as parents may not want blood to be drawn on their newborn and refuse blood collection. TcB values are highly correlated to TSB at levels less than 15 mg/dL and the risk of substantial overtreatment is low. Comment : Prenatal education should also be mentioned here - in the intervention arm Response: This was updated. Comment: Is this because she will probably not be back in time or because she will leave before prenatal education? Response: Thanks for the comment. It is because the mother will not be present in the study area at the time of birth. Comment: When you consider the first aim important in the prevention this is appropriate to list here, but it is not your main outcome. See comments of other reviewers. Response: Thanks, the order of the Aims was reversed. Comment: Sample size calculations are based on many estimations, the percentage of jaundiced newborns that need treatment is based on a literature reference, and it is estimated that 50% of the infants born in facilities receive treatment, and none of the newborns who are born at home. I suggest that the authors use numbers that arise from the population in the research area. This may affect sample size. Response: The figures used for the calculation were based on birth statistics from the local hospital in Shakipur and from talking to local doctors. Comment : Intervention arm consists of three interventions. Should be stated earlier (see major comments). Response: We updated the title and the abstract to highlight this. Comment: ....danger signs including signs of ABE (using the BIND-M score), Response: This comment was addressed in response to the other reviewers Comment: Why do you choose to use the old (2004) AAP guideline and not the more recent one (2022)? Response: Thanks, this comment was addressed in the response to the other reviewers. Comment: On which part of the body is TcB measured? How often are TcB measurements done in the same session? Response: The TcB was measured by gently pressing the meter on the middle part of the sternum. In the same session, three consecutive measurements were taken, and an algorithm took the average of three measurements for the decision-making process. Comment: But how is this overnight pause handled when the jaundiced infant has just started PT? It seems a little bit dangerous to stop for 6 hours when PT has just been started. Please define a minimal PT duration before stopping 6 hours (e.g., 6 hours) and else ... maybe every one should accept one night with less sleep (more will probably follow for other reasons). Response: The timing for the overnight pause was set to be between midnight and 0600. This is highlighted in the operational description that was added. CHW visits will occur in the morning, and then they will visit again 4-6 hours after starting phototherapy in the eligible newborns. The newborns will receive at least 7 hours of treatment, but probably 12 hours of treatment before the overnight pause. We think having a pause overnight will increase the acceptability of the intervention. Comment: And what about signs of infection/sepsis? Are these factors that lower the treatment threshold? Or reason to be admitted to an hospital, which may be difficult (as I understood from the authors). Response: All newborns with signs of sepsis will be referred to a hospital for care. We will not attempt to treat newborns with signs of sepsis at home as a part of this study. Comment: iii....text is missing Response: Updated. Comment : 80 participants seem a rather large sample for these focus groups. Usually no other answers are obtained after fewer than the suggested 80 participants. Please see literature on satiety points in focus groups. Response : We agree with your comments. We will conduct four focus group discussions (8-10 participants in each session) and depending on the saturation of data, will further adjust the numbers. Comment: detect neonatal infection? Words are missing. Response: Updated. Comment: The prenatal education and home..... Response: Updated. Comments: #12: What is the reference source? #13: please provide website or link to appropriate docs Response: Updated View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Hulzebos CV. Peer Review Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.15331.r34000) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v1#referee-response-34000 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2023 Slusher T et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 15 May 2023 | for Version 1 Tina M. Slusher , Department of Pediatrics, Global Health Program, Critical Care Division, University of Minnesota, Minneapolis, MN, USA Zubaida Farouk , Bayero University Kano, Kano, Nigeria 0 Views copyright © 2023 Slusher T et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This study does have the potential to improve outcome in neonates with significant hyperbilirubinemia in Bangladesh and other LMICs if shown to be safe and effective. Obviously, it should be possible to provide more timely access to phototherapy and to treat neonates who are having difficulty getting to their referral center and to do it less expensively—all very important in LMICs. It is well designed as a cluster randomized trial. The most recent 2022 AAP guidelines do allow for careful and limited home phototherapy but as these authors clearly realize a protocol for home phototherapy in other countries including LMICs needs to be carefully studied for safety and efficacy before widespread implementation. We congratulate these authors for this idea. The study team is strong and quite experienced. We do have questions to which we feel answers will improve the study substantially. Thank you for allowing us to review this protocol. We suggest attaching survey questionnaires and other tools including checklists for the study. These materials would likely fill in many of the gaps we mention below. The focus of the study is timely identification and treatment of hyperbilirubinemia, why should aim 1 be about exclusive breastfeeding? We would suggest reversing the aims or simply including encouraging and supporting breastfeeding as a means to decrease hyperbilirubinemia. You do not mention training for the mothers on preventative practices like avoiding triggers for hemolysis in G6PD deficient neonates such as avoiding henna and mentholated products or jaundiced preventative measures beyond adequate breastfeeding. G6PD screening should be included in the baseline labs as Bangladesh has a G6PD deficiency rate greater than 5% in males. Without knowing G6PD status determining risk of significant or severe jaundice will be more difficult. We also wonder about neonates with set up for Rhesus or ABO incompatibility? Will these neonates be enrolled in the study and not transferred to the referral center until after 36-48 hours or will they be excluded and referred sooner? We would be okay with starting home phototherapy in these neonates while transport was arranged but would be uncomfortable keeping these neonates on home phototherapy for a prolonged time because of their risk of rapidly developing severe hyperbilirubinemia which might be missed with only daily bilirubin checks. It would be important to know the outcomes of the comparative group i.e., the number in both the treatment arm and control arms that need hospital referral, EBT and have ABE or die from complication of the treatment or jaundice-related death. Are you looking at the proportion of newborns receiving treatment in both groups? Will the comparative or control group ever get home phototherapy? Will both groups be receiving intensive phototherapy? Agree with need to specifically look for ABE and would suggest either the BIND or modified BIND score in any neonate with possible ABE on exam in both groups. Suggest looking for signs of ABE at the time of starting phototherapy and each time the neonate is examined. You should also assess for ABE at timepoint of referral to the hospital for exchange. We also would strongly suggest surveying/examining for signs of ABE at the endpoint. What is the definition of geographical proximity for the purpose of this study? Suggest minimum distance or some other objective criteria, can individual villages or wards serve as clusters? What is this written test that the CHW will take? Is an aptitude test? Do CHW have any prior medical training? Are they certified health workers? Please clarify in more detail what assessment the CHW’s will carry out and specify how it will be done. Please clarify tool that will be used to assess CHWs. What is the qualification of the field staff that will review performance of the CHW, what is the qualification of the training team? What will be used to assess the knowledge, skill, and attitude? Exactly what type of training and specific skill sets of CHW’s varies from country to country therefore needs to be specified. Is the distance between the neonate and the phototherapy lights/lamps fixed in a way that parents cannot adjust the distance otherwise I would be concerned that they might change the distance which of course affect the PT intensity. What does the training on phototherapy device entails? Does it cover how to provide effective phototherapy to an infant, where to place the infant, eye cover, indications for phototherapy, safety issues regarding phototherapy, exposure? Who is responsible for checking the irradiance of the photo units? CHW? Are the CHWs measuring it and if so, will they be trained how to do it accurately? How will the phototherapy be powered at home? Is there constant and availability of electricity at all homes in the study area? Also please explain why you chose to use the AAP guidelines and if they were adapted for use in Bangladesh as strongly suggested by the AAP themselves. Please state range of values rather than TcB above phototherapy threshold or simply include the graph showing used to determine when phototherapy will be begun. If using the AAP guidelines, then should almost certainly use the more conservative 2004 guidelines not the new 2022 guidelines but it would be much better would be to adapt guidelines specifically for your locale as stated above. Comprehensive guidelines already include jaundice as a danger sign therefore you are already going against these guidelines by keeping the neonate at home therefore you will need to explain this in your protocol. Is visual jaundice on the palm and sole despite TcB a requirement for referral to a hospital in this study? Please clarify. Who will be responsible for checking of the ambient temperature? The parents or CHW? State whether all parents have access to a phone? Please provide a checklist stating the potentials issues that the CHW will be checking. Who is going to do the blood groups CHWs? Are they certified to do heel pricks and run these tests in Bangladesh or is that certification required or is training CHWs to do these test all that is required for them to be able to do them? With training are the CHWs or other study staff able to do these tests in this setting? We are not statisticians, but we do not believe t-test is the appropriate test because t-test is used to compare between means and Chi Square test is used to compare proportions. This would also be true in secondary outcomes. Please find further comments in the annotated pdf hyperlinked above or at the following link: https://gatesopenresearch.s3.eu-west-1.amazonaws.com/linked/208927.Annotated_pdf_-_Review_Drs._Tina_Slusher_and_Zubaida_Farouk_for_Home_PT_in_Bangladesh_%28002%29.pdf Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Partly Are the datasets clearly presented in a useable and accessible format? Not applicable Competing Interests No competing interests were disclosed. We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 17 Sep 2024 Eric Foote, Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, USA Responses to reviewer 1 comments Comment: We suggest attaching survey questionnaires and other tools including checklists for the study. These materials would likely fill in many of the gaps we mention below. Response: These were added. Comment: The focus of the study is timely identification and treatment of hyperbilirubinemia, why should aim 1 be about exclusive breastfeeding? We would suggest reversing the aims or simply including encouraging and supporting breastfeeding as a means to decrease hyperbilirubinemia. Response: Thanks, we reversed the aims as suggested. Comment: You do not mention training for the mothers on preventative practices like avoiding triggers for hemolysis in G6PD deficient neonates such as avoiding henna and mentholated products or jaundiced preventative measures beyond adequate breastfeeding. G6PD screening should be included in the baseline labs as Bangladesh has a G6PD deficiency rate greater than 5% in males. Without knowing G6PD status determining risk of significant or severe jaundice will be more difficult. Response: We did not provide training on practices to avoid triggers for hemolysis. This is something we could add to future protocols. We thought for this protocol it was best to focus on breastfeeding, identifying newborn danger signs and developing a plan to go to the hospital for care. The ability to measure G6PD and obtain results could not be completed in the study region in a time frame to have the results change management or provide risk stratification. In addition, not all newborns with G6PD deficiency develop hemolytic hyperbilirubinemia. We think providing a longer duration phototherapy of 36 hour at high intensity (~50 µW/cm2/nm) and evaluating newborns twice on the day of phototherapy initiation and daily thereafter for danger signs and referring newborns to the hospital who have danger signs during phototherapy also provides a margin of safety. Initiating phototherapy at a transcutaneous bilirubin (TcB) level <15mg/dL will also provide a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels = 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most to nearly all cases of neonatal hyperbilirubinemia either through treatment at home or hospital referral and will markedly improve care for those newborns who would not otherwise be diagnosed or treated. Newborns will be provided high quality treatment at home where it was otherwise not available. Comment: We also wonder about neonates with set up for Rhesus or ABO incompatibility? Will these neonates be enrolled in the study and not transferred to the referral center until after 36-48 hours or will they be excluded and referred sooner? We would be okay with starting home phototherapy in these neonates while transport was arranged but would be uncomfortable keeping these neonates on home phototherapy for a prolonged time because of their risk of rapidly developing severe hyperbilirubinemia which might be missed with only daily bilirubin checks. Response: We limited the home treatment population to newborns >=35 weeks and >= 2kg without danger signs. We think that referring newborns >= 35 weeks and >= 2kg who are identified initially with a TcB >=15 mg/dL or with danger signs to the hospital provides a margin of safety. The transcutaneous bilimeter level also tends to overestimate the serum bilirubin measure at levels <15 mg/dL, providing a margin of safety. Likely those with severe hemolytic hyperbilirubinemia will be referred for care based on these criteria. The AAP 2004 phototherapy treatment thresholds are lower for hemolytic disease, and those at risk for ABO or rhesus incompatibility in this study will be treated at home at these lower thresholds provided the TcB is <15 mg/dL and no danger signs are present, providing a margin of safety. The newborns we identified whose mother is blood type O and the newborn blood type is A or B or whose mother is rhesus negative and the newborn is rhesus positive are not known to have ABO or rhesus disease, but are at risk based on their and their mother’s blood type and rhesus type. We think providing a longer duration phototherapy of 36 hours at high intensity (>50 µW/cm2/nm), evaluating newborns twice on the day of phototherapy initiation and daily thereafter, and referring newborns who have danger signs during phototherapy also provides a margin of safety. We will also check the TcB level daily for 2 days after treatment completion and refer those with a TcB>= 15 mg/dL or with danger signs, providing an additional margin of safety. We think this is sufficient to prevent morbidity and mortality from most cases of neonatal hyperbilirubinemia either through home treatment or hospital referral and will markedly improve care for those newborns who would not otherwise be treated. We think referring every newborn at risk for hemolytic disease due to rhesus or ABO incompatibility will not be feasible in a setting where newborn care is already limited. Newborns will be provided high quality treatment at home where it was otherwise not available. In addition, we are not limiting study participants from seeking care outside of what is provided by the CHWs. Comment: It would be important to know the outcomes of the comparative group i.e., the number in both the treatment arm and control arms that need hospital referral, EBT and have ABE or die from complication of the treatment or jaundice-related death. Response: We will provide data in both arms on hospitalization for hyperbilirubinemia, exchange transfusion, phototherapy treatment, and mortality. We think these outcomes are sufficient to provide awareness of the safety of the treatment. We will not have hospitalization referral data in both arms as the study design does not make it possible to collect this information. Comment: Are you looking at the proportion of newborns receiving treatment in both groups? Response: Yes Comment: Will the comparative or control group ever get home phototherapy? Response: In the comparison group, newborns could receive hospital phototherapy if they obtain it through the existing postnatal care system in rural Bangladesh. The comparison group will not be provided home phototherapy by the study. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Will both groups be receiving intensive phototherapy? Response: See the response directly above. Newborns in the intervention group could receive phototherapy through the existing health care system, at home by study CHWs or by study CHW referral for hospital care. Newborns will not be restricted from obtaining additional care due to participation in the study. Comment: Agree with need to specifically look for ABE and would suggest either the BIND or modified BIND score in any neonate with possible ABE on exam in both groups. Suggest looking for signs of ABE at the time of starting phototherapy and each time the neonate is examined. You should also assess for ABE at timepoint of referral to the hospital for exchange. We also would strongly suggest surveying/examining for signs of ABE at the endpoint. Response: We did not do this and do not think this is indicated. Neonatal danger sign measurement is an evidence-based method for CHWs to identify sick newborns in need of referral level care and is widely used in Bangladesh and in other LMICs. The likelihood of a newborn having ABE with a transcutaneous bilirubin <15 mg/dL is extremely low. Neonatal danger sign assessment could also identify newborns who may have ABE or BIND and they would then be referred for hospital level care, since a newborn with BIND or ABE will likely have newborn danger signs. There is no evidence that CHWs determining the BIND score or evaluating for ABE by CHWs will necessarily improve outcomes for newborns. Adding this procedure will make the CHW process more burdensome for unclear benefit, potentially making the process untenable to adopt at scale. In addition, rates of ABE and newborn related mortality are low ~1-2/1000 in South Asia. There would be a limited number of cases in our study population of 530 infants. It is unlikely we would find a statistically significant difference, given the sample size of the study. We think evaluating serum bilirubin levels in newborns that are referred, deaths, hospitalizations and need for exchange transfusion will sufficiently determine potential risks of the intervention. Comment: What is the definition of geographical proximity for the purpose of this study? Suggest minimum distance or some other objective criteria, can individual villages or wards serve as clusters? Response: We enrolled pregnant mothers fulfilling our enrollment criteria and formed a cluster of households that share a minimum distance of 100 meters between two households. Between two clusters we maintained a buffer zone of 1 km. Comment: What is this written test that the CHW will take? Is an aptitude test? Do CHW have any prior medical training? Are they certified health workers? Please clarify in more detail what assessment the CHW’s will carry out and specify how it will be done. Response: The eligibility criteria to become CHWs include female gender (due to cultural sensitivities with providing breastfeeding support), at least 20 years of age, completion of secondary school, and a minimum passing score of 60% on the written test. The written test will assess the candidates’ knowledge on community mobilization and sensitization. Candidates for study CHWs do not need previous experience as a healthcare worker. Work experience with government community groups will be considered favorably as a hiring criterion. Twelve CHWs who meet the requirements for initial CHW enrollment will be invited for a five-day training conducted by icddr,b staff and physicians from Dhaka Shishu (Children’s) Hospital and physicians from Sakhipur Health Complex. The training model is adopted from the “Validation of community health workers’ assessment of neonatal illness in rural Bangladesh” by Darmstadt et al. 13 The training will contain didactic and hands-on portions taught by physicians at icddr,b, Dhaka Shishu Hospital, and the local referral hospital. The first phase of training will be three days and cover the following topics: neonatal jaundice and responsibilities of CHWs, pregnancy care and maternal danger signs, delivery planning and safe delivery preparations, newborn care, infection prevention practices, breastfeeding and management of breastfeeding problems, risk of developing neonatal jaundice and management, neonatal jaundice symptoms and causes, communication and counselling. CHW knowledge acquisition will be assessed by a pre-test and post-test evaluation. The second phase of training over two days at Dhaka Shishu Hospital will primarily focus on hands-on teaching and include the following topics: recognizing neonatal illness and common neonatal problems, newborn danger sign assessment, postnatal services and the responsibilities of CHWs, referral process for sick newborns, neonatal jaundice symptoms and causes, management of neonatal jaundice in the home, and training on use of equipment (transcutaneous bilimeter, phototherapy device, thermometer). Bedside training will include danger sign assessment of neonates and using the transcutaneous bilimeter and phototherapy device. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Comment: Please clarify tool that will be used to assess CHWs. What is the qualification of the field staff that will review performance of the CHW, what is the qualification of the training team? What will be used to assess the knowledge, skill, and attitude? Exactly what type of training and specific skill sets of CHW’s varies from country to country therefore needs to be specified. Response: CHW knowledge acquisition in the first phase of training will be assessed by a pre-test and post-test evaluation. There will also be a pre-test and post-test assessment on the content of the second phase of training. CHWs will be trained to make newborn danger sign and lactation assessments in the hospital under the supervision of physicians and receive feedback on their assessment of five newborns in the hospital. Then, the CHWs will be observed performing physical examinations and using equipment in the field for three days under supervision from the study physician. The ten CHWs that performed best on the assessments will be invited to participate in the study. The study physician will observe CHWs’ neonatal danger sign assessments over the course of the study to evaluate the sensitivity and specificity of CHW newborn danger sign assessments in comparison to physician examination. The study physician will repeat the newborn danger sign assessment independently within 4 hours of the CHW assessment. The study physician will repeat 20% of the newborn danger sign assessments conducted by each CHW. The sensitivity and specificity of CHW physical newborn examination in identifying newborns with clinical danger signs will be determined in comparison to a physician’s physical examination. Feedback will be given to CHWs based on their danger sign assessments. In addition, the study physician and field staff will observe CHWs administering home phototherapy and provide feedback as necessary. Comment: Is the distance between the neonate and the phototherapy lights/lamps fixed in a way that parents cannot adjust the distance otherwise I would be concerned that they might change the distance which of course affect the PT intensity. Response: The phototherapy arm distance is fixed at 49.5 centimeters above the newborn and cannot be adjusted. This is indicated now in the text. Comment: What does the training on phototherapy device entails? Does it cover how to provide effective phototherapy to an infant, where to place the infant, eye cover, indications for phototherapy, safety issues regarding phototherapy, exposure? Response: Yes. We added the checklist that will be used. Comment: Who is responsible for checking the irradiance of the photo units? CHW? Response: The CHW on initiation of phototherapy. Comment: Are the CHWs measuring it and if so, will they be trained how to do it accurately? Response: Yes Comment: How will the phototherapy be powered at home? Response: It will be powered via home electricity. The units have a 12-hour battery backup that can help the unit maintain power during intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Is there constant and availability of electricity at all homes in the study area? Response: Power is available at all homes. The units have a 12-hour battery backup that can help the unit maintain power for intermittent outages. If power is not available, newborns will be referred for hospital treatment. Comment: Also please explain why you chose to use the AAP guidelines and if they were adapted for use in Bangladesh as strongly suggested by the AAP themselves. Response: We wanted to use an internationally recognized guideline that could be applied in different countries. We also wanted to have a clear phototherapy threshold based on age in hours. Comment: Please state range of values rather than TcB above phototherapy threshold or simply include the graph showing used to determine when phototherapy will be begun. If using the AAP guidelines, then should almost certainly use the more conservative 2004 guidelines not the new 2022 guidelines but it would be much better would be to adapt guidelines specifically for your locale as stated above. Response: We will add the 2004 AAP phototherapy threshold graph. Comment: Comprehensive guidelines already include jaundice as a danger sign therefore you are already going against these guidelines by keeping the neonate at home therefore you will need to explain this in your protocol. Is visual jaundice on the palm and sole despite TcB a requirement for referral to a hospital in this study? Please clarify. Response: Visible jaundice of the palms of the hands or soles of the feet is considered a danger sign and those newborns will be referred for hospital-level care irrespective of the TcB value and will be checked with every single CHW assessment. Comment: Who will be responsible for checking of the ambient temperature? The parents or CHW? Response: The CHW. Comment: State whether all parents have access to a phone? Response: During enrollment we conducted a short survey and found all the parents have access to a mobile phone, which was important for CHWs to arrange to follow-up. Comment: Please provide a checklist stating the potentials issues that the CHW will be checking. Response: We have included the phototherapy checklist that CHWs will be using. Comment: Who is going to do the blood groups CHWs? Are they certified to do heel pricks and run these tests in Bangladesh or is that certification required or is training CHWs to do these test all that is required for them to be able to do them? With training are the CHWs or other study staff able to do these tests in this setting? Response: The blood grouping and rhesus type will be done by trained medical technologists during the birth survey. CHWs are not certified to do heel pricks and run tests. The trained medical technologist will conduct the on-spot blood grouping of parents and newborns. Comment: We are not statisticians, but we do not believe t-test is the appropriate test because t-test is used to compare between means and Chi Square test is used to compare proportions. This would also be true in secondary outcomes. Response: We will change this to a chi-square test. View more View less Competing Interests None reply Respond Report a concern Slusher TM and Farouk Z. Peer Review Report For: Community health worker-led household screening and management of neonatal hyperbilirubinemia in rural Bangladesh: a cluster randomized control trial protocol [version 2; peer review: 1 approved, 2 approved with reservations] . Gates Open Res 2024, 7 :58 ( https://doi.org/10.21956/gatesopenres.15331.r33065) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-58/v1#referee-response-33065 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with Gates Open Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Community health worker-led household screening...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://gatesopenresearch.org/articles/7-58/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://gatesopenresearch.org/articles/7-58/v2&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://gatesopenresearch.org/articles/7-58/v2" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Foote EM et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://gatesopenresearch.org/articles/7-58/v2/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://gatesopenresearch.org/articles/7-58", templates : { twitter : "Community health worker-led household screening and management.... Foote EM et al., published by " + "Gates Open Research" + ", https://gatesopenresearch.org/articles/7-58/v2" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/14033/16516") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "16516"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "36672": 0, "36673": 0, "36674": 0, "36675": 0, "34375": 0, "33992": 0, "33993": 0, "36810": 0, "33994": 0, "36811": 0, "34379": 0, "33995": 0, "36812": 0, "33996": 0, "36813": 0, "33997": 0, "36814": 0, "33998": 0, "34382": 0, "36815": 0, "33999": 0, "34383": 0, "36816": 0, "34000": 28, "34384": 0, "36817": 13, "34001": 0, "34385": 0, "36818": 0, "34386": 0, "36819": 0, "34387": 0, "34388": 0, "34389": 0, "33061": 0, "33062": 0, "33063": 0, "33064": 0, "33065": 34, "35758": 16, "35759": 0, "36666": 0, "36667": 0, "36668": 0, "36669": 0, "36670": 0, "36671": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "32276d4e-7357-4298-af25-27c0bd13fd92"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); Are you a Gates-funded researcher? If you are a previous or current Gates grant holder, sign up for information about developments, publishing and publications from Gates Open Research. First Name * You must provide your first name Last Name * You must provide your last name Email * You must provide a valid email address Institution You must provide an institution. Submit Thank you! We'll keep you updated on any major new updates to Gates Open Research Gates Open Research Browse Gateways How to Publish About Contact Legal For Developers Cookie Notice Privacy Notice RSS Submit via VeriXiv © F1000 Research Limited and its licensors ISSN 2572-4754 var F1000platform = new F1000.Platform({ name: "gates", displayName: "Gates Open Research", hostName: "gatesopenresearch.org", id: "3", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });